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THE FLOW-MEDIATED DILATION RESPONSE TO ACUTE EXERCISE IN  
 
OVERWEIGHT MEN 
 
INTRODUCTION     Inflammation has been found to play a role in the etiology of 
coronary heart disease as well as induce endothelial dysfunction. Brachial artery flow-
mediated dilation (FMD) is a measure of nitric oxide dependent vasodilation and 
represents a non-invasive measurement of endothelial function.  The aim of the present 
study was to 1) investigate the interaction of inflammatory biomarkers on the FMD 
response to acute exercise in overweight men and 2) determine if FMD following 
moderate intensity acute exercise is reproducible.   
METHODS     Sixteen overweight men ages 46-68 years were classified as either being 
active or inactive. Subjects performed three acute exercise treatments (25%, 50%, and 
75% VO2peak), separated by at least two days apart.  The 50% intensity was repeated in 
9 subjects to investigate FMD reproducibility in response to acute exercise.  Following 
the initial insertion of a venous catheter, brachial artery Flow-Mediated Dilation (FMD) 
and subsequent blood samples were taken pre exercise and every hour for three hours 
thereafter.   
RESULTS     The active group displayed a 24% increase (p=.034) in FMD following 
acute exercise compared to a 32% decrease (p=.010) in FMD observed in the inactive 
group.  Both groups exhibited an elevated concentration of IL-6 following moderate 
(50% VO2) and high (75% VO2) intensity acute exercise (p<.001 and p<.001, 
respectively), whereas no change (p=.669) in IL-6 following low intensity (25% VO2) 
exercise in either group was observed.  No differences in TNF-α were observed between 
 vi
groups (p=.433) or in response to acute exercise (p=.584).  A significant FMD correlation 
(r = 0.531; p=.008) following exercise between trial 1 and trial 2 was found.   
CONCLUSION     FMD following exercise appears to be as reproducible as resting 
controlled conditions.  In addition, the FMD response to acute exercise is enhanced in 
overweight active men when compared to their inactive counterparts; however, 
inflammation did not provide insight into the physiological mechanisms associated with 
the improvement of FMD.     
This research was supported by the Gatorade Sport Science Institute and Indiana 
University HPER Research Grant-in-Aids. 
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REPRODUCIBILITY OF THE FLOW-MEDIATED DILATION RESPONSE TO 
ACUTE EXERCISE IN OVERWEIGHT MEN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Running Title: Reproducibility of flow-mediated dilation 
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ABSTRACT  
 
     Flow-mediated dilation (FMD) has been established as a reliable non-invasive 
measurement of endothelial function.  The reproducibility of FMD under resting 
conditions has previously been reported; however, the reproducibility of FMD in 
response to exercise remains to be investigated.  On two separate days, we determined if 
flow-mediated dilation is reproducible in response to acute exercise in nine overweight 
men.  Following pre-exercise FMD measurements, subjects were asked to walk on a 
treadmill for 45 minutes at 50% of their VO2peak.  Subsequently, FMD was measured 
immediately, and every hour for three hours thereafter.  Reproducibility of FMD 
following exercise was assessed utilizing: 1) a two-way ANOVA, 2) Intra-class 
correlation coefficients (ICC), 3) Pearson correlations (r), 4) coefficient of variation (CV 
%), and  coefficient of variation prime (CV’) for FMD at each time period. Four 
acceptable reproducibility assessments were required to confirm FMD reproducibility in 
response to acute exercise. No differences (F1,8 = .01; p=.942) in FMD were observed 
between trials collapsing for time. All the ICCFMD fell within the reproducible criterion 
set and are as follows: pre-exercise 0.602, immediately post 0.840, 1 hr post 0.632, 2 hr 
post 0.724, and 3 hr post 0.631.  The correlation and the average CV% for FMD between 
trials was 0.579 and 25.2%, respectively.  The FMD response to an acute bout of 
moderate treadmill exercise appears to be as reproducible as FMD measured during 
resting conditions. The findings of the present study support the use of FMD as an 
outcome variable in response to acute exercise. 
 
Key words: Intra-class correlation coefficient, Coefficient of variation, Endothelial-
dependent vasodilation, Brachial artery, Physical activity 
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INTRODUCTION 
 
     Atherosclerotic cardiovascular disease remains the leasing cause of morbidity and 
mortality in the United States.  Atherosclerosis is a progressive inflammatory disease 
characterized by the accumulation of lipids and fibrous elements in medium to large 
arteries (Lusis 2000) and has been suggested to be the result of endothelial dysfunction 
(Munro and Cotran 1988; Ross 1986).  Endothelial cells participate in multiple essential 
functions to maintain vascular homeostasis and health, including regulation of vascular 
smooth muscle tone, control of thrombosis, inhibition of leukocyte and platelet adhesion, 
and promotion of intra-arterial permeability (Celermajer 1997; Rubanyi 1993; Vane et al. 
1990), all of which contribute to atherosclerotic cardiovascular disease.  Moreover, many 
clinical populations (Edwards et al. 2004; Guerci et al. 2001; Maiorana et al. 2003) 
present with endothelial dysfunction.  
     Flow-mediated dilation (FMD) is a non-invasive ultrasonic measurement of 
endothelial function (Uehata et al. 1997) which has been shown to correlate with invasive 
testing of coronary artery endothelial function (Anderson et al. 1995; Takase et al. 1998).   
The occlusion-induced production of reactive hyperemia to promote endothelial nitric 
oxide dependent vasodilation (ie. flow-mediated) evaluates the shear stress mechanism of 
NO production.  FMD has been most commonly studied in the brachial artery (Smith et 
al. 2000) and is widely used and accepted as a marker of endothelial function. 
     For decades, the use of diet and exercise has been indicated as non-pharmacological 
interventions in the treatment and prevention of disease.  Recently exercise has been 
found to preserve and/or reverse endothelial (dys)function (Edwards et al. 2004; Gokce et 
al. 2002; Hambrecht et al. 2003).  There is substantial evidence suggesting an 
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improvement in FMD following exercise training in healthy and clinical populations 
(Gokce et al. 2002; Kasikcioglu et al. 2005) with the subsequent reduction of  
cardiovascular disease risk; however, the physiological mechanisms associated with the 
improvement in endothelial function are not fully understood (Brunner et al. 2005).  
Furthermore, 45 minutes of moderate intensity (acute) exercise has been shown to 
improve FMD (Harvey et al. 2005) and other measures of endothelial function (Bode-
Boger et al. 1994; Camsari et al. 2003; Gill et al. 2004; Kingwell et al. 1997).  The 
advantage of utilizing an acute paradigm allows for the investigation into possible 
physiological response mechanisms and efficient manipulation of exercise variables (i.e. 
intensity, duration, volume, etc.) both to detect changes in the outcome variable of 
interest, in this case FMD.   
      Although investigations are focusing on the benefit of exercise to improve endothelial 
function in various clinical populations and conditions, the reproducibility of FMD 
following exercise remains to be investigated.  In view of the fact that exercise elicits 
many physiological changes (i.e. heart rate, blood pressure, sympathetic activity, etc.) 
that may influence the measurement of FMD, it seems imperative that the reproducibility 
of FMD following such stimulus is investigated.  The purpose of the present study was to 
determine if flow-mediated dilation is reproducible in response to acute exercise in a 
population that is susceptible to endothelial dysfunction.  Overweight men were recruited 
to represent a population susceptible to endothelial dysfunction; a cohort typically 
targeted in exercise intervention.   It was hypothesized that the FMD response to a bout 
of moderate intensity exercise would be similar on two different days. 
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METHODS 
 
Experimental Design     
     On two separate occasions, participants reported to the Indiana University Clinical 
Exercise Physiology Laboratory at 0730 hrs following an overnight fast (Corretti et al. 
2002).   The two trials were separated by at least 2 days to control for any training effects.  
Following pre-exercise FMD measurements, subjects were asked to walk on a motor 
driven treadmill for 45 minutes at 50% of their exercise capacity (VO2peak).  For each 
trial, FMD was assessed pre-exercise, immediately following exercise, and every hour for 
three hours thereafter.  
Subjects 
    Nine overweight men aged 46 to 66 years old participated in this investigation.  All 
subjects had prior physician approval to participate in this study.  Subjects were excluded 
if they 1) had any known cardiovascular, pulmonary or metabolic diseases, 2) had 
orthopedic problems that would limit their exercise tolerance, and 3) were on any 
medications that influence arterial compliance.  Following the guidelines for the 
ultrasonic assessment of endothelial dependent FMD of the brachial artery (Corretti et al. 
2002), subjects were asked to abstain from physical activity, tobacco products, and 
vitamin supplementation for 12 hours prior to each trial day.  All procedures were 
approved by the Indiana University Committee for the Protection of Human Subjects.  
Written informed consent was obtained from each subject prior to participation in the 
study.   
Brachial artery Flow-Mediated Dilation 
     Endothelial function was measured via brachial artery flow-mediated dilation (FMD).  
FMD was assessed pre-exercise, immediately, and 1, 2, and 3 hours following the 
cessation of exercise.  For each measurement (excluding the immediate), subjects were 
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instructed to lie supine for 20 minutes to establish a hemodynamic steady state in a 
climate controlled room (22°-24°C).  The brachial artery was imaged longitudinally by a 
2D high resolution Sonoace Pico ultrasound system (Universal Medical Systems, 
Bedford Hills, NY, USA) using a 7.0 MHz linear transducer,  placed 2-10 cm above the 
antecubital fossa.   Once a clear image was obtained, the transducer was placed in a 
stabilized holder and the position marked to ensure the same placement for each FMD 
measurement.  Following 20 minutes of acclimation, the average diameter and blood 
velocity for 10 cardiac cycles were recorded and analyzed for baseline values.  A 5 cm 
forearm occlusion cuff (D.E. Hokanson, Bellevue, WA, USA) was placed around the 
right forearm and rapidly inflated using compressed air (E-20 rapid cuff inflator, D.E. 
Hokanson, Bellevue, WA, USA) to induce occlusion and subsequent reactive hyperemia 
of the brachial artery.  Forearm occlusion was maintained for 5 minutes at 250 mm Hg.  
Doppler measurements of peak hyperemic blood velocity were made during the first 10 
seconds following rapid cuff release at an isonation angle of 70o (Harris et al. 2006; 
Wright et al. 2006)  before switching back to continuous 2D ultrasound imaging for the 
remainder of the 2 minute collection period.  EKG gaiting was utilized to capture end-
diastolic arterial diameters, triggered by the QRS complex, which were analyzed using 
the Vascular Analysis Integrative System (Medical Imaging Applications, Coralville, 
Iowa, USA). The highest 10 second averaged interval throughout the 2 minute collection 
period represented the peak hyperemic diameter.   Hyperemic velocity and baseline 
diameter were converted to hyperemic local shear stress (HLSS) using the following 
equation (Mitchell et al. 2004): HLSS = 8 x μ x VH/DBL, where μ is blood viscosity, 
assumed to be 0.035 dyne x s/cm2, VH is peak hyperemic velocity, and DBL is baseline 
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diameter.  FMD is expressed as a percent increase in diameter from baseline and 
calculated as: FMD = (peak hyperemic diameter – baseline diameter)/ baseline diameter.  
All image acquisitions were performed by the same investigator.  In addition, all 
measurement analyses were performed by the same investigator who was blinded to the 
trial. Intra-observer reliability yielded an ICC of 0.987 with a variation of 2.2%. 
Treadmill Exercise 
    Prior to the start of the investigation each subject performed a maximal treadmill 
exercise test to obtain their peak oxygen consumption (VO2peak).  VO2peak was then used 
to calculate the moderate intensity exercise (50% of VO2peak) to be performed for each 
trial.  Following pre-exercise FMD measurements, subjects were instructed to walk on a 
motor driven treadmill at 50% VO2peak for 45 minutes.  Sensor Medics 2900 metabolic 
cart (Sensor Medics Corporation, Yorba Linda, CA, USA) was used to collect expired 
gases between the 5th and 10th minute to confirm the appropriate exercise intensity.  The 
work rate was adjusted if the VO2 was not within ± 5% of the target exercise intensity.  
Expired gases were then measured again between the 10th and 15th minute to confirm the 
new exercise intensity.  Heart rate (EKG lead II), blood pressure (auscultation), and 
rating of perceived exertion (RPE; Borg Scale 6-20) were recorded every 5 minutes to 
ensure similar exercise induced stimuli between trials.  For trial 2, the same speed and 
grade as the previous trial was utilized; however actual VO2 was not measured.  
Assessment of Reproducibility 
     Reproducibility of brachial artery FMD following exercise was assessed utilizing an 
ANOVA, Intra-class correlation coefficients (ICC), Pearson correlation coefficients (r), 
and coefficients of variation (CV) for: FMD, baseline diameter, peak hyperemic 
diameter, baseline blood velocity, peak hyperemic blood velocity, and hyperemic local 
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shear stress at each time period between trials.  In addition, to determine the 
reproducibility of FMD in response to acute exercise, area under the curve (AUC) in 
arbitrary units (au) and a Bland-Altman (Bland and Altman 1986) plot were utilized.  
AUC for each trial was calculated by summing the area of successive trapezoids in 
relation to the pre-exercise values and assessed by ICC.  The ICC, r, and CV was 
reported for the mean FMD at each time period between trials.  Since FMD is expressed 
as a percent and is very sensitive to changes in baseline diameter, coefficients of variation 
prime (CV’) has also been reported as a measurement of FMD reproducibility 
(Herrington et al. 2001) and utilized in our assessment.  CV’ was calculated and reported 
for the same variables as CV.  ICC values of <0.40, 0.40-0.75, and >0.75 represent poor, 
fair to good, and excellent agreements, respectively (Landis and Koch 1977).  A non- 
significant F-ratio, Intra-class correlation coefficients (ICC) and Pearson correlation 
coefficients greater than fair-to-good  (Landis and Koch 1977), and CV’s less than 35% 
were deemed acceptable.  Four acceptable assessments were required to confirm 
reproducibility. 
Statistical Analysis 
     Descriptive statistics were used to describe the sample characteristics.  A two-way 
(trial x time) repeated measures ANOVA was performed to identify differences in: FMD, 
baseline diameters, peak hyperemic diameters, baseline blood velocity, peak hyperemic 
blood velocity, and hyperemic local shear stress.   ICC, Pearson correlation coefficients 
and CV between trials were determined for FMD, baseline diameter, peak hyperemic 
diameter, baseline blood flow, peak hyperemic blood flow, and hyperemic local shear 
stress at each time period. The ICC for the FMD AUC between trials was also 
determined.  A Bland-Altman plot was used to assess the agreement between trial 1 and 
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trial 2.  CV and CV’ were calculated for each subject from the mean and SD of both trials 
as follows: CV(%) = ((SD/mean) x 100) and CV’ = ((100 x SD)/(mean + 100) 
(Herrington et al. 2001).    All data are reported as mean ± SEM.  Significance was set at 
p<.05.   
RESULTS 
 
    Subject characteristics are presented in Table 1.  Recorded exercise outcome variables 
were similar (p>.05) between trials: heart rate (110.11±5.4 vs. 107.1±5.5), systolic blood 
pressure (137.5±6.0 vs. 133.4±3.0), diastolic blood pressure (71.3±2.5 vs. 71.4±22.8), 
and RPE (11.54±0.53 vs. 11.48±0.55).        
     The AUC for the FMD response to exercise for each trial was -8.4±3.8 (au) and            
-4.8±2.1 (au).  The ICCAUC  for the FMD response to exercise was 0.414.  Figure 1 
illustrates the FMD(%) response to a single bout of moderate intensity exercise between 
trials.  The ANOVA indicated no differences (F1,8 = .01; p=.942) in FMD(%) between 
trial 1 and trial 2 collapsing for all time periods investigated.  There were also no 
differences in baseline diameter (F1,8 = .39; p=.549), peak hyperemic diameter (F1,8 = .94; 
p=.360), baseline blood flow (F1,8 = .42; p=.535), peak hyperemic blood flow (F1,8 = .64; 
p=.448), and hyperemic local shear stress (F1,8 = .31; p=594) between trial 1 and trial 2 
among all time periods investigated. The absolute difference in FMD(%) between the two 
trials was as follows: pre-exercise 0.79±1.00%, immediately post exercise 0.36±0.74%, 1 
hr post exercise 0.51±0.72%, 2 hr post exercise 0.22±1.15%, and 3 hr post exercise 
0.32±0.71%.   
     The ICC’s and Pearson correlations for all variables at each individual time period are 
presented in Table 2.  The mean ICCFMD and Pearson correlation for each time period 
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between trials was 0.911; p=.019 and 0.958; p=.01, respectively.  Figure 2 illustrates the 
significant correlation (r = 0.579; p<.001) between trial 1 and trial 2 utilizing all FMD(%) 
measurements.  The Bland-Altman plot is illustrated in figure 3.  Table 3 displays the CV 
and CV’ for all investigated variables among the three hour time course studied.   In 
summary, acceptable criteria was met for all assessments of reproducibility. 
DISCUSSION 
 
     The present study investigated the reproducibility of FMD over a three hour time 
period in a population susceptible to endothelial dysfunction.  The ANOVA detected no 
differences in FMD between trials (Figure 1), ICC and correlations were all > 0.40 (Table 
2), the average CV was well under the 35% criteria set (Table 3), and the Bland-Altman 
plot suggests an agreement between trial 1 and trial 2.  These data support our hypothesis 
that the FMD response to moderate intensity acute exercise is reproducible.    In addition, 
these findings confirm the use of an acute exercise paradigm when studying the favorable 
effects of exercise. 
    Roughly 60% of the United States population is overweight.  Overweight men were 
recruited for this study to 1) represent a population susceptible to endothelial dysfunction 
and 2) elicit a response to the stimuli (exercise).  Studies have shown an improvement in 
endothelial function in populations susceptible to endothelial dysfunction following acute 
exercise (Gaenzer et al. 2001; Harvey et al. 2005), whereas no change was observed in 
their control counterparts.  Although the pre-exercise FMD did not appear compromised 
in our subjects, the acute exercise stimulus elicited a response in FMD that was 
consistently observed for both trials.  
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     Investigations have been conducted to evaluate the stability of brachial artery FMD 
under controlled resting conditions, and report it to be reproducible (Hijmering et al. 
2001; Welsch et al. 2002; West et al. 2004).  In contrast, some researchers have found the 
measurement of FMD to be ‘invalid’ when observing FMD in healthy volunteers on 
multiple occasions mainly because of physiological factors (Hijmering et al. 2001) (ie. 
time of day and dietary intake) and reading variation (De Roos et al. 2003).  By following 
the guidelines (Corretti et al. 2002), the confounding physiological factors suggested by 
Hijmering (2001) did not influence the robustness of our findings.          
     Exercise introduces physiological changes (i.e. sympathetic and vascular) which may 
influence the reproducibility of FMD.  It has long been known that there are protective 
cardiovascular benefits associated with exercise.  Most importantly, exercise plays a 
multifaceted beneficial role in the improvement of endothelial function as well as the 
reduction in cardiovascular disease risk.  The intensity and duration of exercise utilized in 
the present investigation complies with the current exercise recommendation for 
prevention and treatment of disease (ACSM 2005).  Moreover, the present study found 
similar responses to exercise in heart rate, blood pressure, and the subjects rating of 
perceived exertion between trials.  FMD AUC was utilized to represent the global 
response to exercise.  The AUC is a way to normalize the FMD response to pre-exercise 
values.  Our results depict an acceptable ICC for the FMD AUC suggesting that each 
subject’s response to exercise was similar on two separate days, which has never been 
reported to our knowledge. 
     There is no single ideal criterion used in practice to assess the reproducibility of 
brachial artery FMD (Corretti et al. 2002).  Within any measurement of conduit artery 
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endothelial function, physiological factors may introduce a wide array of confounding 
variables.   In an attempt to establish consistency and standardization when measuring 
brachial artery FMD, Corretti and colleagues (2002) published guidelines for the 
ultrasonic assessment of brachial artery endothelial function.  These guidelines suggest 
performing correlation coefficients (r), mean differences, and coefficients of variations 
(CV) as a complete approach to report reproducibility of FMD.   The present study 
incorporated multiple indices of reproducibility, including all three suggested by the 
guidelines.   
     Furthermore, there is no concrete threshold when observing the reproducibility of the 
FMD measurement.  For example, in biological analysis, a CV < 20% is traditionally 
accepted to define reproducibility of multiple assayed samples.  Given that FMD is 
expressed as a percent increase, it is very sensitive to a small change in arterial diameter.  
It is unclear what the CVFMD reported in literature represents.  It may represent the CV of 
the baseline diameters, post hyperemic diameters, the standard deviation, or perhaps even 
the magnitude of change (De Roos et al. 2003).  Due to the sensitive nature of the FMD 
measurement, the reported CV in literature have been above the acceptable CV for 
biochemical analysis; however, based on the guidelines of ultrasound assessment, a mean 
difference in FMD over time that is within 2-3% is acceptable (Corretti et al. 2002).  In 
an average brachial artery FMD of 10%, this would translate to an FMD reproducibility 
criterion for CV’s between 20-35%. West and colleagues (2004) reported a CVFMD = 
29.7% for individuals with Type 2 diabetes and stated their findings were within the low 
range of published values for CVFMD of healthy individuals. The average CVFMD reported 
in the present study falls below that reported by West and colleagues (2004) and is well 
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within the lower end of the calculated acceptable range suggested by the guidelines; 
albeit introducing exercise prior to the assessment of FMD reproducibility.  In addition, 
the present study evaluates the reproducibility of FMD using several methods, of which 
all demonstrate FMD and the primary components (i.e. diameters, velocities, and shear 
stress) to be reproducible. 
     Day to day FMD variation under resting controlled conditions has previously been 
reported for healthy controls as well as in clinical populations (Kanani et al. 1999; Roos 
et al. 2002; Sorensen et al. 1995; Uehata et al. 1997).  The CVFMD for these investigations 
has ranged from 2-84% and has been assessed the same day or on different days.   
Variability in FMD is most likely a result of measurement error, biological variability, 
and differences in technique over repeated testing sessions (De Roos et al. 2003).  Flow-
mediated dilation variability may also be attributed to the uncontrolled nature of the 
evoked shear stress stimulus (Pyke et al. 2004), one of the most important stimulus for 
vasodilation.  Pyke and colleagues (2004) demonstrate a reduction in FMD variation 
(CVFMD = 36.16% vs. 51.8%, respectively) utilizing a controlled hyperemia test 
compared to a reactive hyperemia test.  In the present study, the ICCHLSS shows evidence 
of an excellent agreement between trials, suggesting similar stimuli on both days and 
validity of our FMD measurements.  In addition, the ICC’s for both baseline and peak 
hyperemic diameter between trials exhibit an excellent agreement which is consistent 
with literature (De Roos et al. 2003).   
     The sample size needed to assess reproducibility of FMD in recent published literature 
has ranged from as few as three subjects (Kanani et al. 1999) to as many as 127 subjects 
(Herrington et al. 2001).  In addition, the number of FMD measurements has ranged from 
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2-6 in a single day period (De Roos et al. 2003) up to 2-5 one month apart (Uehata et al. 
1997).  The present study investigated nine subjects following exercise on two separate 
days which fall within the controlled FMD reproducibility power criteria reported in the 
literature (Hashimoto et al. 1995; Kanani et al. 1999; Lundman et al. 1997; Uehata et al. 
1997). 
     Conclusions.  Although FMD has been utilized as a primary non-invasive 
measurement of endothelial dysfunction following acute and chronic exercise, the present 
study is the first of its kind to evaluate the reproducibility of FMD following (acute) 
exercise.  The findings of the present investigation support the hypothesis that FMD in 
response to acute exercise is reproducible.  In addition, the inclusion of FMD 
reproducibility using AUC is a novel aspect of the present investigation.  Our findings 
support the reproducibility of FMD as an outcome variable in response to acute exercise 
in subjects susceptible to endothelial dysfunction.   
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Figure 1.  
The FMD response to acute exercise on two separate days. 
 
Figure 2.  
The relationship of FMD across time between trial 1 and trial 2. 
 
Figure 3. 
Agreement of trial 1 and trial 2 using the Bland-Altman plot 
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Table 1. Subject Characteristics  
Variables   
Age, years 57.1±2.3 
BMI, kg/m2 29.2±0.9 
Systolic blood pressure, mm Hg 114±3.0 
Diastolic blood pressure, mm Hg 75±3.2 
VO2peak, ml/kg/min 33.8±1.4 
Total cholesterol, mg/dL 198.7±15.0 
HDL cholesterol, mg/dL 48.3±5.3 
LDL cholesterol, mg/dL 119.8±13.3 
Triglycerides, mg/dL 153±25.0 
Fasting glucose, mg/dL 94±1.6 
C-reactive protein, mg/L 3.9±1.9 
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Table 2. Intra Class Correlation Coefficients and Pearson correlations for each time period     
  Immediately      
Variable Pre-Exercise  Post   1 Hr Post  2 Hr Post  3 Hr Post 
Flow-mediated dilation  0.602 / 0.432 0.840 / 0.734  0.632 / 0.486 0.724 / 0.573 0.631 / 0.464 
Baseline diameter  0.958 / 0.923 0.975 / 0.953  0.933 / 0.879 0.949 / 0.949 0.979 / 0.972 
Peak hyperemic diameter  0.930 / 0.876 0.983 / 0.967  0.941 / 0.890 0.977 / 0.961 0.966 / 0.938 
Baseline blood velocity  0.711 / 0.558 0.577 / 0.415  0.560 / 0.400 0.543 / 0.414 0.577 / 0.475 
Peak hyperemic blood velocity  0.613 / 0.442 0.827 / 0.705  0.767 / 0.689 0.812 / 0.734 0.770 / 0.680 
Hyperemic local shear stress  0.854 / 0.748  0.931 / 0.871   0.860 / 0.800  0.865 / 0.871  0.876 / 0.879 
Values are presented as ICC / r.  ICC's and r >0.400 were deemed acceptable.    
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Table 3. Comparison of variables for both trials among all time periods investigated                
         Pre-Exercise      Immediately Post           1 Hr Post           2 Hr Post           3 Hr Post Average 
Variable Trial 1 Trial 2   Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2 
CV/CV' 
(%) 
Flow-mediated dilation (%) 7.8±1.0 7.0±0.9  5.0±0.9 5.3±1.1 5.4±0.6 5.9±0.8 5.9±1.2 5.7±1.3 5.0±0.7 5.4±0.6 25.2/1.3 
Baseline diameter (mm) 4.13±0.14 4.08±0.13  4.15±0.15 4.12±0.15 4.16±0.16 4.13±0.14 4.07±0.16 4.06±0.12 4.13±0.16 4.10±0.13 2.3/0.1 
Peak hyperemic diameter (mm) 4.46±0.16 4.36±0.14  4.36±0.15 4.33±0.16 4.40±0.15 4.35±0.15 4.32±0.18 4.28±0.16 4.32±0.15 4.32±0.13 2.0/0.1 
Baseline blood velocity (cm/s) 20.9±3.0 21.8±3.4  25.2±1.8 29.2±2.3 17.6±2.2 15.8±2.3 13.3±1.3 13.5±2.1 11.0±0.8 11.9±1.4 18.0/2.8 
Peak hyperemic blood velocity 
(cm/s) 93.9±4.7 91.4±4.7  87.9±4.8 88.9±4.6 97.3±7.4 84.6±4.2 80.3±3.7 82.1±4.3 79.2±4.9 83.7±5.9 8.9/4.2 
Hyperemic local shear stress 
(AU) 6.5±0.5 6.6±0.5   6.3±0.5 6.2±0.5 6.0±0.5 6.5±0.6 5.9±0.5 6.0±0.6 6.1±0.7 5.8±0.5 10.0/0.6 
Values are mean± SEM. CV = ((SD/mean) x 100); CV’ = ((100 x SD)/(mean + 100).          
No significant (p<.05) differences were observed between trials.         
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ABSTRACT 
 
Background – Inflammation has been found to play a role in the etiology of 
cardiovascular disease as well as provoke endothelial dysfunction.  Inflammatory 
cytokines associated with endothelial function include IL-6 and TNF-α.  IL-6 is exercise 
intensity dependent and has been shown to directly inhibit TNF-α expression. The aim of 
the present study was to investigate the interaction of IL-6 and TNF-α on endothelial 
function in response to acute exercise in overweight men exhibiting different physical 
activity profiles.   
Methods and Results – In a randomized mixed factorial design 16 overweight men (8 
active, VO2peak = 34.2±1.7, BMI = 27.4±0.7 and 8 inactive, VO2peak = 30.9±1.2, BMI 
= 29.3±1.0) performed three different intensity acute exercise treatments.  Brachial artery 
Flow-Mediated Dilation (FMD) and subsequent blood samples were taken pre-exercise 
and 1 hr following the cessation of exercise.  Although intensity did not influence the 
FMD response, a significant (P =.002) group x time interaction indicated the two groups 
responded differently.  Elevated (P<.001) concentrations of IL-6 following moderate 
(50% VO2) and high (75% VO2) intensity acute exercise were observed in both groups; 
however, concentrations of TNF-α were unchanged in response to acute exercise (P 
=.584).   
Conclusion – The FMD response to acute exercise is enhanced in active men who are 
overweight, whereas inactive men who are overweight exhibit an attenuated response.  
The interaction of IL-6 and TNF-α did not provide insight into the physiological 
mechanisms associated with the differential FMD response observed between groups.   
 
Key Words: physical activity, endothelial function, inflammation, cardiovascular disease 
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INTRODUCTION 
 
     Obesity has emerged as a problematic epidemic in the United States and has recently 
been considered an independent risk factor for atherosclerotic cardiovascular disease.1     
Atherosclerosis is a progressive inflammatory disease characterized by the accumulation 
of lipids and fibrous elements in medium to large arteries 2 and is a manifestation of 
endothelial dysfunction.3, 4  Brachial artery flow-mediated dilation (FMD) is a measure of 
nitric oxide dependent vasodilation and represents a non-invasive measurement of 
endothelial function.  Unsurprisingly, individuals who are overweight or obese exhibit an 
increase in systemic inflammation5 and are more likely to develop risk factors and co-
morbidities of cardiovascular disease.  There appears to be a positive relationship 
between overweight and all cause mortality in men6; however, overweight men who are 
active may have a lesser risk for heart disease than their sedentary counterparts.7 
     Inflammation has been found to play a role in the pathogenesis of coronary heart 
disease and provoke endothelial dysfunction.8, 9  High sensitive C-reactive protein 
(CRP)10, Tumor Necrosis Factor- Alpha (TNF-α)11, and Interleukin-6 (IL-6)12 are all bio-
markers of systemic inflammation which have been associated with future atherosclerotic 
events.  Recently, IL-6 has been proposed to provide anti-inflammatory effects13 and 
accepts the role as a myokine,14 a cytokine secreted from active skeletal muscle. The 
production of  IL-6 is exercise intensity dependent13 and has been shown to directly 
inhibit TNF-α expression in cardiac muscle15 and skeletal muscle.13  In a longitudinal 
study, Drenth and colleagues16 found that exercise (training) increased IL-6, attenuated 
TNF-α, and reduced the acute inflammatory response.  Consequently, the augmentation 
of FMD associated with acute exercise17, 18 may be linked to the exercise induced IL-6 
mediated TNF-α suppression; which has not been investigated.  The physiological 
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mechanisms underlying the anti-atherogenic effects of the exercise associated 
improvements in endothelial function remain ambiguous.19  The specific counteracting 
effects of IL-6 observed on TNF-α13, 15 has led us to believe that the exercise induced 
increase in IL-6 may play a role in regulating the pro-inflammatory response and 
subsequent enhancement in FMD.   
     The aim of the present study was to investigate the interaction of IL-6 and TNF-α on 
the FMD response to acute exercise of different intensities in overweight men exhibiting 
different physical activity profiles.  It was hypothesized that 1) the FMD response 
following acute exercise would be enhanced in overweight active men when compared to 
their inactive counterparts 2) baseline CRP and TNF-α would be elevated in the inactive 
men who are overweight compared to their active counterparts, 3) IL-6 would exhibit a 
positive exercise intensity dependent association, which would decrease the 
concentrations of TNF-α and provide a possible mechanism associated with the 
improvement in FMD. 
 
METHODS 
 
Experimental Design 
 
     In a randomized mixed factorial design subjects performed three different acute 
exercise treatments, separated by at least two days apart.  Prior to each exercise 
investigation day, subjects were instructed to report to the Indiana University Clinical 
Exercise Physiology Laboratory at 0730 hrs having 1) fasted from the night before, 2) 
abstained from exercise for 24 hrs, and 3) abstained from caffeine and tobacco for 12 hrs.  
Following an initial left upper extremity venous catheter placement, brachial artery Flow-
Mediated Dilation (FMD) and subsequent blood samples were taken pre-exercise and 1 
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hr following the cessation of exercise.  Subjects were asked to remain in the laboratory 
and perform sedentary activities between measurements. 
Subjects 
 
     Sixteen overweight men ages 46 to 68 years participated in this investigation.  
Subjects were classified into either an active (n=8) or inactive (n=8) group.  Overweight 
was defined as having a body mass index (BMI) > 25 kg/m2.  Physically active was 
defined following the Surgeon General’s guidelines20; 30 minutes of moderate physical 
activity most days of the week.   Subjects were excluded if they 1) had prior history of 
cardiovascular disease, pulmonary disease or diabetes, 2) could not exercise at 75% VO2 
peak for 45 minutes, 3) had a known allergy to heparin, 4) had orthopedic problems that 
would limit their exercise, or 5) were on any medications that influence vascular 
compliance.  Subjects were asked to abstain from prophylactic aspirin and vitamin 
supplementation three days prior to the start of the study and throughout the investigation 
time period.  All procedures were approved by Indiana University’s Committee for the 
Protection of Human Subjects and the Institutional Biosafety Committee.  Written 
informed consent was obtained from each subject prior to participation in the study.   
 
Risk Stratification and Screening 
 
     Eligibility to participate in this investigation was determined by risk stratification.  A 
risk stratification form detailing information of medical/family history of disease, height 
and weight, and current medications was completed by all subjects following initial 
informed consent.  In addition, a fasting venous blood draw was performed to obtain 
CRP, total serum cholesterol, low density lipoprotein cholesterol, and high density 
lipoprotein cholesterol. 
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Maximal Graded Exercise Test 
 
     The maximal graded exercise test was performed to measure the subjects maximal 
exercise capacity (VO2peak) and obtain each subjects individual exercise treatment 
intensity.  Briefly, subjects walked at a predetermined speed on a motor-driven treadmill 
with the grade increasing 2.5% every two minutes until volitional fatigue.  Expired gases 
were collected into a mixing chamber through a unidirectional flow mouthpiece and 
analyzed using a Sensor Medics 2900 Metabolic Cart (Sensor Medics, Yorba Linda, CA).  
A maximal test was confirmed using the American College of Sports Medicine maximal 
exercise test criteria. 
 
Flow-Mediated Dilation Acquisition/Analysis 
 
     Endothelial function was measured via brachial artery Flow-Mediated Dilation 
(FMD).  FMD was measured pre-exercise and 1 hr following the cessation of exercise.  
For each FMD measurement, subjects were instructed to lie supine in a climate controlled 
room (22°-24°C) for 20 minutes to establish a hemodynamic steady state.  The brachial 
artery was imaged longitudinally by a 2D high resolution Sonoace Pico ultrasound 
system (Universal Medical Systems, Bedford Hills, NY) using a 7.0 MHz linear 
transducer, placed 2-10 cm above the antecubital fossa.   Once a clear image was 
obtained, the transducer was stabilized in a holder and the position was marked to ensure 
the same placement for each FMD measurement.  The average diameter and blood 
velocity for 10 cardiac cycles was recorded and analyzed for baseline values.  Following 
baseline measurements, A 5 x 84 cm forearm occlusion cuff (D.E. Hokanson, Bellevue, 
WA) was placed around the subjects’ right forearm and rapidly inflated (E-20 rapid cuff 
inflator, D.E. Hokanson, Bellevue, WA) to induce occlusion for 5 minutes at 250 mm Hg 
and subsequent reactive hyperemia.  Doppler measurements of peak hyperemic blood 
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velocity were made during the first 10 seconds following cuff release at an isonation 
angle of 70o before switching back to continuous 2D ultrasound imaging for the 
remainder of the 2 minute collection period.  EKG gaiting was utilized to capture end-
diastolic arterial diameters, triggered by each QRS complex, which were analyzed using 
the Vascular Analysis Integrative System (Medical Imaging Applications, Coralville, 
Iowa).  The highest 10 second averaged interval throughout the 2 minute post occlusion 
collection period represented the peak hyperemic diameter.  Hyperemic velocity and 
baseline diameter were converted to hyperemic local shear stress (HLSS) using the 
following equation21: HLSS (arbitrary units, AU) = 8 x μ x VH/DBL, where μ is blood 
viscosity, assumed to be 0.035 dyne x s/cm2, VH is peak hyperemic velocity, and DBL is 
baseline diameter.  FMD is expressed as a percent increase in diameter from baseline and 
calculated as: FMD = (peak hyperemic diameter – baseline diameter)/ baseline diameter.  
All image acquisitions were performed by the same investigator.  In addition, all 
measurement analyses were performed by the same investigator who was blinded to the 
exercise treatment. 
 
Acute Exercise Treatments 
 
     Immediately following pre-exercise measurements, subjects’ performed either a low 
(25% VO2peak), moderate (50% VO2peak), or high (75% VO2peak) intensity treadmill 
walking session for 45-minutes.  Each exercise treatment was separated by at least 2 days 
to eliminate any training effect.  Oxygen uptake (VO2) was measured via a Sensor 
Medics 2900 metabolic cart  between the 5th and 10th minute of each exercise treatment to 
confirm the appropriate exercise intensity.  The work rate was adjusted if the VO2 was 
not within ± 5% of the target exercise intensity.  Expired gases were then measured again 
between the 10th and 15th minute to confirm the new exercise intensity.  Heart rate 
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(EKG), blood pressure (auscultation), and rating of perceived exertion (Borg Scale 6-20) 
were measured every 5 minutes throughout each exercise session. 
 
Laboratory Procedures 
 
     All blood samples were collected from each subject and transferred into 
ethylenediaminetetraacetic acid (EDTA) tubes after an overnight fast (pre-exercise) and 1 
hr following the cessation of exercise.  All blood was centrifuged immediately at 1,000 x 
g for 15 minutes.  The plasma supernatant was immediately transferred into microtubes 
and stored at -80°C until analyzed.  Concentrations of TNF-α and IL-6 were measured 
using a high sensitive Enzyme-Linked Immunosorbent Assay (ELISA) kit according to 
manufacture specifications (R & D Systems, Minneapolis, MN).  The mean detection 
limits of the kits are 0.106 pg/mL and 0.039 pg/mL for TNF-α (4th generation) and IL-6 
(3rd generation), respectively.  All samples were run in triplicate.  Sample concentrations 
that fell above a coefficient of variation (CV) of 20% were re-run.  The mean 
concentration of each sample was used in the statistical analyses. Concentrations of CRP, 
triglycerides, cholesterol and lipid sub-fractions (HDL and LDL) were obtained by 
standard laboratory procedures and only collected for pre-investigation characteristic 
values. 
 
Statistical Analysis 
 
     Descriptive statistics and independent t tests were utilized to compare subject 
demographics and exercise induced physiological variables between groups.  To 
determine the FMD, IL-6 and TNF-α response to acute exercise, comparisons were made 
using three-way (group x intensity x time) mixed factorial ANOVA’s (SPSS Inc., 
Chicago, IL, USA: V 14.0).  For any significant interactions, simple main effects were 
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employed.  When indicated by a significant F-ratio, Dunnett’s post hoc analysis was 
performed to identify differences.  All data are expressed as mean ± standard error of the 
mean (SEM).  Statistical significance was set at P<0.05. 
 
RESULTS 
 
Subject Characteristics 
 
     Sixteen subjects were recruited for this investigation and were placed into either an 
active (n=8) or inactive (n=8) group based on their physical activity profile.  Table 1 
summarizes the subject’s characteristics.  The active group reported more physically 
active days per week when compared to the inactive group (4.4±0.5 vs. 0.7±0.3; 
(P<.001), whereas all other physical characteristics were similar between the two groups.   
 
HR, BP, RPE, and VO2 in Response to Acute Exercise 
 
     Table 2 illustrates the heart rate (HR), blood pressure (BP), rating of perceived 
exertion (RPE), and oxygen consumption (VO2) in response to acute exercise of different 
intensities.  Oxygen consumption is presented as the absolute VO2 obtained in response 
to acute exercise, as well as the VO2 obtained expressed as a percentage of VO2peak.  No 
differences  in exercise induced physiological variables were identified among acute 
exercise intensities between groups. 
 
FMD in Response to Acute Exercise 
 
    Figure 1 illustrates the effect of exercise intensity on the FMD response 1hr following 
the cessation of exercise in overweight men who are active and inactive.  For both 
groups, the FMD response was similar (F2,28 = .02; P =.982) independently of exercise 
intensity.  Although intensity did not influence the FMD response, a significant (F1,14 = 
14.22; P =.002) group x time interaction indicated the two groups responded differently. 
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Pre-exercise FMD was similar (F1,14 = 0.21; P =.654) between groups; therefore, the 
FMD values were normalized to reflect the absolute response to exercise.  Figure 2 
illustrates the group x time interaction (F1,14 = 14.22; P =.002)for post-exercise FMD 
normalized to pre-exercise values.  Independent of exercise intensity, the active group 
displayed a 24% increase (F1,14 = 5.49; P =.034) in FMD following acute exercise 
compared to a 32% decrease (F1,14 = 8.95; P =.010) in the inactive group.  Baseline 
arterial diameters, baseline and hyperemic blood velocities, and hyperemic local shear 
stress are presented in Table 3.  For both groups, baseline diameters decreased (P=.03) 
following the low intensity acute exercise, no change (P=.725) was observed for the 
moderate intensity exercise; however, an increase (P=.002) following high intensity acute 
exercise was observed.  In addition, baseline blood velocity was decreased (P=.019) 1 hr 
following exercise in both groups independent of exercise intensity.  The active group 
displayed a decrease (P=.006) in hyperemic velocity following acute exercise 
independent of exercise intensity, whereas no change was observed in the inactive group.  
It is important to note that no differences in hyperemic local shear stress upon cuff 
release, a stimulus for vasodilation, were observed for either group throughout the 
analysis. 
 
IL-6 in Response to Acute Exercise 
 
     Pre-exercise concentrations of IL-6 were similar (F1,14 = 1.38; P =.259) between the 
active and inactive groups (1.3±0.3 pg/mL vs. 1.8±0.3 pg/mL, respectively).  ANOVA 
indicated a significant (F2,28 = 27.17; P<.001) intensity x time interaction for the IL-6 
response to exercise.  Figure 3 illustrates, for both groups, a significant elevation in 
plasma concentrations of IL-6 following moderate and high intensity acute exercise (F1,28 
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= 27.32; P<.001 and F1,28 = 99.61; P<.001, respectively), whereas no change (F1,28 = 
0.19; P =.669) in IL-6 was observed following low intensity exercise. 
 
TNF-a in Response to Acute Exercise 
 
        No differences (F1,14 = 0.31; P =.584) in pre-exercise concentrations between groups 
were observed.  In addition, no change (F1,14 = .00; P =.983) in plasma TNF-α in 
response to acute exercise was observed in either group.  Figure 4 illustrates plasma 
concentrations of TNF-α in response to different intensities of acute exercise between 
groups. 
 
DISCUSSION 
 
     The aim of the present study was to investigate the interaction of IL-6 and TNF-α on 
the FMD response to acute exercise of different intensities in overweight men exhibiting 
different physical activity profiles.  Our findings support the main hypothesis that FMD 
in response to acute exercise would be enhanced in overweight active men when 
compared to their inactive counterparts; however, the pro- and anti- inflammatory state 
pre- as well as post- exercise may not explain the improvement in FMD observed. 
     Elevated BMI is associated with higher concentrations of CRP.5  It was hypothesized 
that the state of global systemic inflammation would differ between overweight men who 
exhibited different physical activity profiles.  Although the baseline characteristic of CRP 
does not exhibit a statistical difference, there appeared to be a trend towards separation 
between the two groups.  In addition, contrary to our original hypothesis, there is no 
difference in the pre-exercise concentrations of TNF-α between groups.  This similarity 
may be explained by a recent study by Van Guilder and colleagues22 who found similar 
concentrations of TNF-α between normal weight and obese subjects; however, the obese 
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who presented with metabolic syndrome exhibited significantly elevated concentrations 
of TNF-α when compared to the normal weight subjects and the obese without metabolic 
syndrome.  Further, the similar TNF-α response to acute exercise leads us to believe that 
the change in FMD observed in overweight men is independent of this plasma marker of 
inflammation. 
     TNF-α is postulated to be the first responder of the pro-inflammatory cytokine family, 
whereas IL-6 is typically the last responder.16  The production of IL-6 during exercise is 
related to the intensity and duration of the exercise.13  The findings of the present study 
strongly support this phenomenon.  It is possible that the increase in IL-6 in response to 
moderate and high intensity exercise inhibited the TNF-α response, however, the 
response of IL-6 and TNF-α to acute exercise was similar in both groups, which does not 
explain the different response in endothelial function.  Although no changes in plasma 
TNF-α were observed, evidence supports an increase in myocardial TNF-α expression 
immediately following an acute bout of moderate intensity exercise of similar duration.23  
It is important to note that a possible increase in TNF-α may have appeared prior to the 1 
hr post-exercise time period evaluated in the present study; again, the similar cytokine 
concentrations pre- and post- exercise observed between the two groups would suggest 
the timing of the post-exercise measurement did not influence the difference in FMD 
observed.  There are many benefits from habitual exercise that may elucidate 
cardioprotective effects and explain the different FMD response observed between the 
two groups. 
     There is substantial evidence suggesting that habitual exercise enhances FMD in 
healthy as well as clinical populations.24, 25  Exercise training has been shown to augment 
blood flow and shear stress, which in turn increases NO production, leads to an increase 
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in NO bioavailability,26 and enhances endothelial function.27  A strong association exists 
between inflammation and training intensity28, 29 which may have an impact on the FMD 
response to exercise.  In the present study, both groups received the same relative 
exercise intensity (stimuli) which is evident by the similar response of physiological 
variables.  Further, the present study investigated the FMD in response to acute exercise, 
there does not appear to be an effect of exercise intensity for either group.  These findings 
are in contrast to Goto and colleagues30 investigation who have reported an improvement 
in endothelial function following moderate intensity exercise training, whereas no change 
following low or high intensity training was discovered.  The fact that there was a 
differential FMD response between groups; independent of exercise intensity, may 
suggest the use of a single exercise intensity when utilizing an acute exercise model. 
Evidence suggests that an acute bout of exercise can reduce triglycerides, reduce blood 
pressure, increase high density lipoprotein cholesterol, improve insulin sensitivity, and 
improve glucose homeostasis;31 therefore, utilizing an acute exercise model to investigate 
the anti-atherogenic effects in endothelial function is supported.  In general, the findings 
of the present investigation support the school of thought that being fit in overweight may 
reduce the hazards of obesity.6, 32, 33  More specifically, habitual exercise may reduce 
vascular expression of NAD(P)H oxidase which results in decreased local reactive 
oxygen species generation (ROS),34 increase antioxidant status,35 and/or improve insulin 
sensitivity.36  
    The increase in oxygen uptake during acute exercise produces an increase in oxidative 
stress (OS),37 which has been shown to impair endothelial function.38  The acute exercise-
induced OS may conceptually appear to contradict the enhancement in FMD observed 
following exercise.17, 18  Evidence supports an exacerbated oxidative stress response to a 
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single bout of exercise in obese subjects;37 however, active individuals have a greater 
resistance to acute exercise-induced oxidative stress.35  The extent of oxidative damage is 
not only a factor of ROS generation, but also the capacity of antioxidant defense.35  The 
resistance to acute exercise-induced ROS may be through the mechanism of (exercise) 
training induced enhanced antioxidant capacity.35  Although, subjects were instructed to 
abstain from vitamin supplementation throughout this investigation, the dietary influence 
of antioxidants between the active and inactive overweight men is unknown and may 
have influenced the FMD response.  The balance of pro- and anti- oxidant status may 
provide explanation to the endothelial function observed in response to acute exercise in 
the present study.  In addition, the improvement in insulin sensitivity associated with 
habitual exercise in obesity may be related to changes in skeletal muscle fatty acid 
metabolism and the enhancement of post absorptive fat oxidation.39  We can only 
speculate to the possible mechanism(s) involved in the different FMD responses observed 
in the present study. The physiological adaptations proposed may support the potential 
mechanism(s) associated with our findings; however, to our knowledge they have not 
been investigated in overweight or obesity following an oxidative challenge such as acute 
exercise. 
     In conclusion, the present study is the first of its kind to evaluate the FMD response to 
acute exercise of different intensities in overweight men. Our findings support the 
hypothesis that the FMD response to acute exercise is enhanced in overweight active men 
when compared to the attenuation observed in their inactive counterparts; however, the 
interaction of IL-6 and TNF-α does not support the disparity in FMD observed in 
response to acute exercise.  In general, it appears that physical activity profile is an 
independent determinant of the FMD response to acute exercise observed between the 
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two groups.  More specifically, habitual physical activity may result in an improvement 
in oxidative stress, antioxidant capacity, insulin resistance, and/or a combination of all 
three which may explain our results; however, future investigations of this kind in 
overweight and obesity are warranted. 
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FIGURE LEGEND 
 
Figure 1. The effect of exercise intensity on the FMD response 1hr following the 
cessation of exercise between groups.  Note: A significant group x time interaction exists 
independent of exercise intensity. 
 
Figure 2. Illustration of the group x time interaction, collapsing for exercise intensity, of 
FMD normalized to pre-exercise values. 
*Significant from pre-exercise values. 
†Significantly different from the inactive group. 
 
Figure 3.  The effect of acute exercise intensity on plasma concentrations of IL-6 between 
groups.  *Significant from pre-exercise values. 
 
Figure 4.  The effect of acute exercise intensity on plasma concentrations of TNF-α 
between groups.
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Table 1. Subject Characteristics    
Variables 
Inactive 
(n=8) 
Active 
(n=8) P 
Age, y 56.9±2.6 59.9±2.8 ns 
BMI, kg/m2 29.3±1.0 27.4±0.7 ns 
Systolic blood pressure, mm Hg 118.1±2.8 115±4.7 ns 
Diastolic blood pressure, mm Hg 79.4±2.7 73.3±2.3 ns 
Physical Activity, d/week 0.7±0.3 4.4±0.5 P<.001 
VO2peak, ml/kg/min 30.9±1.2 34.2±1.7 ns 
Total cholesterol, mg/dL 181.9±12.2 205.1±15.1 ns 
HDL cholesterol, mg/dL 48.0±5.5 54.3±5.3 ns 
LDL cholesterol, mg/dL 100.6±9.4 129.1±13.0 ns 
Triglycerides, mg/dL 166.8±27.0 108.4±15.8 ns 
Fasting glucose, mg/dL 95.0±1.6 92.4±3.2 ns 
C-reactive protein, mg/L 4.0±2.2 1.5±0.3 ns 
Values are mean ± SEM.    
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Table 2. Physiological variables in response to acute exercise            
   Low (25% VO2peak)   Moderate (50% VO2peak)       High (75%VO2peak) 
Variables Inactive Active  Inactive Active  Inactive Active 
Heart rate, bpm 87.8±3.6 75.5±2.9  113.9±5.3 105.4±3.3  143.1±4.3 139.4±4.1 
Systolic blood pressure, mm Hg 122.8±4.7 126±6.3  142.4±5.8 132.1±5.6  164.6±6.7 157.6±88.2 
Diastolic blood pressure, mm Hg 78.6±4.1 74.1±3.8  74.5±3.3 70.5±2.0  75.1±4.0 69.9±3.0 
Rating of perceived exertion 8.0±0.4 7.7±0.2  11.3±0.6 11.4±0.6  14.2±0.5 13.7±0.4 
VO2, ml/kg/min 8.0±0.2 8.7±0.4  15.6±0.7 17.3±0.8  23.3±1.1 25.8±1.3 
VO2, % 26.1±0.5 25.6±0.6  50.4±0.5 50.5±0.4  75.2±1.0 75.4±0.6 
Values are mean ± SEM.     
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Table 3. Pre- and post- exercise artery characteristics by group           
Inactive Group (n=8) Low (25% VO2peak)  Moderate (50% VO2peak)  High (75%VO2peak) 
Variables Pre-exercise 1 Hr Post  Pre-exercise 1 Hr Post  Pre-exercise 1 Hr Post 
Baseline diameters, mm 4.21±0.12 4.15±0.18*  4.08±0.16 4.12±0.18  4.04±0.15 4.30±0.19* 
Baseline velocity, cm/s 21.0±3.4 16.5±3.2*  20.5±2.4 18.5±2.4*  22.2±2.6 21.5±3.0* 
Peak hyperemic velocity, cm/s 107.0±3.8 99.1±8.0  96.2±8.1 104.4±5.6  98.9±4.0 103.2±5.4 
Hyperemic local shear stress, AU 7.2±0.4 6.8±0.7  6.7±0.7 7.3±0.7  6.9±0.4 6.8±0.4 
         
Active  Group (n=8) Low (25% VO2peak)  Moderate (50% VO2peak)  High (75% VO2peak) 
Variables Pre-exercise 1 Hr Post  Pre-exercise 1 Hr Post  Pre-exercise 1 Hr Post 
Baseline diameters, mm 4.16±0.16 4.00±0.14*  4.04±0.15 4.04±0.13  4.02±0.15 4.09±0.17* 
Baseline velocity, cm/s 18.5±2.2 14.2±2.1*  18.5±3.6 13.4±1.2*  15.1±1.9 13.6±1.1* 
Peak hyperemic velocity, cm/s 83.7±7.7 77.2±6.3*  89.3±7.9 82.5±9.0*  99.0±8.0 78.5±6.5* 
Hyperemic local shear stress, AU 5.7±0.6 5.5±0.5  6.3±0.7 5.7±0.6  7.0±0.6 5.5±0.6 
* Significant from pre-exercise.  Values are mean ± SEM.       
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APPENDIX A – REVIEW OF LITERATURE 
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INTRODUCTION TO ENDOTHELIAL FUNCTION 
 
     The endothelium is a thin monolayer of cells that lines the walls of all the vessels in 
the body (figure 1).  Until recently, the 
endothelium was thought to serve as an 
inert barrier.   Instead, the endothelium 
is suggested to be the largest organ in 
the body that plays multiple essential 
homeostatic functions.   
 
FUNCTIONS OF THE ENDOTHELIUM 
    
     Endothelial cells control 
thrombosis, inhibit leukocyte and 
platelet adhesion, promote intra-
arterial permeability, and regulate 
vascular smooth muscle tone (17, 
94, 119).  In addition, there are 
many substances released from the endothelium that aid in the function of the 
endothelium which include but are not limited to prostacyclin, nitric oxide (NO), 
endothelins, endothelial cell growth factors, interleukins, and plasminogen inhibitors.  
These substances either individually or in conjunction with one another provide different 
functions illustrated in figure 2, and described below. 
 
Control of Thrombosis and Platelet Adhesion 
     Endothelial cells are the major site for anticoagulant reactions involving thrombin 
(28).  Prostacyclin is the major endothelial derived anticoagulant that is released from 
Figure 1. Anatomy of veins and arteries (Spence 
1990)
Figure 2. Functions of a healthy endothelium 
(Landmesser et al. 2004). 
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thrombin, which is the same stimuli that activates platelets, ADP, and ATP (76). 
Aggregating platelets secrete serotonin and Thromboxane A2, which cause endothelium 
independent contraction (95).  A healthy endothelium maintains production of 
prostacyclin which limits the extent of platelet plug formation (53).  Furthermore, tissue 
type plasminogin activator (t-PA) is also an endothelial derived endogenous 
anticoagulant that is stimulated by norepinephrine, vasopressin, and thrombin to help 
protect against platelet formation and thrombosis (16). 
 
Leukocyte Adhesion 
     Activated polymorphonuclear leukocytes (PMN’s) contribute to the production of free 
radical formation and contribute to the pathology of endothelial dysfunction.  Nitric oxide 
released from a healthy endothelium has been postulated to provide a protective chemical 
barrier against free radicals (95).  Prostacyclin has also been shown to interact 
synergistically with NO to prevent tissue damage by activated PMN’s (95).  In addition,   
cell surface adhesion molecules (endothelial leukocyte adhesion molecule-1 (ELAM-1), 
intracellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 
(VCAM-1)) help regulate leukocyte and platelet adhesion.  ELAM-1 is produced in 
response to an immune injury stimulus to provide a site for neutrophil attachment.  
Subsequently, VCAM-1 and ICAM-1 are expressed to promote lymphocyte attachment 
and initiate the local immune facilitation (95).   
 
Permeability 
     The endothelium serves as the barrier, providing permeability access between the 
lumen and the intracellular structure of the blood vessel.  Low density Lipoprotein (LDL) 
is constantly migrating back and forth from the blood to the smooth muscle to provide 
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structural aid in maintaining vascular tone.  The release of NO from a normal functioning 
endothelium promotes inhibition of superoxide anion radicals to oxidize/modify the 
passing LDL (50).  In contrast, a dysfunctional endothelium would produce inadequate 
concentrations of NO to provide the LDL with protection against oxidization and the 
permeability of the modified LDL would be restricted. 
 
Regulation of Vascular Smooth Muscle Tone 
     The regulation of vascular smooth muscle tone assumes a balance between 
vasoconstriction and vasodilation.  Endothelin (ET) is the major class of vasoconstricors 
which are composed of three different isoforms; however, only ET-1 has been shown to 
be released from endothelial cells (70).  Endothelin-1 is present in healthy populations in 
low concentrations, has a short half life, and is suggested to play the role of a local 
vasoconstrictor.  In contrast to the limited endothelial derived vasoconstrictors, there are 
many smooth muscle relaxors.  Endothelial derived vasodilators include endothelium-
derived hyperpolarizing factor (EDRH), prostacyclin, and NO. 
     Endothelium-derived hyperpolarizing factor works independent of NO and plays an 
important role by increasing the K+ conductance and promoting smooth muscle relaxation 
(16).  Prostacyclin, the first discovered endothelial derived vasoactive substance, is 
produced via the cyclooxygenase enzyme and also promotes smooth muscle cell 
relaxation.  Just like NO, prostacyclin is chemically unstable and has a limited half-life; 
however, unlike NO it is produced via stimulation of adenylate cyclase and an increase in 
intracellular concentrations of cAMP (16). Nitric oxide, a potent vasodilator is the 
primary molecule responsible for promoting endothelial function is described in detail 
below. 
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     In 1980, Furchgott and Zawadki (33) discovered one of the most important 
vasodilators released from the endothelium and named it EDRF.  They investigated 
endothelial function by constricting vessels with norepinephrine and infusing 
acetylcholine (Ach), which they proposed would induce vasodilation.  They were 
intrigued to discover that the Ach induced vasodilatation was inhibited if the endothelium 
was damaged.  In 1987 Palmer and colleagues (85) took Furchgott and Zawadki’s 
investigation one step further and identified the EDRF as Nitric Oxide (NO). 
     Nitric Oxide is a very soluble, highly reactive gas that can be produced by certain 
animal and plant cells from the amino acid L-arginine.  The formation of NO through the 
breakdown of L-arginine produces L-citruline.  L-citruline can then be recycled back into 
L-arginine, which can then produce more NO.  Nitric Oxide is a perfect messenger 
because it is fast, easily passes through cells and membranes and is produced in 
abundance.  Nitric Oxides primary role as an endogenous vasodilator has an intravascular 
half-life of ~2 milliseconds and extravascular half-life of ~2 seconds (54, 71).   Nitric 
oxide plays an important role in controlling the cardiovascular system by inhibiting 
platelet-endothelial wall interaction and proliferation of vascular smooth muscle cells 
(51, 54).  The amount of nitric oxide available to provide protective vascular effects is 
termed NO-bioavailability.  An increase in NO-bioavailability decreases the rate of 
endothelial dysfunction.  Endothelial dysfunction has been proposed as the earliest 
identifiable event in the process of atherosclerosis (120).  
 
PATHOPHYSIOLOGY OF ENDOTHELIAL DYSFUNCTION 
      
     There are many mechanical and chemical factors that come in contact with the 
monolayer of cell lining the vessel wall that may induce damage to the endothelium and 
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increase the rate of cardiovascular disease.  Dysfunction of the endothelium can be 
defined as an imbalance between relaxing and contracting factors (95) that were 
discussed in the previous section.  Possible contributors of endothelial dysfunction 
leading to atherosclerosis include, but are not limited to elevated and modified LDL, 
smoking, free radicals production, hypertension, diabetes mellitus, genetics, elevated 
plasma concentrations of homocysteine, and chronic infections (92).  In addition, 
NADPH oxidase expression has been linked to vascular reactive oxygen species (ROS) 
production, in particular superoxide (O2-) (63).  Reactive oxygen species induce 
programmed cell death, induce or suppress the expression of many genes, and activate 
cell signaling cascades (45).  Further, ROS contributes to endothelial dysfunction and 
atherosclerosis in sedentary populations (63).     
     Atherosclerosis is a progressive inflammatory disease characterized by the 
accumulation of lipids and fibrous elements in medium to large arteries (65) and has been 
suggested to be the result of endothelial dysfunction (79, 93).   A dysfunctional 
endothelium allows for oxidized LDL to infiltrate in the vessel wall and initiate the 
inflammatory response.  The immune defense is initiated and macrophages are recruited 
to engulf the oxidized LDL and facilitate the formation of foam cells.  Foam cells are too 
big to depart the inner vessel space and eventually begin to disrupt the vessel lumen.  
Once the endothelium becomes dysfunctional, a viscous cycle of atherosclerotic plaque 
development causes a further increase in endothelial cell dysfunction, which limits the 
functional properties of the endothelium described above.  Unsurprisingly, endothelial 
dysfunction has been associated with an increase risk for cardiovascular disease in many 
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different clinical populations (27, 41, 68).  The functions of the endothelial cells are 
tested under many different methodological environments described below. 
 
MEASURES OF ENDOTHELIAL DYSFUNCTION 
      
     Arterial health can be measured several different ways either invasively or non 
invasively.  The ultimate invasive procedure involves direct measures of endothelial 
function within the coronary arteries via femoral artery catheterization; however, this 
technique is very risky and costly.  Another semi invasive procedure utilizes an infusion 
of Acetylcholine (Ach) into the artery as a vasodilatory agent.  The dose dependent 
infusion of Ach influences vascular tone and the amount of resistance vessel blood flow 
stimulating the endothelial vasodilatory response.  Blood flow, a function of arterial 
diameter, blood viscosity and velocity, is measured either by ultrasound or strain gauge 
plethysmography in response to arterial Ach infusion. The increase in diameter in 
response to the Ach induced increase in flow compared to the baseline diameter is 
postulated to be an endothelial dependent response, a measure of endothelial function; 
however there may be reason to think otherwise.  As discussed further in this section, the 
difference in stimulus profiles 
and its affect on shear stress may 
influence whether the response 
will be nitric oxide (NO) -
dependent or independent (91) . 
     A rather simple non invasive 
measure of endothelial function 
Figure 3. The nitric oxide cyclic GMP pathway. 
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is obtained by the Pulse Trace® Pulse Contour Analysis (PCA).  The PCA tests for an 
indirect measurement of endothelial function by detecting indexes of arterial stiffness.  A 
compliant artery is suggested to have an enhanced endothelial function, whereas a stiffer 
artery is suggested to represent a dysfunctional endothelium.  The PCA uses a photo-
plethysmography transducer with signal conditioning circuitry to obtain an extremely 
accurate and noise free signal of the Digital Volume Pulse waveform (90).  Once again, 
these pulse waves are utilized as an indirect non invasive measure of the endothelium.  
The non-invasive methodology most often used and accepted in the literature is the 
technique of brachial artery flow-mediated dilation (FMD).   
     The non invasive measurement of brachial artery FMD was first described by 
Celermajer in 1992 (18).  If a variety of conditions are controlled for (23, 91), FMD has 
been proposed as a non-invasive measurement of NO-dependent endothelial response.  
To ensure accurate NO dependency, specific conditions to control the shear stress 
stimulus include but are not limited to the room temperature, diet (fasting or not), 
previous physical activity, vitamin supplementation, pharmacological interventions 
(vasoactive medications), the placement of the cuff on the arm (proximal or distal), the 
duration of occlusion (5 min or longer), smoking, awaking time, and the elimination of 
actively induced increases in blood flow (23, 91).  The brachial artery flow-mediated 
dilation procedure utilizes ultrasound images of the brachial artery to assess the change in 
brachial artery diameter in response to occlusion induced reactive hyperemia.  Hyperemic 
flow produces a mechanical force that is exerted parallel (shear) to the long axis of the 
vessel (82). The increase in shear triggers the G-protein expression of phosphokinase A 
(mechanisms unknown), signaling an increase of endothelial nitric oxide synthase 
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(eNOS) expression.  L-arginine is upregulated in conjunction with eNOS to produce NO, 
a potent vasodilator (99).  NO diffuses into the tunica media where it upregulates cyclic 
guanasine triphosphate (cGTP).  Guanalyl cyclase converts cGTP to guanasine 
monophosphate (cGMP) to induce a direct relaxation of the smooth muscle and 
vasodilation (Figure 3).  It is important to note that NO also acts directly to produce 
smooth muscle relaxation as well.  The percent increase in the post reactive hyperemia 
diameter compared to the baseline diameter is expressed as FMD (%).  The measurement 
of flow-mediated dilation (FMD) via ultrasound has been established as a reliable non-
invasive measurement of endothelial function (115) and has been shown to correlate with 
invasive testing of coronary artery endothelial function (2, 109).   
 
BENEFITS OF EXERCISE ON ENDOTHELIAL FUNCTION 
      
     Exercise is indicated in the treatment and prevention of modern disease and may 
translate to the prevention and/or reversal of endothelial dysfunction.  It has long been 
known that there are protective cardiovascular benefits associated with exercise.  Regular 
physical activity has many benefits including a reduced risk of cardiovascular and all-
cause mortality (11).  The benefits of exercise have been associated with conditions such 
as myocardial infarction (122), depression (69), cancer (126), arthritis (52), fibromyalgia 
(81), osteoporosis (102), and has been perceived as homeopathic therapy for many other 
diseases and conditions; however, the exact mechanisms of the exercise induced benefits 
are not fully understood.  Long before the advanced measurement of arterial health, the 
benefits of exercise were investigated on traditional risk factors.  Physical training 
decreases body weight (5), increases insulin sensitivity (46), lowers blood pressure (11), 
serum triglycerides, and increases serum HDL cholesterol (14).  Interestingly, there is 
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evidence to suggest that exercise still provides physiological benefits even in the presence 
of well established cardiovascular disease predictors such as smoking and elevated 
systolic blood pressure and cholesterol (29).  In addition, there is evidence to suggest that 
exercise training does not alter plasma lipids, blood pressure, blood glucose, waist to hip 
ratio, or body mass index in Type II diabetics and healthy controls, despite significant 
improvements in both FMD and Ach responses (39).  Most importantly, exercise plays a 
multifaceted beneficial role in the improvement of endothelial function as well as the 
number one killer in the United States, cardiovascular disease and risk discussed below.  
      Recent studies suggest the mechanism associated with exercise induced 
improvements of cardiovascular risk is though improvements in vascular tone (43, 110). 
Exercise training has been shown to increase the transport of L-arginine (87) and 
augment blood flow and shear stress, which in turn increases NO production and 
decreases NO inactivation leading to an increase in NO bioavailability (49), all of which 
upregulates eNOS activity (124).  The increase in L-arginine and eNOS together produce 
the formation of NO as depicted in Figure 2, which may contribute to the increase in 
endothelial function.   
   Regular aerobic endurance exercise decreases the age associated increase in endothelin-
1 in women, which may have beneficial effects on the cardiovascular system for 
prevention of hypertension and atherosclerosis (67).  In addition, moderate aerobic 
training (six, 30-minute sessions per week for 8-weeks) in sedentary subjects resulted in 
an altered autonomic regulation of HR toward vagal dominance (114), thus reducing the 
cardiovascular work of the heart.  
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     Exercise also improves adaptations in the muscle itself.  Endurance exercise has been 
associated with an increase in muscle density, mitochondrial enzymes, and glycolytic 
proteins which allow for an increase in oxidative metabolism and an improvement in 
maximal oxygen consumption and muscle lactate clearance(13); however, endurance 
exercise also accelerates the production of free radical formation (24).  Furthermore, 
exercise training reduces vascular expression of NAD(P)H oxidase which results in 
decreased local ROS generation (1).  In addition, exercise has been shown to up regulate 
antioxidants and decreases indexes of oxidative stress in porcine endothelium (96) as well 
as in human subjects (32).        
 
ANTIOXIDANTS AND ACUTE EXERCISE 
    
      The increase in anti/pro oxidant balance may be adequate to augment endothelial 
function in response to exercise training in itself; however, there appears to be no change 
in muscle antioxidant capacity (86), total antioxidant status (121) and capacity (113), or 
superoxide dismutase (113) following acute exercise which would counteract the increase 
in OS and explain the augmentation of FMD.    
     Parise and colleagues (86) investigated the effect of a 12-week progressive resistance 
exercise training using only one leg on skeletal muscle antioxidant capacity (CuZnSOD; 
muscle biopsy) in 12 older men (71 ± 7 years of age).  Following the 12-week program, 
the skeletal muscle antioxidant capacity was measured in the non trained leg following an 
acute bout of the same resistance exercise.  Post training, the trained limb demonstrated 
an increase in antioxidant capacity, whereas no differences in antioxidant capacity were 
observed following acute exercise in the untrained limb. 
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     Tozzi-Ciancarelli and colleagues (113) investigated total plasma antioxidant capacity 
(TPAC) and superoxide dismutase (SOD) in 15 healthy sedentary men following an acute 
bout of strenuous and moderate exercise.  There was a decrease in both TPAC and SOD 
following strenuous acute exercise, whereas no significant changes in TPAC or SOD 
were observed following moderate acute exercise.  
     Vincent and colleagues (121) investigated the total antioxidant status (TAS) following 
either acute resistance (RX) or aerobic (AX) exercise in 28 obese and non-obese subjects.  
Interestingly, Vincent and colleagues observed an increase and no change in total 
antioxidant status (TAS) following acute resistance exercise in non-obese and obese 
subjects, respectively and no change and a decrease in TAS following acute aerobic 
exercise in non-obese and obese subjects, respectively.  
    In summary, there is conclusive evidence that supports the increase in antioxidant 
capacity following chronic exercise; however, there appears to be no change in 
concentrations of antioxidants measured by TPAC, SOD, or TAS following acute 
exercise.  Further, the similar concentrations of antioxidant status pre and post acute 
exercise does not provide explanation for the improvement in FMD. 
      
CHRONIC EXERCISE AND ENDOTHELIAL FUNCTION 
      
     Within the past decade the effects of exercise on endothelial function has received a 
vast amount attention.  This section will touch upon the dose of chronic exercise 
evaluating different modes, durations, and intensities.  The effect of exercise training on 
endothelial function has been fully investigated by manipulating mode, frequency and 
duration of exercise, and using different subject populations.   
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     Kasikcioglu and colleagues (55) report that endothelial dependent vasodilation and 
reactive hyperemic flow rates are significantly (p<.05) higher in endurance athletes  than 
in controls (VO2max = 61.24 ml·kg-1·min-1 and 44.49 ml·kg-1·min-1, respectively); 
however, this may not always be the case as discussed later in this section. 
     In a study utilizing female Yucatan pigs, exercise training influenced both antioxidant 
and pro-oxidant enzymes to decrease indexes of oxidative stress.  Twenty-four 8-12 
month old pigs performed 16-19 weeks of treadmill running at 40-50% of maximal 
oxygen uptake.  Antioxidant enzyme SOD activity of the aorta was significantly (p<.05) 
increased, whereas pro-oxidant enzyme NAD(P)H and MDA an index of oxidative stress 
were reduced (p<.05) following exercise training.  Endothelial function was not measured 
directly; however, Rush and colleagues (96) speculate these adaptations may contribute 
to improved endothelial function.  Chronic Exercise training has been associated with 
reversal of different variations of cardiovascular disease as well as traditional risk factors 
for cardiovascular disease.   
 
Cardiovascular Disease, Exercise, and Endothelial Function 
     Endothelial dysfunction occurs early in atherosclerosis in response to cardiovascular 
risk factors and is primarily the result of reduced nitric oxide bioavailability (123).  
Patients with cardiovascular disease have demonstrated an attenuated dependent and 
independent endothelial response compared to controls (2.61±2.91 vs 8.10±7.81% and 
17.20±7.93 vs. 23.19 ± 8.89%, respectively) (127).  Gokce and colleagues (36) 
investigated FMD in 40 patients with coronary artery disease (CAD) at baseline and 
following 10 weeks of supervised cardiac rehabilitation (three 30-minute sessions per 
week).  Exercise was associated with a 29% improvement of functional capacity as well 
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as a significant increase (p<.05) in the posterior tibial artery FMD; however, no change in 
the brachial artery FMD was observed.  In addition, Edwards and colleagues (27) 
observed 12 weeks of standard cardiac rehabilitation on FMD, oxidative stress, and 
antioxidant defenses in CAD patients.  Exercise training resulted in an improvement of 
endothelial function via brachial artery FMD (7.9% to 11.1%) and also increased plasma 
nitrite and nitrate levels, SOD activity and decreased oxidative stress. Coronary 
endothelial function was assessed using Ach induced vasodilation in 10 patients at 
baseline and following 4 weeks of supervised exercise.  Subjects performed six 10-
minute bouts of bicycle ergometer at 80% of HRmax.  The findings from Hambrecht and 
colleagues (44) suggest an increase in endothelial dependent vasodilation in both the 
epicardial coronary vessels as well as the resistance vessels.  The improvement in 
endothelial function via Ach induced dilation was observed by Hambrecht and colleagues 
(42) in 17 patients with CAD following 10-minutes of rowing and 10 minutes of bicycle 
ergometer, each three times daily.  This improvement in endothelial function was related 
(r=.59) to a shear stress induced phosphorylation of eNOS.  Handgrip training, 30-
minutes per day, for 8 weeks has also been shown to improve vasodilatory responses to 
Ach in 12 patients with heart failure (56).  
Cardiovascular Risk Factors, Exercise, and 
Endothelial Function 
     Traditional cardiovascular risk factors have 
also been associated with an attenuation of 
endothelial function (illustrated in Figure 3).  
Green and colleagues (40) investigated an 8-week 
circuit training program including resistance 
Figure 3.  Cardiovascular risk 
factors mediating endothelial 
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training, cycle ergometry, and treadmill walking on brachial artery FMD in patients 
exhibiting cardiovascular risk factors.   Findings from this investigation suggest that that 
short term exercise training improves endothelial dependent nitric oxide-mediated 
vascular function.  In addition, Watts and colleagues (125) investigated the effect of eight 
weeks of a different circuit training regimen (cycle ergometer at 65-85% HRmax and 
weight training) on the endothelial response via brachial artery FMD in 19 obese (BMI > 
34.0 kg/m2) adolescents.  Circuit training not only increased functional capacity, 
muscular strength, and body composition, but normalized conduit vessel function 
following training.   In contrast to the improvements in EF observed with chronic 
exercise above, Green and colleagues (39) investigated specific traditional cardiovascular 
risk factor markers in a diverse clinical population as well as in controls.  Eight weeks of 
circuit training exercise (the same as above) did not significantly (p>.05) alter plasma 
lipids, blood pressure, blood glucose, waist to hip ratio, or BMI; however as described 
above, exercise did improve brachial artery FMD and Ach induced vasodilatory 
responses (39).  Age is often overlooked as a risk factor for heart disease; although, it has 
been associated with a decrease in endothelial function (118).  The most important age 
related structural changes may include 1) increased fragmentation and decreased density 
of elastin in the artery wall, 2) increased collagen content mediated by increased 
synthesis and decreased turnover, and 3) increased cross-linking of collagen molecules  
associated with increased advanced glycation end-products (98).  In addition, an increase 
in arterial wall thickness, addition of medial lamellae, and loss of orderly arrangement of 
elastin in the media may compromise arterial structure and function due to aging (20).  
These structural changes related to aging (summarized in Table 1) will eventually 
 71 
increase the risk of clinical consequences.  Non 
structural age related changes such as increased 
cardiovascular risk factors and decreased NO 
bioavailability, may also contribute to the reduction 
in endothelial function; however, there is evidence 
to suggest possible ways to prevent this age related 
impairment in previously sedentary middle aged 
(22-35 yrs) and older (50-76 yrs) apparently healthy 
men (25).   
     Physical activity has been shown to prevent the age related attenuation in NO 
availability in the elderly (108).  Elderly subjects (~65 yrs old) who were regular 
exercisers displayed a higher acetylcholine induced forearm blood flow than age matched 
subjects who where sedentary.  In a cross-sectional study comparing elderly athletic 
subjects (exercise at least 45 minutes, 3+ times per week) to age matched sedentary 
controls, FMD was significantly (p<.05) greater in the elderly athletic subjects than their 
sedentary counterparts (97).  Decreases in endothelial function, independent of sex, has 
been observed using the indirect measurement of endothelial function, PWV.  Further, in 
a crossectional investigation, 150 healthy sedentary men (~25 – 75 years old) were split 
into age associated quartiles (young, middle age, and old) and carotid artery compliance 
was measured.  Elderly subjects exhibited a 40-50% decrease in compliance compared to 
young subjects.  Similar decreases (~38%) in aortic PWV were seen in 50 women ages 
26-96 years old (118).  The mechanisms associated with the age related impairment in 
arterial compliance has been attributed to structural and non structural properties of the 
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arterial wall (98).  In addition, higher physical conditioning status, indexed by VO2max, 
was associated with reduced arterial stiffness measured by aortic PWV (118). 
     Interestingly, similar results were found in apparently healthy young men of average 
fitness (19).  Brachial artery flow-mediated dilation was performed at baseline and 
following 10 weeks of aerobic and anaerobic exercise in 25 healthy male military 
subjects (aged 17-24 years old).  Findings from Clarkson and colleagues (19) support an 
improvement in brachial artery FMD following 10 weeks of ‘general’ exercise training in 
young healthy men (19).  In addition, O’Sullivan (84) investigated the effect of a 5 week 
moderate aerobic cycle exercise program in young healthy adult males and report an 
enhanced endothelium-dependent dilator function measure by FMD.  Similar to the 
results found in young men, Moe and colleagues (74) found that the young women (23.7 
± 2.1 yrs old) also have well preserved endothelial function measured by brachial artery 
FMD.  Interestingly, age matched female endurance trained athletes (VO2max = 60.6± 4.5 
ml/kg/min) did not display an improved dilating capacity any further than that of the non- 
trained females (VO2max = 40.5 ± 5.6 ml/kg/min) (74). 
     In summary, there is conclusive evidence that physical activity/exercise plays a 
significant role in regressing or eliminating cardiovascular risk factors; although, there is 
one investigation that does not support this statement.  Exercise seems to improve 
endothelial dysfunction in populations that have an attenuated endothelial function at 
baseline.   In addition, physical activity and exercise appears to preserve endothelial 
function in young healthy adults as well as elderly subjects.    
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ACUTE EXERCISE AND ENDOTHELIAL FUNCTION 
      
     A great deal of attention has focused on how and why exercise improves vascular 
health; however, there is limited research investigating how acute exercise improves 
endothelial function which is summarized in Table 2.  The importance of a single bout of 
exercise is indisputable.  There is strong evidence that an acute bout of exercise can 
reduce triglycerides, increase high density lipoprotein cholesterol, reduce blood pressure, 
and improve insulin sensitivity and glucose homeostasis (112).  Furthermore, there is 
evidence to suggest that acute exercise does in fact have an effect on endothelial function.   
     Harvey and colleagues (48) investigated endothelial function via FMD in pre and 
postmenopausal women using an exercise stimulus of a single bout of treadmill walking 
at 60% VO2max for 45 minutes.  Baseline measurements and post exercise measurements 
starting 45- minutes after cessation of exercise were taken in both groups.  There was 
only a significant (p<.05) increase in FMD following exercise in the postmenopausal 
women.  Harvey and colleagues speculate that the similar post exercise FMD observed in 
the pre menopausal women was due to a ceiling effect.  A non compromised endothelium 
maintains its maximum NO bioavailability and the exercise induced increase in shear 
stress production of NO cannot facilitate any more improvement in endothelial function 
than already observed.  These findings suggest that acute treadmill exercise at 
60%VO2max improves endothelial function only in postmenopausal women. 
     In contrast to the beneficial findings of Harvey and colleagues at moderate intensity, 
maximal acute exercise induces endothelial dysfunction in claudicants (103). Thirty one 
patients with intermittent claudication were separated into two groups to participate in 
exercise either until the claudication pain became intolerable (maximal exercise) or until 
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the onset of claudication pain (sub-maximal).  Flow-mediated dilation was measured at 
baseline and immediately following cessation of treadmill exercise at a constant speed 
and increasing the slope 3% every three minutes.  A decrease in FMD was only seen 
following acute symptom limited maximal exercise in claudicants.  Seven days following 
the initial visit, the same protocol as day 1 was initiated with the addition of either a 
placebo or IV administration of Vitamin C (50mg/min for 20min).  Endothelial function 
following maximal exercise was similar to baseline values with the addition of Vitamin C 
supplementation.  Silvestro and colleagues (103) identified the beneficial role of 
antioxidant therapy on possible mechanisms associated with the attenuation of FMD 
following maximal exercise.  Vitamin C inhibits the rate of LDL oxidation and 
upregulates superoxide (O2-) scavengering, thus increasing the activation of NO directly.  
These findings suggest that Vitamin C supplementation prevents acute endothelial 
dysfunction induced by maximal exercise in patients with intermittent claudication. 
     The concentrations of urinary nitric oxide and byproducts of NO has been 
acknowledged and recognized by many (68, 77, 123) as an indirect output measure of 
endothelial function.  Bode-Boger and colleagues (12) investigated the effect of urinary 
nitrate and cGMP at rest, during, and following acute exercise in 16 men.  Sub-maximal 
exercise was performed on a cycle ergometer for 30 minutes at 60% of their individual 
maximal work capacity.  Urinary nitrate were significantly elevated during the acute 
exercise and decreased rapidly back to baseline after completion of the exercise bout.  
Findings from this investigation may support the beneficial role of a single bout of 
exercise improving ‘endothelial function’ reflected by the increase in nitrate and cGMP; 
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however, no direct measurement of endothelial function was measured nor was there 
discussion of the ceiling effect introduced above. 
     A similar study conducted by Camsari and colleagues (15) investigated the role of 
Endothelin-1 (ET-1); a potent vasoconstrictor and NO in 25 patients with slow coronary 
flow (SCF) and 20 control subjects.  Plasma samples were collected at baseline and 
immediately following a standard maximal graduated treadmill exercise test.  Endothelin-
1 was significantly elevated in the SCF patients and significantly reduced in the control 
subjects when compared to baseline values.  Nitric oxide was significantly elevated in 
both groups with no difference between the two.  The findings of this study suggest that 
the pathophysiology of SCF patients play a key role in modulating the vasodilatory 
response following a maximal exercise test and this pathological condition may influence 
more direct measures of endothelial function. 
     Kingwell and colleagues (60) investigated arterial compliance following one bout of 
moderate-intensity cycling in 12 sedentary men.  Subjects performed 30-minutes of 
cycling exercise at 65% of maximal oxygen consumption.  Whole body arterial 
compliance (WBAC) via PWV, aortic flow, and carotid pressure was measured at 
baseline, 30 minutes and 60 minutes following cessation of exercise.  Following a single 
bout of cycling exercise, WBAC was significantly (p<.05) increased immediately (30-
minutes) following exercise and returned to baseline values within one hour of exercise 
cessation.  Findings from this study indicate both central and leg arterial compliances 
independent of changes in mean arterial pressure.  Kingwell and colleagues (60) 
speculate the mechanism related to vasodilation of both the large proximal vessels and 
the muscle beds for central and peripheral effects, respectively.  
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     Benjamin and colleagues (6) used the Framingham offspring data to compared the 
FMD of 2142 subjects following a 6-minute walk test (Bruce protocol stages I and II).  
Endothelial function testing following the 6-minute walk test was improved compared to 
baseline values.  Benjamin and colleagues (6) attribute this improvement in FMD to an 
NO-dependent increase in forearm blood flow during leg exercises (38). 
     Investigating the effect of prior exercise on postprandial metabolism and vascular 
function in obese men, Gill and colleagues (35) performed endothelial function via Ach 
induced dilation at baseline and ~16-18 hours following 90-minutes of treadmill walking 
at 50% of VO2max. The results of the postprandial metabolism will not be discussed; 
however, vascular function was improved ~16-18 hours following a single session of 
moderate exercise.  The specific finding of this investigation is that a 90-minute bout of 
treadmill walking at moderate intensity improved small vessel vasodilator response in a 
group of middle aged men. 
     Gaenzer and colleagues (34) investigated femoral and brachial artery dilation in 
response to 40-minutes of cycle ergometer exercise in ‘healthy’ smoking and 
nonsmoking men.  Interestingly, exercise induced hyperemic bloods flow were similar 
between the two groups.  The only diameter change that occurred during exercise was 
observed in the femoral artery in both groups; however, of the two groups the smokers 
displayed a diminished percent vasodilation in comparison to the nonsmokers (4.8±1.6% 
vs. 9.2±1.9%, respectively).  Gaenzer and colleagues (34) utilized a non traditional 
method of FMD, and suggest that the diminished vasodilatory response observed in the 
smokers was attributable to the endothelial dysfunction induced by smoking.  
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     In summary, there is limited evidence providing the increase in endothelial function 
following and acute bout of exercise.  There is also limited research utilizing the non-
invasive methodology of FMD when utilizing the acute paradigm.  None of the studies 
presented in this section offer consistent methodology when measuring endothelial 
function in the response to acute exercise.  It is highly interpretable (based on limited 
research) that acute exercise improves endothelial function whether measured by 
byproducts, in the conduit arteries or the resistance arteries.  In addition, the doses of 
exercise used in the presented investigations are different and may play an important role 
when investigating the effects of acute exercise on endothelial function. There also 
remains one major unanswered question:  There are many reasons why exercise training 
may improve endothelial function, but why does endothelial function improve after a 
single bout of exercise?  Possible insight to the answer of this question can be found in 
the following sections. 
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DOSE RESPONSE OF EXERCISE ON ENDOTHELIAL FUNCTION 
      
     The dose of exercise can be broken up into four different elements; mode, intensity, 
frequency, and duration.  Each element may contribute in different ways in identifying 
the effect of the dose response relationship of exercise on endothelial function.  High 
intensity training has been associated with greater increases in performance goals where 
as moderate intensity exercise is often recommended for health related benefits (57, 117).  
The research investigating the dose response of acute and chronic exercise and its 
relationship with endothelial function is limited and presented below. 
     Forjaz and colleagues (31) investigated the role of exercise intensity on post exercise 
hypotension (PEH) in 23 normotensive subjects.  Subjects performed 45-minutes of cycle 
ergometer exercise at 30%, 50% and 75% of VO2peak.  Their findings suggest that PEH is 
greater and longer following more intense exercise (50% and 75% VO2peak).  In addition, 
Moriguchi and colleagues (78) found an improvement in brachial artery flow mediation 
following low frequency mild aerobic exercise (60-minutes of 50% VO2max, 2 times per 
week) for 12 weeks in mild hypertensive subjects.    
     Bergholm and colleagues (7) investigated endothelial function via Ach induced 
vasodilation, in nine healthy males at baseline and following three months of marathon 
training (~70%-80% of VO2max).  The intense exposure to repeated bouts of free radical 
formation impaired endothelial function and deceased circulating antioxidant 
concentrations in these athletes.  
      An epidemiological study was conducted by Tanasescu and colleagues (111), looking 
at a cohort of 44,452 men.  Exercise intensities were analyzed separately and related to a 
reduced risk of coronary heart disease.  Further analysis and findings of this study 
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suggest that certain moderate intensity activities/exercise (4-6 METS; walking, running, 
and weight training) were associated with the greatest relative risk reduction, where as 
cycling, swimming and racquet sports were not (111).  In addition, King and colleagues 
(59) analyzed C-reactive protein (CRP, and inflammatory biomarker) data from 4072 
subjects and found a significant relationship between different types of physical activity 
and inflammation.  Regular jogging and aerobic dancing had a lower likelihood of 
elevating CRP than that of cycling and swimming; however, exercise intensity and 
duration were not documented and these differences may be a result of the dose of 
exercise presented.   
     In addition, Lee and colleagues (64) investigated the role of moderate intensity 
exercise relative to the individuals exercise capacity.  Subjects (n=7337) reported their 
actual activities and rated their perceived exertion (RPE) of exercise intensity using the 
Borg Scale.  Findings suggest that RPE was a strong predictor of lower cardiovascular 
disease.  More specifically, there appears to be a dose response relationship, with higher 
perceived intensities associated with greater decrements in coronary heart disease rates.  
     Kemi and colleagues (57) investigated the relative effectiveness of 10-weeks of high 
and moderate exercise intensity on cellular and cardiovascular function in rats.  Sprague-
Dawley rats preformed treadmill running exercise at either a high (85%-90% VO2ma) or 
moderate (65%-70% VO2max) intensity for one-hour per day, five days per week.  
Following 10-weeks of training, carotid artery endothelial function improved similarly 
with both intensities.  Findings from this investigation suggest that cardiovascular 
adaptations to training are intensity dependent and moderate intensity exercise improved 
endothelial function to nearly the full effect. 
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     Goto and colleagues (37) investigated the effects of three different intensities of 
exercise on endothelial function in humans.  Twenty six apparently healthy Japanese men 
were divided into three groups to perform either mild (25% VO2max), moderate (50% 
VO2max), or high intensity cycle ergometer exercise, for 30-minutes, 5-7 times per week, 
for 12 weeks.  Endothelial function via Ach induced vasodilation was performed at 
baseline and following exercise training. Endothelial function was significantly 
augmented in the moderate intensity group; however, no change was observed in the mild 
or high intensity group.  Findings from this investigation suggest that the increase in 
endothelial dependent dilation following moderate intensity cycling may be due to the 
increased production of nitric oxide, where as the high intensity exercise increased 
oxidative stress.  
     In summary, research supports that most exercise induced benefits appear to occur 
following moderate intensity activity/exercise.  In addition, certain modes of exercise 
may be more beneficial than others. Most of the literature utilizing the elements of the 
dose response of exercise involves epidemiological investigations which may be 
associated with vast amounts of subjectivity-reported error.  There is limited data 
controlling for exercise intensity and its effect on endothelial function.  Furthermore, 
there are no studies to my knowledge that investigate the dose response of acute exercise 
on endothelial function measured by brachial artery flow mediated dilation. 
 
BIOMARKERS, EXERCISE AND ENDOTHELIAL FUNCTION 
      
     There is a strong relationship between inflammation and endothelial dysfunction.  
There is also a strong relationship between exercise induced inflammation and 
endothelial function.  As depicted in figure 4 below, inflammatory signals activate the 
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release of IkB (not seen in the diagram) which allows the translocation of nuclear factor 
kappa beta (NF-kB) to migrate inside the nucleus and bind to the kB sites in the promoter 
region of the DNA.  Subsequently, messenger RNA is expressed promoting the 
production of inflammatory proteins.  This next section will attempt to identify the 
exercise induced response of two specific cytokines (TNF-alpha and Interleukin-6) and 
their relationship to the outcome variable of interest; endothelial function. 
 
Tumor Necrosis Factor- Alpha 
     Tumor Necrosis Factor-alpha (TNF-α) is a pro inflammatory cytokine produced 
primarily by macrophages and cytoxic CD8 and CD4 T cells, that also plays a positive 
feedback role to increase its own production and stimulate the acute phase proteins 
(systemic inflammatory markers, ie. CRP) and cellular components of the immune 
system (72).   Other functions of TNF-α include; decrease glucose uptake in working 
muscles (107), recruitment of additional macrophages, direct killing of infected cells, 
Figure 4.  Schematic diagram of inflammatory protein release in response to 
activation signals (Barnes and Karin 1997). 
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localized inflammation, and increases in core temperature (66).  In addition, TNF-α is a 
mediator of ROS (10) by stimulating the generation of superoxide ion via activation of 
NAD(P)H oxidase (58), which may diminish NO bioavailability (47) and decrease 
endothelial function.  Furthermore, TNF-α is postulated to be the first responder (26) of 
the cytokine family in mediating ROS (10) and may reflect a change associated with 
exercise induced endothelial function; however, this needs to be investigated further.  
     Bhagat and Vallance (9) have shown that infusion of TNF-α impairs endothelial 
function in healthy subjects.  In addition, consistent elevations in TNF-α results in loss of 
its anti- tumor activity producing anti-TNF antibodies which may result in additional cell 
necrosis (8).  There is evidence suggesting patients with attenuated endothelial function 
have elevated plasma concentrations of TNF-α (21, 62).  Studies by Anker and 
colleagues (3) further support the role of TNF-α induced endothelial dysfunction by 
contributing to skeletal muscle fatigue/weakness in CHF patients.  There is also evidence 
that suggests combined endurance/resistance exercise training (60-minutes per day, three 
times per week) decreases plasma TNF-α receptor expression in patients with chronic 
heart failure (21).  In addition, plasma TNF-α was reduced following 12-weeks of cycle 
ergometer exercise for 30-minutes per day, three days per week in CHF patients (62).   
     Natelson and colleagues (80) observed a decrease in direct gene expression of TNF-α 
following a maximal graded exercise stress test; however, there was no change in plasma 
concentrations of TNF-α.  Similar findings of no change in plasma TNF-α were observed  
following long duration exercise (3 hours of cycling and inclined walking) at 60-65% 
VO2max (105), 60-minutes of moderate cycle ergometry exercise (~75% of VO2max) (116), 
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and six hours of endurance running in well trained athletes (26).  It is important to note 
that the dose response of exercise; specifically, intensity and duration, plays a key role in 
the reduction and elevation of TNF-α. In addition, the population studied may also 
influence the results of TNF-α following exercise. 
     Interestingly, in a subsequent analysis of three hours of endurance exercise, Starki and 
colleagues (105) found that long duration endurance exercise inhibits the endotoxin-
induced TNF-α production.  They suggest that the exogenous infusion of endotoxin 
mediated TNF-α production is blunted by an exercise induced mechanism and there 
appears to be a down regulation of TNF-α production.  They further postulate that the 
exercise mediates an increase in anti-inflammatory activity through an Interleukin-6 
mechanism. 
 
Interleukin-6 
     Interleukin-6 (IL-6) is also a key player of the immune system and is the major 
cytokine responsible for mediating the release of acute phase proteins from the liver (66); 
although, it is typically the last inflammatory cytokine to respond (26).   Interleukin-6 
may be produced by many cells, primarily monocytes, activated lymphocytes, and 
adipose tissue.  Interleukin-6 can also be released from the liver and the gut in non 
exercise induced stress (30).  Interleukin-6 has been classified as both a pro- and anti-
inflammatory cytokine; however, the current view accepts the primary role as having 
anti-inflammatory effects (89).  Interleukin-6 acts to stimulate the hypothalamus-pituitary 
axis in response to inflammation, promotes osteoclastogenesis, and influences 
intermediary metabolism (73).  Elevations in IL-6 concentrations may be due to increases 
in immune activity (101), unrelated inflammation (22), catecholamine production (105), 
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and exercise (73).  The exercise-induced increase in IL-6 concentrations has been 
suggested to be a consequence of  an immune response do to local damage in the working 
muscle (83), until recently debated.   
     Starkie and colleagues (106) have demonstrated that the immune cells are not the 
source of the increase in plasma IL-6 during exercise.  Furthermore, Febbraio and 
colleagues (30) suggest the production of IL-6 in response to exercise is not an exercise 
induced immune response, it’s a direct release from the muscle contraction itself.  They 
refer to IL-6 as a myokine, a cytokine released from the skeletal muscle itself.  The 
investigations from Pedersen and colleagues (88) support this phenomenon by suggesting 
that IL-6 is linked more so with metabolism (exercise) than it is with inflammation. 
Furthermore, the production of IL-6 during exercise is related to the intensity and 
duration of the exercise (89). 
     Ullum and colleagues (116) report an increase in IL-6 in response to one-hour of cycle 
ergometry at 75% of maximal oxygen intake.  In addition a 3 hour combination of cycle 
ergometry and treadmill running at 60-65% VO2max  increased IL-6 concentration greater 
than 18 fold compared to baseline values (75).   Increases in IL-6 in response to cycling, 
treadmill, rowing, and eccentric exercise have all been reported (100).  In addition, there 
appears to be a dose response relationship of amount of plasma IL-6 observed and 
exercise intensity (40% - 90%) with the greatest increase occurring at a relative intensity 
of ~75% (100).  
     There is conclusive evidence that IL-6 is released in response to all types, modes, and 
durations of exercise; however, the remaining unanswered question of why it is released 
is debated. During exercise there may be an increase in IL-6 from muscle to increase 
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lipolysis and fat oxidation, but Pedersen and colleagues (88) report that IL-6 is not the 
sole mediator of these outcomes.  IL-6 has also been shown to impair TNF-a expression 
in cardiac muscle (107) and skeletal muscle (89); consequently, the augmentation of 
endothelial function associated with acute and chronic exercise may be associated with 
the IL-6 mediated TNF-a suppression.   
     In summary, it appears that TNF-α and IL-6 are tightly linked. TNF-α is released in 
response to high levels of stress hormones (ie. catecholamines and cortisol), whether it be 
physical stress or psychosocial stress.  Furthermore, chronic exercise has been shown to 
decrease TNF-α concentrations in clinical populations.  There is concrete evidence that 
there are exercise associated increases in plasma concentrations of IL-6; however, there 
appears to be no change in plasma TNF-α in response to acute exercise unless the dose 
consists of high intensity and long duration.  IL-6 has been classified as both an anti and 
pro inflammatory cytokine; however, recent evidence suggests its primary responsibility 
is an anti-inflammatory myokine.  It still remains unclear whether IL-6 acts directly as an 
anti-inflammatory mediator or whether it acts to stimulate other anti-inflammatory 
cytokines (ie. IL-1ra and IL-10).  In addition, it is unclear if the elevated concentrations 
of IL-6 in response to exercise directly influence the endothelial response. The increase in 
concentrations of IL-6 in response to exercise may be a factor in controlling the pro-
inflammatory response, thus limiting the TNF-α response, resulting in an improvement of 
endothelial function.  Or is the major production of IL-6 produced in conjunction with 
depleted muscle glycogen, and does not play a contributing role in the endothelial 
response at all? Needless to say, further investigations are warranted to identify this 
phenomenon. 
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OVERALL CONCLUSION  
     Over the past 20 years, research has discovered essential physiological functions from 
a mono layer of cells known as the endothelium.  A dysfunctional endothelium has been 
identified to be the first indicator of several pathological diseases.  More and more 
research is focusing on exercise training as a non-pharmacological agent in providing 
maintenance or improvements in endothelial function, yet there is limited research 
utilizing an acute exercise model.  There is no doubt that exercise in general improves 
endothelial function; however, the mechanisms associated with this improvement are not 
fully understood. There are several biomarkers that need to be investigated to assist in 
identifying the possible mechanisms associated with the exercise mediated improvements 
in endothelial function.  It may seem intuitive to assess markers of oxidative stress and/or 
antioxidants to help explain the improvement of FMD following chronic exercise; 
however, there is conclusive evidence that suggests an increase in oxidative stress along 
with no change in antioxidant status following acute exercise.  This evidence would not 
support the augmentation of endothelial function.  So what are the possible mechanisms 
associated with the improvement in endothelial function following acute exercise?  This 
review has supported investigating the combination of TNF-alpha and IL-6 together 
following acute exercise.  The relationship of these two biomarkers may provide insight 
into linking the possible physiological mechanisms associated with the improvement in 
FMD following a single exercise session. 
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TABLE 1.  SUBJECT DEMOGRAPHICS  
 
 
 
 
BMI – Body mass index, SBP – Systolic blood pressure (mm Hg), DBP – Diastolic blood pressure (mm Hg),  
TG – Triglycerides (mg dL) 
Subject 
# Sex 
Age 
(yrs) 
Height 
(cm) 
Weight 
(kg) 
BMI 
(ht2/kg) Exercise/Week
Resting 
SBP 
Resting 
DBP 
Fasting 
Glucose TG 
3042 M 62 175.2 81.93 26.7 1.5 107 79 89 51 
3043 M 46 177.6 96.75 30.7 0.0 110 72 95 246 
3044 M 58 166.2 80.15 29.0 1.5 122 70 97 137 
3045 M 63 181.9 102.6 31.0 0.0 122 89 96 98 
3046 M 53 177.2 87.1 27.7 1.5 116 73 92 182 
3047 M 50 171 101.8 34.8 1.0 116 90 103 289 
3050 M 68 171.4 84.31 28.7 0.0 132 82 90 176 
3054 M 55 174.4 77.16 25.4 0.0 120 80 98 155 
Mean   56.9 174.4 89.0 29.3 0.7 118.1 79.4 95.0 166.8 
SD   7.3 4.8 10.0 2.9 0.8 7.8 7.5 4.6 76.2 
SEM   2.6 1.7 3.5 1.0 0.3 2.8 2.7 1.6 27.0 
3048 M 66 181 89 27.2 3.0 110 60 87 151 
3049 M 47 179.5 101.4 31.5 4.0 106 82 94 74 
3051 M 65 173.6 79.5 26.4 5.0 122 78 77 74 
3052 M 68 173.7 75.5 25.0 7.0 102 76 96 176 
3053 M 62 174.6 86.13 28.3 3.5 96 70 95 109 
3055 M 54 173.1 81.55 27.2 4.0 126 72 92 114 
3056 M 66 180.7 87.13 26.7 3.5 132 76 89 39 
3057 M 51 174.2 81.81 27.0 5.0 126 72 109 130 
Mean   59.9 176.3 85.3 27.4 4.4 115.0 73.3 92.4 108.4 
SD   8.0 3.4 7.9 1.9 1.3 13.2 6.6 9.1 44.8 
SEM   2.8 1.2 2.8 0.7 0.5 4.7 2.3 3.2 15.8 
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TABLE 1. (Continued) SUBJECT DEMOGRAPHICS  
 
Subject # CRP TC LDL HDL 
VO2peak 
(ml/kg) 
3042 0.62 141.0 78.0 53.0 31.6 
3043 1.58 218.0 135.0 34.0 31.4 
3044 6.31 148.0 77.0 44.0 36.8 
3045 18.3 218.0 116.0 82.0 31.5 
3046 0.84 184.0 96.0 52.0 31.3 
3047 2.55 204.0 111.0 35.0 27.5 
3050 1.01 204.0 130.0 39.0 25.2 
3054 0.54 138.0 62.0 45.0 32.0 
Mean 3.97 181.9 100.6 48.0 30.9 
SD 6.10 34.5 26.7 15.4 3.4 
SEM 2.16 12.2 9.4 5.5 1.2 
3048 2.89 242.0 156.0 56.0 40.1 
3049 1.01 218.0 135.0 68.0 35.1 
3051 0.61 193.0 119.0 59.0 36.2 
3052 0.52 185.0 112.0 38.0 25.4 
3053 1.06 158.0 107.0 29.0 36.0 
3055 0.91 275.0 202.0 50.0 38.1 
3056 2.42 148.0 80.0 60.0 33.4 
3057 2.30 222.0 122.0 74.0 29.6 
Mean 1.47 205.1 129.1 54.3 34.2 
SD 0.92 42.6 36.7 14.9 4.7 
SEM 0.33 15.1 13.0 5.3 1.7 
 
CRP – C-reactive protein (mg/L), TC – Total cholesterol (mg/dL), LDL – Low-density lipoprotein cholesterol (mg/dL),  
HDL – High-density lipoprotein (mg/dL) 
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TABLE 2.  EXERCISE INDUCED VARIABLES 
 
Subject 
# 
VO2 
(25%) 
RPE 
(25%) 
HR 
(25%) SBP(25%) DBP(25%)
VO2 
(50%) 
RPE 
(50%) HR(50%) SBP(50%) DBP(50%)
3042 8.4 10 104 104 66 16.2 12.0 141 138 70 
3043 7.76 8.5 95 108 69 16.0 14.6 123 122 68 
3044 9.33 7 72 119 77 18.9 10.0 92 133 67 
3045 7.79 9 83 127 76 16.2 9.5 100 160 82 
3046 8.2 7 86 128 87 15.5 11.0 116 137 76 
3047 7.3 7.25 97 138 83 13.3 10.4 117 172 82 
3050 7.34 7.9 81 141 101 12.2 12.0 106 146 89 
3054 8.1 7.6 84 117 70 16.5 11.0 116 131 62 
Mean 8.0 8.0 87.8 122.8 78.4 15.6 11.3 113.8 142.4 74.5 
SD 0.7 1.1 10.0 13.2 11.6 2.1 1.6 14.9 16.4 9.3 
SEM 0.2 0.4 3.5 4.7 4.1 0.7 0.6 5.3 5.8 3.3 
3048 10.19 8 59 99 63 20.6 13.0 89 130 73 
3049 9.26 7.6 80 133 94 17.8 11.8 118 148 77 
3051 9.2 8.1 74 122 78 18.4 11.9 104 135 75 
3052 7.5 7 74 105 63 12.8 9.0 100 114 69 
3053 8.7 8.25 84 145 73 17.9 11.5 111 114 62 
3055 9.39 7.6 77 119 65 18.6 11.9 102 132 63 
3056 8.47 8 72 141 75 16.5 13.0 104 160 70 
3057 7.09 7 84 144 82 15.4 9.0 115 124 75 
Mean 8.7 7.7 75.5 125.8 74.1 17.3 11.4 105.4 132.1 70.4 
SD 1.0 0.5 8.2 17.8 10.9 2.4 1.6 9.2 15.9 5.7 
SEM 0.4 0.2 2.9 6.3 3.8 0.8 0.6 3.2 5.6 2.0 
 
 
RPE – Rating of perceived exertion (6-20), HR – Heart rate, Systolic blood pressure (mm Hg) 
DBP – Diastolic blood pressure (mm Hg) 
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TABLE 2. (Continued) EXERCISE INDUCED VARIABLES 
 
Subject # 
RPE 
(50%R) HR(50%R) SBP(50%R) DBP(50%R)
VO2 
(75%) 
RPE 
(75%) HR(75%) SBP(75%) DBP(75%)
3042 12.0 137 137 79.3 23.5 14.0 162 140 68 
3043 14.7 108.1 129 69.2 23.5 17.2 150 159 79 
3044 11.5 97.4 134.8 72 28.7 14.0 126 159 70 
3045 9.0 86.9 139.6 78.2 22.9 13.2 140 190 80 
3046 11.0 116.6 137.6 78.9 24.7 13.9 146 154 76 
3047 10.1 114.6 144 76.8 19.6 14.3 145 196 79 
3050     18.4 12.8 126 164 94 
3054     25.1 14.0 150 155 55 
Mean 11.4 110.1 137.0 75.7 23.3 14.2 143.3 164.4 75.1 
SD 1.9 17.3 5.0 4.2 3.2 1.3 12.4 19.1 11.3 
SEM 0.7 6.1 1.8 1.5 1.1 0.5 4.4 6.8 4.0 
3048 12.6 83.8 130.5 70 30.5 14.5 132 157 65 
3049     26.9 14.9 161 180 79 
3051     27.9 12.9 127 156 78 
3052     19.6 11.5 133 114 58 
3053 10.4 116.1 112.3 63.5 26.9 15.3 140 147 62 
3055 12.0 104.1 135.5 54.3 28.5 13.8 141 166 64 
3056     24.6 13.8 130 191 76 
3057     21.5 13.1 151 150 77 
Mean 11.7 101.3 126.1 62.6 25.8 13.7 139.2 157.5 69.6 
SD 1.1 16.3 12.2 7.9 3.7 1.2 11.6 23.1 8.4 
SEM 0.4 5.8 4.3 2.8 1.3 0.4 4.1 8.2 3.0 
 
 
RPE – Rating of perceived exertion (6-20), HR – Heart rate, Systolic blood pressure (mm Hg), R – reproducibility, 
DBP – Diastolic blood pressure (mm Hg) 
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TABLE 3.  FLOW-MEDIATED DILATION SUMMARY (25%) 
 
 25%     
Subject A B C D E 
R3042 14.39219 14.28968 11.0932 12.41165 9.883886 
R3043 6.411502 3.434304 9.192037 4.188895 10.82431 
R3044 8.426184 2.422548 2.783019 5.299861 6.413302 
R3045 1.778291 4.220009 4.295333 4.507435 5.91716 
R3046 6.689965 4.891304 6.364562 6.18478 4.572009 
R3047 12.75964 7.089552 9.706601 8.940397 8.606752 
R3048 3.355057 4.883382 1.319003 -1.26614 1.15636 
R3049 6.939281 11.3477 10.28278 7.42512 6.108026 
R3050 9.001866 7.465155 5.782629 7.157846 7.949791 
R3051 6.141975 3.939674 10.04507 6.414849 10.61169 
R3052 2.771809 1.626751 8.188825 0.877983 4.064097 
R3053 1.756919 4.366919 6.109635 3.597296 4.584248 
R3054 7.025219 7.746281 5.443819 6.336854 8.504484 
R3055 6.623979 3.472683 7.870882 9.347874 4.993283 
R3056 4.253713 0.721696 4.795521 1.540313 2.958153 
R3057 9.434792 12.0399 16.69184 15.8793 11.17346 
Mean 6.735149 5.872346 7.497798 6.177769 6.770063 
SD 3.591203 3.874962 3.727418 4.261778 3.005329 
SEE 0.897801 0.968741 0.931855 1.065444 0.751332 
N= 16 16 16 16 16 
 
FMD is expressed as a percent (%) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 4.  FLOW-MEDIATED DILATION SUMMARY (50%) 
 
 50%     
Subject A B C D E 
R3042 6.19252 8.593272 6.631709 9.798832 8.930292 
R3043 8.658281 8.163265 4.279919 10.53719 2.588528 
R3044 14.11146 6.898215 5.633479 1.114801 4.42055 
R3045 4.716336 1.644885 4.449541 4.498594 3.69357 
R3046 7.55988 2.39899 3.096903 4.802831 6.678608 
R3047 8.565154 5.377658 7.647345 9.846079 7.573599 
R3048 4.252704 1.079963 4.186834 2.480774 3.110571 
R3049 12.5194 17.64072 17.08323 9.888399 8.869239 
R3050 3.397028 5.258216 5.521749 4.192726 5.081157 
R3051 6.590347 7.210626 6.037152 6.523116 8.333333 
R3052 4.067642 1.110854 5.860983 3.60549 5.531506 
R3053 6.600249 5.589744 8.192231 3.559707 4.138106 
R3054 8.600159 4.904338 6.893777 9.6 8.121411 
R3055 9.250903 5.147392 4.808331 6.450878 4.151706 
R3056 1.389227 -3.97045 2.389967 -0.21388 4.777308 
R3057 10.5549 6.764082 13.1712 10.97473 11.90818 
Mean 7.314137 5.238236 6.617772 6.103767 6.119229 
SD 3.386625 4.640193 3.730859 3.6189 2.602852 
SEE 0.846656 1.160048 0.932715 0.904725 0.650713 
N= 16 16 16 16 16 
 
FMD is expressed as a percent (%) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 5.  FLOW-MEDIATED DILATION SUMMARY (75%) 
 
 75%     
Subject A B C D E 
R3042 3.896104 2.118138 4.172921 5.0625 9.042049 
R3043 8.201058 6.604375 8.571985 7.716049 7.610063 
R3044 7.652823 4.902416 5.097947 5.260594 5.288578 
R3045 7.729575 5.598622 4.831338 7.667659 8.514851 
R3046 13.23496 5.715552 7.627866 8.623771 6.59293 
R3047 6.035122 3.059478 3.29849 9.124907 7.070949 
R3048 2.696133 -1.12474 3.359766 2.486002 0.563063 
R3049 12.84523 11.19247 13.68204 9.851952 8.2054 
R3050 8.55792 3.773585 4.903955 6.378132 2.95104 
R3051 6.244057 7.160883 10.94205 8.759362 8.383035 
R3052 3.219829 -3.76263 4.988345 4.100069 6.213365 
R3053 6.560738 2.784388 8.571429 4.856568 1.276596 
R3054 8.0466 6.073753 7.807571 5.772314 6.522883 
R3055 5.723669 4.072598 9.090909 1.79301 2.79476 
R3056 7.476869 0.996755 1.222379 2.455032 3.708222 
R3057 10.17935 6.857826 8.987952 11.26695 8.241506 
Mean 7.393752 4.126466 6.697309 6.323429 5.811205 
SD 2.973118 3.545246 3.246753 2.828959 2.734763 
SEE 0.743279 0.886311 0.811688 0.70724 0.683691 
N= 16 16 16 16 16 
 
FMD is expressed as a percent (%) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 6.  FLOW-MEDIATED DILATION SUMMARY (50% R) 
 
 50%R     
Subject A B C D E 
R3042 4.220293 6.251973 5.649718 3.625838 8.131068 
R3043 8.02626 7.591457 5.122951 14.87475 6.724283 
R3044 7.05913 9.036922 5.238221 2.576408 6.525038 
R3045 5.336154 1.755986 4.62963 2.801978 1.950313 
R3046 9.951764 4.397852 6.997389 7.82331 5.177665 
R3047 11.94409 10.16097 10.7089 5.886736 5.643013 
R3048 3.549161 0.479343 1.824292 2.177636 3.311753 
R3049 0 0 0 0 0 
R3050 0 0 0 0 0 
R3051 0 0 0 0 0 
R3052 0 0 0 0 0 
R3053 5.78215 4.112923 6.476868 6.202501 6.656841 
R3054 0 0 0 0 0 
R3055 6.891767 4.303233 6.866953 5.162175 4.035167 
R3056 0 0 0 0 0 
R3057 0 0 0 0 0 
Mean 6.973419 5.343406 5.946102 5.681259 5.350571 
SD 2.695033 3.21615 2.369284 3.938948 1.945129 
SEE 0.673758 0.804038 0.592321 0.984737 0.486282 
N= 16 16 16 16 16 
 
FMD is expressed as a percent (%) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
R- reproducibility 
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TABLE 7.  BASELINE DIAMETER SUMMARY (25%) 
 
 25%     
Subject A B C D E 
R3042 3.891 3.604 3.723 3.537 3.531 
R3043 5.147 5.183 5.124 5.061 4.804 
R3044 4.308 4.293 4.24 4.302 4.21 
R3045 4.33 4.218 4.307 4.304 4.056 
R3046 4.006 4.048 3.928 3.929 3.937 
R3047 4.044 4.02 4.09 4.228 4.206 
R3048 4.143 4.116 4.094 4.028 3.978 
R3049 4.035 3.851 3.89 3.973 3.962 
R3050 4.288 4.233 4.306 4.289 4.302 
R3051 3.24 3.249 3.106 3.071 2.959 
R3052 4.654 4.426 4.152 4.442 4.306 
R3053 4.155 4.099 4.141 4.142 4.101 
R3054 3.886 3.563 3.729 3.598 3.457 
R3055 4.529 4.521 4.523 4.493 4.466 
R3056 3.973 4.434 4.108 4.155 4.158 
R3057 4.547 4.211 3.972 4.043 4.099 
Mean 4.1985 4.129313 4.089563 4.099688 4.03325 
SD 0.41869 0.525621 0.484344 0.504384 0.416596 
 
Diameter is expressed in millimeters (mm)  
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 8.  BASELINE DIAMETER SUMMARY (50%) 
 
 50%     
Subject A B C D E 
R3042 3.262 3.27 3.242 3.082 3.113 
R3043 4.77 4.802 4.93 4.84 4.829 
R3044 4.181 4.146 4.349 4.216 4.185 
R3045 4.389 4.438 4.36 4.268 4.386 
R3046 3.939 3.911 3.83 3.758 3.94 
R3047 4.098 4.091 4.106 4.093 4.212 
R3048 4.068 4.352 4.132 4.031 4.115 
R3049 3.866 3.713 3.881 3.853 3.732 
R3050 4.239 4.26 4.437 4.317 4.251 
R3051 3.232 3.162 3.23 3.158 3.108 
R3052 4.376 4.321 4.129 4.299 4.158 
R3053 4.015 3.9 4.016 3.961 3.939 
R3054 3.779 3.711 3.728 3.625 3.657 
R3055 4.432 4.41 4.513 4.387 4.456 
R3056 4.103 4.332 4.226 4.208 4.019 
R3057 4.235 4.243 4.153 4.155 4.182 
Mean 4.0615 4.066375 4.078875 4.015688 4.017625 
SD 0.503368 0.516392 0.569167 0.587028 0.571327 
 
Diameter is expressed in millimeters (mm)  
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 9.  BASELINE DIAMETER SUMMARY (75%) 
 
 75%     
Subject A B C D E 
R3042 3.234 3.352 3.331 3.2 3.163 
R3043 3.78 4.709 5.133 4.86 4.77 
R3044 4.286 4.304 4.237 4.106 4.141 
R3045 4.541 4.644 4.595 4.369 4.545 
R3046 4.337 4.514 4.536 4.476 4.611 
R3047 4.043 4.674 4.305 4.011 4.172 
R3048 4.525 4.89 4.792 4.465 4.44 
R3049 3.838 3.824 3.881 3.715 3.778 
R3050 4.23 4.399 4.425 4.39 4.473 
R3051 3.155 3.17 3.089 3.071 3.018 
R3052 4.317 4.651 4.29 4.317 4.265 
R3053 3.902 4.202 3.955 3.974 3.995 
R3054 3.691 3.688 3.804 3.742 3.802 
R3055 4.263 4.518 4.323 4.406 4.58 
R3056 3.999 4.314 4.254 4.114 4.099 
R3057 4.126 4.185 4.15 4.278 4.356 
Mean 4.016688 4.252375 4.19375 4.093375 4.138 
SD 0.472633 0.518409 0.593403 0.56207 0.580634 
 
Diameter is expressed in millimeters (mm) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 10.  BASELINE DIAMETER SUMMARY (50% R) 
 
 50%R     
Subject A B C D E 
R3042 3.341 3.167 3.363 3.282 3.296 
R3043 4.722 4.729 4.88 4.511 4.744 
R3044 3.839 3.873 3.799 3.959 3.954 
R3045 4.254 4.385 4.32 4.247 4.307 
R3046 4.008 3.96 4.004 3.956 3.908 
R3047 3.935 3.976 3.978 4.026 4.129 
R3048 4.17 4.381 4.166 4.087 4.016 
R3049 0 0 0 0 0 
R3050 0 0 0 0 0 
R3051 0 0 0 0 0 
R3052 0 0 0 0 0 
R3053 4.168 4.109 4.215 4.079 4.071 
R3054 0 0 0 0 0 
R3055 4.324 4.485 4.427 4.378 4.436 
R3056 0 0 0 0 0 
R3057 0 0 0 0 0 
Mean 4.084556 4.118333 4.128 4.058333 4.095667 
SD 0.378821 0.455261 0.423102 0.347853 0.400569 
 
Diameter is expressed in millimeters (mm)  
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
R- reproducibility 
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TABLE 11.  HYPEREMIC DIAMETER SUMMARY (25%) 
 
 25%     
Subject A B C D E 
R3042 4.451 4.119 4.136 3.976 3.88 
R3043 5.477 5.361 5.595 5.273 5.324 
R3044 4.671 4.397 4.358 4.53 4.48 
R3045 4.407 4.396 4.492 4.498 4.296 
R3046 4.274 4.246 4.178 4.172 4.117 
R3047 4.56 4.305 4.487 4.606 4.568 
R3048 4.282 4.317 4.148 3.977 4.024 
R3049 4.315 4.288 4.29 4.268 4.204 
R3050 4.674 4.549 4.555 4.596 4.644 
R3051 3.439 3.377 3.418 3.268 3.273 
R3052 4.783 4.498 4.492 4.481 4.481 
R3053 4.228 4.278 4.394 4.291 4.289 
R3054 4.159 3.839 3.932 3.826 3.751 
R3055 4.829 4.678 4.879 4.913 4.689 
R3056 4.142 4.466 4.305 4.219 4.281 
R3057 4.976 4.718 4.635 4.685 4.557 
Mean 4.479188 4.3645 4.393375 4.348688 4.303625 
SD 0.431717 0.448394 0.537683 0.44527 0.497594 
 
Diameter is expressed in millimeters (mm) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 12.  HYPEREMIC DIAMETER SUMMARY (50%) 
 
 50%     
Subject A B C D E 
R3042 3.464 3.551 3.457 3.384 3.391 
R3043 5.183 5.194 5.141 5.35 4.954 
R3044 4.771 4.432 4.594 4.263 4.37 
R3045 4.596 4.511 4.554 4.46 4.548 
R3046 4.331 4.083 4.098 4.052 4.144 
R3047 4.449 4.311 4.42 4.496 4.531 
R3048 4.241 4.399 4.305 4.131 4.243 
R3049 4.35 4.368 4.544 4.234 4.063 
R3050 4.383 4.484 4.682 4.498 4.467 
R3051 3.445 3.39 3.425 3.364 3.367 
R3052 4.554 4.369 4.371 4.454 4.388 
R3053 4.28 4.118 4.345 4.102 4.102 
R3054 4.104 3.893 3.985 3.973 3.954 
R3055 4.842 4.637 4.73 4.67 4.641 
R3056 4.16 4.16 4.327 4.199 4.211 
R3057 4.682 4.53 4.7 4.611 4.68 
Mean 4.364688 4.276875 4.354875 4.265063 4.253375 
SD 0.573852 0.539655 0.563596 0.642097 0.52819 
 
Diameter is expressed in millimeters (mm) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 13.  HYPEREMIC DIAMETER SUMMARY (75%) 
 
 75%     
Subject A B C D E 
R3042 3.36 3.423 3.47 3.362 3.449 
R3043 4.09 5.02 5.573 5.235 5.133 
R3044 4.614 4.515 4.453 4.322 4.36 
R3045 4.892 4.904 4.817 4.704 4.932 
R3046 4.911 4.772 4.882 4.862 4.915 
R3047 4.287 4.817 4.447 4.377 4.467 
R3048 4.647 4.835 4.953 4.576 4.465 
R3049 4.331 4.252 4.412 4.081 4.088 
R3050 4.592 4.565 4.642 4.67 4.605 
R3051 3.352 3.397 3.427 3.34 3.271 
R3052 4.456 4.476 4.504 4.494 4.53 
R3053 4.158 4.319 4.294 4.167 4.046 
R3054 3.988 3.912 4.101 3.958 4.05 
R3055 4.507 4.702 4.716 4.485 4.708 
R3056 4.298 4.357 4.306 4.215 4.251 
R3057 4.546 4.472 4.523 4.76 4.715 
Mean 4.314313 4.421125 4.47 4.3505 4.374063 
SD 0.58811 0.588955 0.692093 0.640557 0.612194 
 
Diameter is expressed in millimeters (mm)  
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 14.  HYPEREMIC DIAMETER SUMMARY (50% R) 
 
 50%R     
Subject A B C D E 
R3042 3.482 3.365 3.553 3.401 3.564 
R3043 5.101 5.088 5.13 5.182 5.063 
R3044 4.11 4.223 3.998 4.061 4.212 
R3045 4.481 4.462 4.52 4.366 4.391 
R3046 4.311 4.055 4.128 4.146 4.169 
R3047 4.405 4.38 4.404 4.263 4.362 
R3048 4.318 4.402 4.242 4.176 4.149 
R3049 0 0 0 0 0 
R3050 0 0 0 0 0 
R3051 0 0 0 0 0 
R3052 0 0 0 0 0 
R3053 4.409 4.278 4.488 4.332 4.342 
R3054 0 0 0 0 0 
R3055 4.622 4.678 4.731 4.604 4.615 
R3056 0 0 0 0 0 
R3057 0 0 0 0 0 
Mean 4.359889 4.325667 4.354889 4.281222 4.318556 
SD 0.429293 0.466585 0.450592 0.471478 0.400248 
 
Diameter is expressed in millimeters (mm) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
R- reproducibility 
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TABLE 15.  BASELINE VELOCITY SUMMARY (25%) 
 
 25%     
Subject A B C D E 
R3042 16 19.1 21.7 15.2 16.5 
R3043 37 41.8 35.8 22.4 13.2 
R3044 16 24 13.4 12.8 10.6 
R3045 13 27.2 12.9 9.7 7.3 
R3046 20 23 11.4 13.2 9.2 
R3047 12 15.5 7.3 9.3 11.1 
R3048 24 12.6 7.3 6.3 9.9 
R3049 22 20.5 15.7 7.7 7.4 
R3050 36 20 19.6 19.1 15.9 
R3051 12 16.5 7.9 10 8.5 
R3052 11 9.6 11.3 7.6 6.9 
R3053 29 10.8 10.9 6.2 7.7 
R3054 18 31.3 9.5 8.2 8.6 
R3055 20 21.2 22.4 19.6 12 
R3056 19 34.2 22.3 11.9 11.4 
R3057 12 13.7 16 11.5 11.8 
Mean 19.7375 21.3125 15.3375 11.91875 10.5 
SD 9.024781 9.133236 10.30251 4.78191 3.212112 
 
Velocity is expressed in centimeters per second (cm/s) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 16.  BASELINE VELOCITY SUMMARY (50%) 
 
 50%     
Subject A B C D E 
R3042 19.6 27.5 24.9 18.8 13.7 
R3043 29.7 25.9 29.5 17 11.9 
R3044 20.8 29.8 23.8 16.6 13.8 
R3045 18.3 25.1 13.5 16.6 14.3 
R3046 18.8 23.1 12.4 10.5 8.8 
R3047 10.9 23 11.9 8.9 9.6 
R3048 10.2 34.2 13.8 10.1 8.6 
R3049 23.6 21.1 20.2 10.7 8.2 
R3050 30.8 25.5 15.9 9.8 11.8 
R3051 12.9 18.4 10.7 7.4 9.1 
R3052 7.4 16.4 8.9 8.7 9.1 
R3053 38.9 23.7 14 9.1 8.8 
R3054 15.4 27.3 15.9 12.4 11.1 
R3055 21.1 14.5 14.6 12.1 9.6 
R3056 21.7 27.7 13.1 12.5 12.4 
R3057 12.5 19.2 11.9 13.1 12.4 
Mean 19.5375 23.9 15.9375 12.14375 10.825 
SD 6.023759 2.626531 7.637452 4.014806 2.34215 
 
Velocity is expressed in centimeters per second (cm/s) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 17.  BASELINE VELOCITY SUMMARY (75%) 
 
 75%     
Subject A B C D E 
R3042 25.3 33.5 16 13.6 15.2 
R3043 27.4 27.3 35.4 23.8 10.9 
R3044 15.8 31.2 17.3 12.8 11.1 
R3045 18.1 36.3 20.8 24.4 21.2 
R3046 22.1 25.8 25 11.6 8.4 
R3047 10.1 15.5 13.1 12.7 10.4 
R3048 16.4 46.8 12.1 10.1 8.2 
R3049 15.8 28.5 16.9 11 9.4 
R3050 33.3 35.1 31.5 17 12.7 
R3051 13.7 18.8 16.3 9.3 9.4 
R3052 10.4 17.4 8.7 8.9 8.2 
R3053 13.3 51.7 15.5 11.7 9.7 
R3054 25.2 31.2 13 12.8 22.6 
R3055 15 24.6 13.8 11.1 9.4 
R3056 26.7 24.1 15.4 13.1 11.7 
R3057 9.5 13.8 10.2 13.7 11 
Mean 18.63125 28.85 17.5625 13.6 11.84375 
SD 6.423083 7.355723 8.050756 5.937143 4.645715 
 
Velocity is expressed in centimeters per second (cm/s) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 18.  BASELINE VELOCITY SUMMARY (50% R) 
 
 50%R     
Subject A B C D E 
R3042 36.5 36.5 28.4 14.4 22 
R3043 40.2 40 20.2 29.3 13.2 
R3044 20.6 24.3 7.9 8.3 13 
R3045 15.2 27 14.4 13.1 8.6 
R3046 12.4 23.4 9.9 11.3 8.2 
R3047 12.7 20.4 14.1 10.3 11.7 
R3048 14.4 34.2 9.4 10 8.3 
R3049 0 0 0 0 0 
R3050 0 0 0 0 0 
R3051 0 0 0 0 0 
R3052 0 0 0 0 0 
R3053 24.9 32.6 23.5 13.1 12.5 
R3054 0 0 0 0 0 
R3055 19.5 24.7 14.6 11.5 10 
R3056 0 0 0 0 0 
R3057 0 0 0 0 0 
Mean 21.82222 29.23333 15.82222 13.47778 11.94444 
SD 10.24985 6.76997 6.909012 6.216265 4.278467 
 
Velocity is expressed in centimeters per second (cm/s) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
R- reproducibility 
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TABLE 19.  HYPEREMIC VELOCITY SUMMARY (25%) 
 
 25%     
Subject A B C D E 
R3042 107.8 125.2 146.7 145.8 132.1 
R3043 109.6 143.4 95.8 99.7 104.7 
R3044 93.3 94.7 95 84.3 86.6 
R3045 93.3 78 70.9 80.6 73.7 
R3046 122.3 97.2 94.3 113 104.3 
R3047 114.6 104.8 86 89.4 103.1 
R3048 73.5 65.4 69.7 57.8 81.4 
R3049 132.5 94.5 102 103.3 90.2 
R3050 115 102.9 113.7 121.1 117.5 
R3051 80 74.6 81.2 81.3 87.3 
R3052 80.5 65.6 61.9 72.6 66.3 
R3053 57.5 53.6 48.1 57.7 55 
R3054 100 103.2 90.4 79.3 66.9 
R3055 73.4 134.3 73.5 78 76.3 
R3056 89.1 80.8 85.4 85 80.8 
R3057 83.1 94 96 103.7 89.8 
Mean 106.8167 107.2167 98.11667 102.1333 100.75 
SD 11.61403 23.44819 25.60292 24.39112 19.74069 
 
Velocity is expressed in centimeters per second (cm/s) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 20.  HYPEREMIC VELOCITY SUMMARY (50%) 
 
 50%     
Subject A B C D E 
R3042 116.9 104.5 131.3 136.2 84.8 
R3043 78.1 96.8 115.4 90 91.8 
R3044 104.8 96.4 85.9 77.4 94 
R3045 91.7 88 101.3 73 84.5 
R3046 120.3 109.7 114.5 86.9 89.1 
R3047 95.1 97 83.2 96.5 91.3 
R3048 75.3 66.6 68.3 59.9 55.7 
R3049 124.1 110.6 98 93.5 85.7 
R3050 111.3 87.3 104.1 84 80.5 
R3051 102.4 60 74.3 73.5 83.6 
R3052 57.6 70.5 52.9 65.1 59 
R3053 83.5 79.4 71.3 70.4 66 
R3054 51.7 79.4 99.7 95.4 74.3 
R3055 100.2 67.3 134.7 82.5 60.4 
R3056 67 60.3 68.1 75.6 82 
R3057 104.1 100 92.7 110.2 94.2 
Mean 101.15 98.73333 105.2667 93.33333 89.25 
SD 16.03318 7.49551 18.67305 22.66007 3.889859 
 
Velocity is expressed in centimeters per second (cm/s) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
   128
TABLE 21.  HYPEREMIC VELOCITY SUMMARY (75%) 
 
 75%     
Subject A B C D E 
R3042 87.7 112.6 100.7 99.5 108.8 
R3043 118.4 110.9 114.4 107.6 98.5 
R3044 85.7 96.9 79.5 78.7 65.6 
R3045 96.5 94.4 102.1 78.9 93.3 
R3046 101 116.4 117.4 107.5 63.9 
R3047 96.5 84.5 98.4 74.7 73 
R3048 71.2 79 62.9 73.2 45.3 
R3049 126.9 104.6 114.2 107.5 88.7 
R3050 111.7 105.3 125.3 98.6 85.6 
R3051 91.8 91.5 90 75.68 89 
R3052 78.5 83.8 59.8 57 52.1 
R3053 84.9 80.4 73.2 70 70.1 
R3054 93.6 84.1 88 83.1 70.1 
R3055 90.9 69 62.8 60 66.8 
R3056 117 77.3 78.9 73.6 83.2 
R3057 130.6 82.3 86.1 101.5 96.6 
Mean 97.63333 102.6167 102.0833 91.15 83.85 
SD 11.71523 12.54327 13.50399 15.38386 18.84258 
 
Velocity is expressed in centimeters per second (cm/s) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 22. HYPEREMIC VELOCITY SUMMARY (50% R) 
 
 50%R     
Subject A B C D E 
R3042 115.4 104.4 112.4 104.5 125.4 
R3043 97.8 97.8 101.7 86.2 102.7 
R3044 90.1 78.1 79.7 90.4 74.4 
R3045 105.1 97.1 78.8 90.8 83.9 
R3046 102.1 94.9 94.9 96.8 109.8 
R3047 99.8 113.2 98.6 85 99.8 
R3048 92.7 66 63 57.9 66.2 
R3049 0 0 0 0 0 
R3050 0 0 0 0 0 
R3051 0 0 0 0 0 
R3052 0 0 0 0 0 
R3053 58 81.9 72.3 63.2 66.4 
R3054 0 0 0 0 0 
R3055 83.2 80.8 85.2 84.6 62.2 
R3056 0 0 0 0 0 
R3057 0 0 0 0 0 
Mean 93.8 90.46667 87.4 84.37778 87.86667 
SD 16.29432 14.7765 15.70287 14.95851 22.4677 
 
Velocity is expressed in centimeters per second (cm/s) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
R- reproducibility 
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TABLE 23.  BASELINE LOCAL SHEAR STRESS SUMMARY (25%) 
 
 25%     
Subject A B C D E 
R3042 1.151375 1.483907 1.632017 1.20328 1.308411 
R3043 1.996503 2.258152 1.956284 1.239281 0.769359 
R3044 1.046425 1.565339 0.884906 0.833101 0.704988 
R3045 0.860046 1.805595 0.838635 0.631041 0.503945 
R3046 1.376935 1.590909 0.812627 0.940697 0.654305 
R3047 0.858556 1.079602 0.499756 0.615894 0.738944 
R3048 1.594979 0.857143 0.499267 0.437934 0.696833 
R3049 1.498885 1.490522 1.130077 0.542663 0.522968 
R3050 2.318097 1.322939 1.274501 1.246911 1.034868 
R3051 1.054321 1.421976 0.71217 0.911755 0.804326 
R3052 0.649764 0.60732 0.762042 0.479063 0.448676 
R3053 1.920578 0.737741 0.73702 0.419121 0.525725 
R3054 1.311374 2.459725 0.713328 0.638132 0.696558 
R3055 1.230294 1.312984 1.38669 1.221456 0.752351 
R3056 1.353134 2.159675 1.519961 0.801925 0.767677 
R3057 0.745107 0.910948 1.127895 0.796438 0.80605 
Mean 1.208779 1.416046 0.972778 0.783471 0.715276 
SD 0.40721 0.471822 0.475894 0.288484 0.240395 
 
Local shear stress is expressed in arbitrary units (AU) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 24.  BASELINE LOCAL SHEAR STRESS SUMMARY (50%) 
 
 50%     
Subject A B C D E 
R3042 1.682403 2.35474 2.150524 1.707982 1.232252 
R3043 1.743396 1.510204 1.675456 0.983471 0.689998 
R3044 1.392968 2.012542 1.532306 1.102467 0.923297 
R3045 1.167464 1.583596 0.866972 1.089035 0.912905 
R3046 1.33638 1.653797 0.906527 0.782331 0.625381 
R3047 0.744754 1.574187 0.811495 0.608844 0.638177 
R3048 0.702065 2.200368 0.93514 0.701563 0.585176 
R3049 1.70926 1.591166 1.457356 0.777576 0.61522 
R3050 2.034442 1.676056 1.003381 0.635627 0.777229 
R3051 1.117574 1.629349 0.927554 0.656111 0.81982 
R3052 0.473492 1.062717 0.603536 0.566643 0.612795 
R3053 2.712827 1.701538 0.976096 0.643272 0.625539 
R3054 1.141043 2.059822 1.194206 0.957793 0.849877 
R3055 1.333032 0.920635 0.905828 0.772282 0.603232 
R3056 1.480868 1.790397 0.86796 0.831749 0.863896 
R3057 0.826446 1.267028 0.802312 0.882792 0.830225 
Mean 1.206976 1.717267 1.186687 0.897602 0.765502 
SD 0.451361 0.374797 0.489053 0.343198 0.207472 
 
Local shear stress is expressed in arbitrary units (AU) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 25.  BASELINE LOCAL SHEAR STRESS SUMMARY (75%) 
 
 75%     
Subject A B C D E 
R3042 2.190476 2.798329 1.344941 1.19 1.345558 
R3043 2.02963 1.623275 1.931034 1.371193 0.639832 
R3044 1.032198 2.02974 1.143262 0.872869 0.750543 
R3045 1.116054 2.18863 1.267465 1.563745 1.306051 
R3046 1.426793 1.600354 1.54321 0.725648 0.510085 
R3047 0.699481 0.928541 0.852033 0.886562 0.697987 
R3048 1.014807 2.679755 0.707012 0.633371 0.517117 
R3049 1.152684 2.08682 1.219273 0.829071 0.696665 
R3050 2.204255 2.234144 1.99322 1.084282 0.794992 
R3051 1.215848 1.660568 1.477501 0.847932 0.872101 
R3052 0.674543 1.047517 0.567832 0.577253 0.538335 
R3053 0.954382 3.445026 1.097345 0.824358 0.67985 
R3054 1.911677 2.368764 0.956887 0.957777 1.664387 
R3055 0.985222 1.524568 0.893824 0.705402 0.574672 
R3056 1.869467 1.56421 1.013634 0.89159 0.799219 
R3057 0.644692 0.923297 0.688193 0.896681 0.707071 
Mean 1.255251 1.864353 1.205356 0.949764 0.787427 
SD 0.504299 0.617477 0.411208 0.32253 0.305335 
 
Local shear stress is expressed in arbitrary units (AU) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 26.  BASELINE LOCAL SHEAR STRESS SUMMARY (50% R) 
 
 50%R     
Subject A B C D E 
R3042 3.058964 3.227029 2.364555 1.228519 1.868932 
R3043 2.383736 2.368365 1.159016 1.818665 0.779089 
R3044 1.502475 1.756778 0.582258 0.587017 0.920587 
R3045 1.00047 1.724059 0.933333 0.863668 0.55909 
R3046 0.866267 1.654545 0.692308 0.799798 0.587513 
R3047 0.903685 1.43662 0.992459 0.716344 0.793412 
R3048 0.966906 2.185802 0.631781 0.685099 0.578685 
R3049 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
R3050 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
R3051 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
R3052 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
R3053 1.672745 2.221465 1.561091 0.89924 0.85974 
R3054 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
R3055 1.26272 1.542029 0.923424 0.735496 0.631199 
R3056 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
R3057 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Mean 1.513108 2.012966 1.093359 0.925983 0.842027 
SD 0.757206 0.559589 0.56334 0.381131 0.40712 
 
Local shear stress is expressed in arbitrary units (AU) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
R- reproducibility 
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TABLE 27.  HYPEREMIC LOCAL SHEAR STRESS SUMMARY (25%) 
 
 25%     
Subject A B C D E 
R3042 7.757389 9.72697 11.03304 11.54198 10.47522 
R3043 5.962308 7.746865 5.234973 5.515906 6.102415 
R3044 6.064067 6.176567 6.273585 5.48675 5.75962 
R3045 6.033256 5.177809 4.609241 5.243494 5.087771 
R3046 8.548178 6.72332 6.721996 8.05294 7.417831 
R3047 7.934718 7.299502 5.887531 5.92053 6.863528 
R3048 4.967415 4.44898 4.766976 4.017875 5.729512 
R3049 9.194548 6.870943 7.341902 7.280141 6.374558 
R3050 7.509328 6.80652 7.393405 7.905806 7.647606 
R3051 6.91358 6.429055 7.320026 7.412569 8.260899 
R3052 4.843146 4.150023 4.174374 4.576317 4.311194 
R3053 3.87485 3.661381 3.252355 3.900531 3.755182 
R3054 7.205353 8.11002 6.787879 6.171206 5.418571 
R3055 4.537867 8.317629 4.550077 4.860895 4.783699 
R3056 6.279386 5.102391 5.820837 5.728039 5.441077 
R3057 5.11722 6.250297 6.767372 7.181796 6.134179 
Mean 6.82186 6.475003 6.336364 6.504851 6.638255 
SD 1.4915 1.645713 1.992339 2.186972 1.757127 
 
Local shear stress is expressed in arbitrary units (AU) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 28.  HYPEREMIC LOCAL SHEAR STRESS SUMMARY (50%) 
 
 50%     
Subject A B C D E 
R3042 10.03433 8.948012 11.33991 12.37378 7.627369 
R3043 4.584486 5.644315 6.554158 5.206612 5.322841 
R3044 7.018417 6.510371 5.530467 5.140417 6.289128 
R3045 5.85008 5.55205 6.505505 4.789128 5.394437 
R3046 8.551409 7.853746 8.370757 6.474721 6.33198 
R3047 6.497804 6.638964 5.673648 6.601515 6.069326 
R3048 5.182891 4.284926 4.628267 4.160754 3.790036 
R3049 8.988101 8.340426 7.070343 6.794705 6.429796 
R3050 7.351734 5.738028 6.569304 5.448228 5.302282 
R3051 8.871287 5.313093 6.440867 6.516783 7.531532 
R3052 3.685558 4.568387 3.587309 4.240056 3.973064 
R3053 5.823163 5.700513 4.971116 4.976521 4.691546 
R3054 3.830643 5.990838 7.488197 7.368828 5.688816 
R3055 6.330325 4.273016 8.35719 5.265557 3.795332 
R3056 4.572264 3.897507 4.512068 5.030418 5.712864 
R3057 6.882645 6.599104 6.24994 7.426233 6.30703 
Mean 6.926437 6.365429 6.570123 6.229847 5.875951 
SD 2.126844 1.589134 2.129608 2.37808 1.292759 
 
Local shear stress is expressed in arbitrary units (AU) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 29.  HYPEREMIC LOCAL SHEAR STRESS SUMMARY (75%) 
 
 75%     
Subject A B C D E 
R3042 7.593074 9.405728 8.464725 8.70625 9.631363 
R3043 8.77037 6.594181 6.240405 6.199177 5.781971 
R3044 5.598693 6.303903 5.253717 5.36678 4.435644 
R3045 5.950231 5.691645 6.221545 5.056535 5.747855 
R3046 6.520636 7.220204 7.246914 6.724754 3.880286 
R3047 6.683156 5.062045 6.400000 5.21466 4.899329 
R3048 4.405746 4.523517 3.675292 4.59037 2.856757 
R3049 9.257947 7.658996 8.239114 8.102288 6.573849 
R3050 7.393853 6.702432 7.928588 6.288838 5.358372 
R3051 8.147068 8.082019 8.15798 6.900163 8.257124 
R3052 5.091499 5.044937 3.90303 3.697012 3.420399 
R3053 6.09226 5.357449 5.182301 4.932058 4.913141 
R3054 7.100515 6.385033 6.477392 6.218065 5.162546 
R3055 5.970443 4.276228 4.067546 3.812982 4.083843 
R3056 8.192048 5.017153 5.19323 5.009237 5.683337 
R3057 8.862821 5.506332 5.809157 6.643291 6.209366 
Mean 6.801842 6.558718 6.380272 6.055799 5.548457 
SD 1.608165 1.547963 1.715273 1.573608 2.143961 
 
Local shear stress is expressed in arbitrary units (AU) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 30.  HYPEREMIC LOCAL SHEAR STRESS SUMMARY (50% R) 
 
 50%R     
Subject A B C D E 
R3042 9.671356 9.230186 9.358311 8.915296 10.65291 
R3043 5.799238 5.790653 5.835246 5.350477 6.061551 
R3044 6.571503 5.646269 5.874177 6.393534 5.268589 
R3045 6.917724 6.200228 5.107407 5.986343 5.454377 
R3046 7.132735 6.710101 6.636364 6.851365 7.86694 
R3047 7.101398 7.971831 6.940171 5.911575 6.76774 
R3048 6.22446 4.218215 4.234277 3.966724 4.615538 
R3049 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
R3050 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
R3051 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
R3052 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
R3053 3.896353 5.58092 4.802847 4.338318 4.566937 
R3054 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
R3055 5.387604 5.04437 5.388751 5.41069 3.92606 
R3056 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
R3057 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Mean 6.522486 6.265864 6.019728 5.902702 6.131183 
SD 1.564368 1.527374 1.513601 1.45628 2.081997 
 
Local shear stress is expressed in arbitrary units (AU) 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
R- reproducibility 
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TABLE 31.  INTERLEUKIN-6 (IL-6) SUMMARY 
 
 25%         50%         75%         
Subject A  B C D E A  B C D E A  B C D E 
R3042 1.84   0.86     2.39 1.81 2.44 3.85 3.14 1.62   1.81     
R3043 1.27 1.33 1.39 1.50 2.28 2.25 2.35 2.75 2.84 3.75 2.62 3.39 3.19 2.82 3.87 
R3044 1.98   1.75     2.10 2.57 2.36 2.71 3.41 3.44   3.25     
R3045 3.75 2.83 3.63 3.20 4.16 2.17 3.16 3.42 7.81 7.89 2.60 3.72 4.08 2.72 2.36 
R3046 0.88   0.85     0.35 1.07 0.61 1.25 2.33 0.98   1.88     
R3047 1.13 1.19 1.34 2.11 2.63 1.22 1.80 2.40 2.52 2.96 0.85 4.31 3.75 3.30 2.51 
R3050 2.84   2.82     2.20 2.29 3.13 2.29 2.29 2.38   2.60     
R3054 1.20   1.07     0.82 1.27 1.48 2.10 2.73 0.74   1.96     
Mean 1.86 1.78 1.71 2.27 3.02 1.69 2.04 2.32 3.17 3.56 1.90 3.81 2.82 2.95 2.91 
SD 0.99 0.91 1.00 0.86 1.00 0.78 0.69 0.90 2.01 1.82 1.00 0.47 0.88 0.31 0.83 
SEE 0.35 0.32 0.35 0.30 0.35 0.27 0.24 0.32 0.71 0.64 0.35 0.16 0.31 0.11 0.29 
R3048 1.43   1.36     0.95 1.14 1.09 1.03 1.60 1.43   2.88     
R3049 0.61   0.40     1.52 1.61 1.55 2.63 2.69 0.60   2.54     
R3051 0.57 0.67 0.43 1.11 1.48 0.41 0.73 0.87 1.68 3.31 0.26 0.91 1.02 2.55 4.04 
R3052 0.82 0.80 0.83 0.99 1.51 0.84 0.93 1.06 1.11 1.55 0.80 1.52 1.99 2.01 2.62 
R3053 1.63   1.87     1.59 2.40 3.27 4.67 15.48 3.49   5.36     
R3055 1.03   1.31     0.88 1.44 1.22 1.40 1.79 0.83   1.81     
R3056 0.96 1.03 1.09 1.14 1.29 1.16 1.51 1.59 1.56 1.61 1.43 1.78 2.05 1.55 1.42 
R3057 2.56   2.78     2.77 2.96 3.51 3.16 3.38 2.03   3.33     
Mean 1.20 0.84 1.26 1.08 1.42 1.26 1.59 1.77 2.16 3.92 1.36 1.41 2.62 2.04 2.69 
SD 0.66 0.18 0.79 0.08 0.12 0.72 0.75 1.03 1.25 4.73 1.03 0.45 1.31 0.50 1.31 
SEE 0.23 0.06 0.28 0.03 0.04 0.25 0.26 0.36 0.44 1.67 0.36 0.16 0.46 0.18 0.46 
 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 32.  TUMOR NECROSIS FACTOR-ALPHA (TNF-α) SUMMARY 
 
 25%         50%         75%         
Subject A  B C D E A  B C D E A  B C D E 
R3042 0.43   0.67     0.54 0.40 0.54 0.42 0.50 0.64   0.95     
R3043 0.92 1.49 0.83 1.53 1.50 1.16 1.29 1.22 1.26 1.11 1.68 1.38 1.46 1.39 1.33
R3044 1.00   0.86     1.13 0.76 1.04 0.85 1.00 1.21   1.30     
R3045 0.68 0.60 0.62 0.78 0.42 0.95 0.36 0.66 0.52 0.57 0.88 0.99 0.92 0.61 0.76
R3046 0.25   0.27     0.67 0.40 0.60 0.38 0.41 0.37   0.45     
R3047 0.66 0.85 0.89 0.86 0.71 1.13 0.90 1.10 1.02 0.85 0.78 1.23 0.88 1.01 1.05
R3050 1.19   1.11     1.43 1.36 1.26 1.10 1.27 1.31   1.20     
R3054 0.94   1.20     1.01 0.78 1.03 1.00 0.92 0.55   0.75     
Mean 0.76 0.98 0.81 1.06 0.88 1.00 0.78 0.93 0.82 0.83 0.93 1.20 0.99 1.00 1.05
SD 0.31 0.46 0.29 0.41 0.56 0.29 0.39 0.29 0.33 0.31 0.44 0.19 0.32 0.39 0.29
SEE 0.11 0.16 0.10 0.14 0.20 0.10 0.14 0.10 0.12 0.11 0.16 0.07 0.11 0.14 0.10
R3048 1.38   1.60     1.33 1.06 1.34 1.15 1.28 1.11   1.19     
R3049 0.60   0.60     0.96 0.95 0.83 0.73 0.75 0.58   0.76     
R3051 0.71 0.99 0.61 0.82 0.83 0.75 0.55 0.95 0.40 0.47 0.58 1.33 0.72 1.57 1.12
R3052 0.73 0.56 0.78 0.89 0.46 0.59 0.71 0.63 0.72 0.67 0.54 0.84 0.43 0.86 0.69
R3053 0.63   0.56     0.95 0.84 1.03 0.75 0.77 0.56   0.68     
R3055 0.24   0.30     0.59 0.76 0.53 0.39 0.30 0.74   0.83     
R3056 0.75 0.88 0.62 0.90 0.67 0.66 0.58 0.72 0.37 0.51 0.95 1.09 0.77 0.73 0.51
R3057 0.99   1.03     0.72 0.58 0.67 0.80 0.76 1.29   1.10     
Mean 0.75 0.81 0.76 0.87 0.65 0.82 0.75 0.84 0.66 0.69 0.79 1.08 0.81 1.05 0.77
SD 0.33 0.22 0.40 0.05 0.19 0.25 0.19 0.26 0.27 0.29 0.29 0.25 0.24 0.45 0.31
SEE 0.12 0.08 0.14 0.02 0.07 0.09 0.07 0.09 0.10 0.10 0.10 0.09 0.08 0.16 0.11
 
A- pre-exercise, B- immediately, C- 1hr post, D- 2hr post, E- 3 hr post 
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TABLE 1. GROUP X INTENSITY X TIME (FMD) 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for FMD using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                  526.36      14     37.60 
 A                           .07       1       .07       .00      .967 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for FMD using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 2                  279.79      28      9.99 
 B                           .36       2       .18       .02      .982 
 A BY B                    11.51       2      5.76       .58      .569 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 Tests of Significance for FMD using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 3                   70.54      14      5.04 
 C                          1.06       1      1.06       .21      .654 
 A BY C                    71.66       1     71.66     14.22      .002 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 Observed Power at the .0500 Level 
                         Noncen- 
 Source of Variation     trality   Power 
 
 C                          .210    .064 
 A BY C                   14.223    .938 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for FMD using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 4                   110.29      28      3.94 
  C BY B                    11.35       2      5.68      1.44      .254 
 A BY B BY C                 3.18       2      1.59       .40      .672 
 
 
A= GROUP (active, inactive), B=INTENSITY (low, moderate, high), AND C = 
TIME (pre-exercise, 1hr post) 
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TABLE 1. (Continued) GROUP X INTENSITY X TIME (FMD) 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   2 * * *  
 
 Tests of Significance for FMD using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                  596.89      28     21.32 
 A W C(1)                  33.65       1     33.65      1.58      .219 
 A W C(2)                  38.08       1     38.08      1.79      .192 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   3 * * *  
 
 Tests of Significance for FMD using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                   70.54      14      5.04 
 C W A(1)                  45.07       1     45.07      8.95      .010 
 C W A(2)                  27.65       1     27.65      5.49      .034 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 Observed Power at the .0500 Level 
                         Noncen- 
 Source of Variation     trality   Power 
 
 C W A(1)                  8.945    .793 
 C W A(2)                  5.487    .586 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 
A= GROUP (active, inactive), B=INTENSITY (low, moderate, high), AND C = 
TIME (pre-exercise, 1hr post) 
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TABLE 2. GROUP X INTENSITY X TIME (BASELINE DIAMETER) 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
  
 Tests of Significance for BLDIAM using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                   13.97      14      1.00 
 A                           .21       1       .21       .21      .654 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 Error 2                    1.90      28       .07 
 B                           .06       2       .03       .43      .658 
 A BY B                      .01       2       .01       .08      .921 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 Error 3                     .58      14       .04 
 C                           .01       1       .01       .35      .566 
 A BY C                      .07       1       .07      1.74      .209 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 Error 4                     .54      28       .02 
 C BY B                      .31       2       .16      8.16      .002 
 A BY B BY C                 .02       2       .01       .50      .614 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   2 * * *  
 
 Tests of Significance for BLDIAM using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                    2.44      56       .04 
 B W C(1)                    .22       2       .11      2.49      .092 
 B W C(2)                    .15       2       .08      1.77      .180 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   3 * * *  
 
 Tests of Significance for BLDIAM using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                     .54      28       .02 
 C W B(1)                    .10       1       .10      5.22      .030 
 C W B(2)                    .00       1       .00       .13      .725 
 C W B(3)                    .23       1       .23     11.73      .002 
 
 
A= GROUP (active, inactive), B=INTENSITY (low, moderate, high), AND C = 
TIME (pre-exercise, 1hr post) 
 
  144
TABLE 3. GROUP X INTENSITY X TIME (HYPEREMIC DIAMETER) 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for HDIAM using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                   15.06      14      1.08 
 A                           .28       1       .28       .26      .617 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 2                    2.87      28       .10 
 B                           .07       2       .04       .36      .703 
 A BY B                      .04       2       .02       .21      .812 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 3                     .61      14       .04 
 C                           .02       1       .02       .37      .553 
 A BY C                      .00       1       .00       .00      .982 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 Error 4                     .76      28       .03 
 C BY B                      .24       2       .12      4.41      .022 
 A BY B BY C                 .04       2       .02       .71      .500 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   2 * * *  
 
 Tests of Significance for HDIAM using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                    3.62      56       .06 
 B W C(1)                    .19       2       .10      1.48      .236 
 B W C(2)                    .12       2       .06       .93      .401 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   3 * * *  
 
 Tests of Significance for HDIAM using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                     .76      28       .03 
 C W B(1)                    .04       1       .04      1.63      .212 
 C W B(2)                    .00       1       .00       .03      .867 
 C W B(3)                    .21       1       .21      7.77      .009 
 
 
A= GROUP (active, inactive), B=INTENSITY (low, moderate, high), AND C = 
TIME (pre-exercise, 1hr post) 
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TABLE 4. GROUP X INTENSITY X TIME (BASELINE VELOCITY) 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for BLFLOW using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                 2734.69      14    195.33 
 A                        473.04       1    473.04      2.42      .142 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 2                  548.57      28     19.59 
 B                          4.56       2      2.28       .12      .890 
 A BY B                   117.15       2     58.57      2.99      .067 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 3                  447.77      14     31.98 
 C                        222.96       1    222.96      6.97      .019 
 A BY C                     9.44       1      9.44       .30      .596 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 4                  638.65      28     22.81 
 C BY B                    50.07       2     25.03      1.10      .348 
 A BY B BY C               10.92       2      5.46       .24      .789 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 
A= GROUP (active, inactive), B=INTENSITY (low, moderate, high), AND C = 
TIME (pre-exercise, 1hr post) 
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TABLE 5. GROUP X INTENSITY X TIME (HYPEREMIC VELOCITY) 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for HFLOW using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                17498.18      14   1249.87 
 A                       6489.53       1   6489.53      5.19      .039 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 Error 2                 7524.64      28    268.74 
 B                        158.71       2     79.36       .30      .747 
 A BY B                   469.67       2    234.83       .87      .428 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 Error 3                 1903.99      14    136.00 
 C                        563.09       1    563.09      4.14      .061 
 A BY C                   979.84       1    979.84      7.20      .018 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 Error 4                 4846.09      28    173.07 
 C BY B                   375.33       2    187.66      1.08      .352 
 A BY B BY C              702.22       2    351.11      2.03      .150 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   2 * * *  
 
 Tests of Significance for HFLOW using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                19402.18      28    692.93 
 A W C(1)                1213.04       1   1213.04      1.75      .197 
 A W C(2)                6256.33       1   6256.33      9.03      .006 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   3 * * *  
 
 Tests of Significance for HFLOW using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                 1903.99      14    136.00 
 C W A(1)                  28.68       1     28.68       .21      .653 
 C W A(2)                1514.25       1   1514.25     11.13      .005 
 
 
A= GROUP (active, inactive), B=INTENSITY (low, moderate, high), AND C = 
TIME (pre-exercise, 1hr post) 
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TABLE 6. GROUP X INTENSITY X TIME (HYPEREMIC LOCAL SHEAR STRESS) 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for HLSS using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                  148.46      14     10.60 
 A                         23.03       1     23.03      2.17      .163 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 2                   41.51      28      1.48 
 B                          1.12       2       .56       .38      .690 
 A BY B                     2.64       2      1.32       .89      .422 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 3                   11.57      14       .83 
 C                          3.31       1      3.31      4.00      .065 
 A BY C                     3.48       1      3.48      4.21      .059 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 4                   26.76      28       .96 
 C BY B                     2.58       2      1.29      1.35      .275 
 A BY B BY C                2.58       2      1.29      1.35      .276 
 
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 
A= GROUP (active, inactive), B=INTENSITY (low, moderate, high), AND C = 
TIME (pre-exercise, 1hr post) 
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TABLE 7. GROUP X INTENSITY X TIME (IL-6) 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for IL6 using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                   54.00      14      3.86 
 A                          5.33       1      5.33      1.38      .259 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 2                   13.67      28       .49 
 B                          7.24       2      3.62      7.42      .003 
 A BY B                      .14       2       .07       .15      .863 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 3                    3.75      14       .27 
 C                          6.93       1      6.93     25.85      .000 
 A BY C                      .12       1       .12       .45      .511 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 4                    2.67      28       .10 
 C BY B                     5.18       2      2.59     27.17      .000 
 A BY B BY C                 .24       2       .12      1.25      .303 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   2 * * *  
 
 Tests of Significance for IL6 using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                   16.33      56       .29 
 B W C(1)                    .20       2       .10       .33      .717 
 B W C(2)                  12.22       2      6.11     20.95      .000 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   3 * * *  
 
 Tests of Significance for IL6 using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                    2.67      28       .10 
 C W B(1)                    .02       1       .02       .19      .669 
 C W B(2)                   2.60       1      2.60     27.32      .000 
 C W B(3)                   9.49       1      9.49     99.61      .000 
 
 
 A= GROUP (active, inactive), B=INTENSITY (low, moderate, high), AND C 
= TIME (pre-exercise, 1hr post) 
  149
TABLE 8. GROUP X INTENSITY X TIME (TNF-α) 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for TNFa using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                    5.92      14       .42 
 A                           .28       1       .28       .65      .433 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for TNFa using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 2                    1.97      28       .07 
 B                           .30       2       .15      2.16      .134 
 A BY B                      .08       2       .04       .58      .564 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -   
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for TNFa using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 3                     .20      14       .01 
 C                           .00       1       .00       .31      .584 
 A BY C                      .00       1       .00       .00      .983 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for TNFa using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 4                     .20      28       .01 
 C BY B                      .02       2       .01      1.37      .270 
 A BY B BY C                 .02       2       .01      1.71      .200 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 
A= GROUP (active, inactive), B=INTENSITY (low, moderate, high), AND C 
= TIME (pre-exercise, 1hr post) 
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TABLE 9.  INDEPENDENT SAMPLES T-TEST FOR ACTIVE VS INACTIVE (EXERCISE VARIABLES) 
 
 
 
   
Levene's Test for 
Equality of Variances t-test for Equality of Means 
    F Sig. t df Sig. (2-tailed) 
Mean 
Difference 
Std. Error 
Difference 95% Confidence Interval of the Difference 
                  Lower Upper 
RPE Equal variances 
assumed 4.558 .051 .814 14 .429 .33750 .41440 -.55131 1.22631
HR Equal variances 
assumed .852 .372 2.656 14 .019 12.25000 4.61268 2.35679 22.14321
SBP Equal variances 
assumed 1.184 .295 -.416 14 .684 -3.25000 7.81653 -20.01480 13.51480
DBP Equal variances 
assumed .041 .842 .809 14 .432 4.50000 5.55934 -7.42360 16.42360
RPE50 Equal variances 
assumed .003 .954 -.095 14 .926 -.07500 .79167 -1.77296 1.62296
HR50 Equal variances 
assumed 1.050 .323 1.366 14 .193 8.50000 6.22029 -4.84119 21.84119
SBP50 Equal variances 
assumed .050 .826 1.270 14 .225 10.25000 8.06973 -7.05785 27.55785
DBP50 Equal variances 
assumed 3.332 .089 1.045 14 .314 4.00000 3.82660 -4.20724 12.20724
RPE75 Equal variances 
assumed .088 .771 .707 14 .491 .45000 .63626 -.91463 1.81463
HR75 Equal variances 
assumed .018 .894 .627 14 .541 3.75000 5.97726 -9.06996 16.56996
SBP75 Equal variances 
assumed .073 .791 .662 14 .519 7.00000 10.57773 -15.68698 29.68698
DBP75 Equal variances 
assumed .031 .864 1.053 14 .310 5.25000 4.98525 -5.44229 15.94229
  151
TABLE 10. TRIAL X TIME (FMD) 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for FMD using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                   37.22       8      4.65 
 S                        261.25       8     32.66      7.02      .006 
 A                           .03       1       .03       .01      .942 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 2                  225.74      32      7.05 
 B                         58.37       4     14.59      2.07      .108 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 3                  103.07      32      3.22 
 B BY A                     5.22       4      1.30       .41      .804 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 
A= TRIAL (TRIAL 1, TRIAL 2), B=TIME (PRE-EXERCISE, IMMEDIATELY, 1HR 
POST, 2HR POST, 3 HR POST) 
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TABLE 11. TRIAL X TIME (BASELINE DIAMETER) 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for BLDIAM using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                     .44       8       .06 
 S                         13.94       8      1.74     31.60      .000 
 A                           .02       1       .02       .39      .549 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 2                     .25      32       .01 
 B                           .07       4       .02      2.20      .091 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 3                     .14      32       .00 
 B BY A                      .00       4       .00       .14      .964 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 
A= TRIAL (TRIAL 1, TRIAL 2), B=TIME (PRE-EXERCISE, IMMEDIATELY, 1HR 
POST, 2HR POST, 3 HR POST) 
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TABLE 12. TRIAL X TIME (HYPEREMIC DIAMETER) 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for HDIAM using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                     .42       8       .05 
 S                         15.95       8      1.99     38.20      .000 
 A                           .05       1       .05       .94      .360 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 2                     .30      32       .01 
 B                           .14       4       .03      3.71      .014 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 3                     .23      32       .01 
 B BY A                      .02       4       .01       .77      .552 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 
A= TRIAL (TRIAL 1, TRIAL 2), B=TIME (PRE-EXERCISE, IMMEDIATELY, 1HR 
POST, 2HR POST, 3 HR POST) 
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TABLE 13. TRIAL X TIME (BASELINE VELOCITY) 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for BLFLOW using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                  312.49       8     39.06 
 S                       1578.43       8    197.30      5.05      .017 
 A                         16.38       1     16.38       .42      .535 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 2                  920.62      32     28.77 
 B                       2911.97       4    727.99     25.30      .000 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 3                  610.34      32     19.07 
 B BY A                    78.75       4     19.69      1.03      .406 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 
A= TRIAL (TRIAL 1, TRIAL 2), B=TIME (PRE-EXERCISE, IMMEDIATELY, 1HR 
POST, 2HR POST, 3 HR POST) 
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TABLE 14. TRIAL X TIME (HYPEREMIC VELOCITY) 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for HFLOW using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                  737.27       8     92.16 
 S                      16824.31       8   2103.04     22.82      .000 
 A                         58.73       1     58.73       .64      .448 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 2                 4347.42      32    135.86 
 B                       1848.07       4    462.02      3.40      .020 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 3                 4245.40      32    132.67 
 B BY A                  1069.80       4    267.45      2.02      .116 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 
A= TRIAL (TRIAL 1, TRIAL 2), B=TIME (PRE-EXERCISE, IMMEDIATELY, 1HR 
POST, 2HR POST, 3 HR POST) 
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TABLE 15. TRIAL X TIME (HYPEREMIC LOCAL SHEAR STRESS) 
 
* * * * * * A n a l y s i s   o f   V a r i a n c e -- design   1 * * *  
 
 Tests of Significance for HLSS using UNIQUE sums of squares 
 Source of Variation          SS      DF        MS         F  Sig of F 
 
 Error 1                    4.44       8       .56 
 S                        201.22       8     25.15     45.31      .000 
 A                           .17       1       .17       .31      .594 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 2                   19.44      32       .61 
 B                          7.30       4      1.82      3.00      .033 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 Error 3                   23.22      32       .73 
 B BY A                     5.41       4      1.35      1.86      .141 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 
A= TRIAL (TRIAL 1, TRIAL 2), B=TIME (PRE-EXERCISE, IMMEDIATELY, 1HR 
POST, 2HR POST, 3 HR POST) 
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TABLE 16. INTRACLASS CORRELATIONS (PRE EXERCISE FMD) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.602 .604 2
 
 
 Inter-Item Correlation Matrix 
 
  Trial1a Trial2a 
Trial1a 1.000 .432
Trial2a .432 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 7.370 6.973 7.767 .794 1.114 .315 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .431(b) -.276 .835 2.513 8.0 8 .107
Average 
Measures .602(c) -.764 .910 2.513 8.0 8 .107
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TABLE 17. INTRACLASS CORRELATIONS (IMMEDIATE FMD) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.840 .847 2
 
 Inter-Item Correlation Matrix 
 
  Trial1b Trial2b 
Trial1b 1.000 .734
Trial2b .734 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 5.166 4.988 5.343 .355 1.071 .063 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .725(b) .172 .931 6.270 8.0 8 .009
Average 
Measures .840(c) .293 .964 6.270 8.0 8 .009
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TABLE 18. INTRACLASS CORRELATIONS (1HR POST FMD) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.632 .654 2
 
 Inter-Item Correlation Matrix 
 
  Trial1c Trial2c 
Trial1c 1.000 .486
Trial2c .486 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 5.691 5.436 5.946 .510 1.094 .130 2
 
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .462(b) -.239 .847 2.721 8.0 8 .089
Average 
Measures .632(c) -.629 .917 2.721 8.0 8 .089
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TABLE 19. INTRACLASS CORRELATIONS (2HR POST FMD) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.724 .728 2
 
 Inter-Item Correlation Matrix 
 
  Trial1d Trial2d 
Trial1d 1.000 .573
Trial2d .573 1.000
 
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 5.790 5.681 5.899 .218 1.038 .024 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .568(b) -.100 .883 3.628 8.0 8 .043
Average 
Measures .724(c) -.222 .938 3.628 8.0 8 .043
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TABLE 20. INTRACLASS CORRELATIONS (3HR POST FMD) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.631 .634 2
 
 Inter-Item Correlation Matrix 
 
  Trial1e Trial2e 
Trial1e 1.000 .464
Trial2e .464 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 5.191 5.032 5.351 .319 1.063 .051 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .461(b) -.241 .846 2.710 8.0 8 .090
Average 
Measures .631(c) -.636 .917 2.710 8.0 8 .090
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TABLE 21. INTRACLASS CORRELATIONS (PRE-EXERCISE BASELINE 
DIAMETER) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.958 .960 2
 
 Inter-Item Correlation Matrix 
 
  Trial1a Trial2a 
Trial1a 1.000 .923
Trial2a .923 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 4.106 4.085 4.128 .044 1.011 .001 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .920(b) .686 .981 23.845 8.0 8 .000
Average 
Measures .958(c) .814 .991 23.845 8.0 8 .000
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TABLE 22. INTRACLASS CORRELATIONS (IMMEDIATE BASELINE 
DIAMETER) 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.975 .976 2
 
 Inter-Item Correlation Matrix 
 
  Trial1b Trial2b 
Trial1b 1.000 .953
Trial2b .953 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 4.133 4.118 4.147 .028 1.007 .000 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .952(b) .804 .989 40.785 8.0 8 .000
Average 
Measures .975(c) .891 .994 40.785 8.0 8 .000
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TABLE 23. INTRACLASS CORRELATIONS (1HR POST BASELINE DIAMETER) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.933 .935 2
 
 Inter-Item Correlation Matrix 
 
  Trial1c Trial2c 
Trial1c 1.000 .879
Trial2c .879 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 4.146 4.128 4.164 .036 1.009 .001 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .874(b) .540 .970 14.838 8.0 8 .000
Average 
Measures .933(c) .701 .985 14.838 8.0 8 .000
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TABLE 24. INTRACLASS CORRELATIONS (2HR POST BASELINE DIAMETER) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.949 .974 2
 
 Inter-Item Correlation Matrix 
 
  Trial1d Trial2d 
Trial1d 1.000 .949
Trial2d .949 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 4.065 4.058 4.071 .012 1.003 .000 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .902(b) .629 .977 19.491 8.0 8 .000
Average 
Measures .949(c) .773 .988 19.491 8.0 8 .000
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TABLE 25. INTRACLASS CORRELATIONS (3HR POST BASELINE DIAMETER) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.979 .986 2
 
 Inter-Item Correlation Matrix 
 
  Trial1e Trial2e 
Trial1e 1.000 .972
Trial2e .972 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 4.113 4.096 4.131 .035 1.009 .001 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .959(b) .831 .991 48.014 8.0 8 .000
Average 
Measures .979(c) .908 .995 48.014 8.0 8 .000
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TABLE 26. INTRACLASS CORRELATIONS (PRE-EXERCISE HYPEREMIC 
DIAMETER) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.930 .934 2
 
 Inter-Item Correlation Matrix 
 
  Trial1a Trial2a 
Trial1a 1.000 .876
Trial2a .876 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 4.411 4.360 4.462 .102 1.023 .005 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .869(b) .527 .969 14.324 8.0 8 .001
Average 
Measures .930(c) .691 .984 14.324 8.0 8 .001
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TABLE 27. INTRACLASS CORRELATIONS (IMMEDIATE HYPEREMIC 
DIAMETER) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.983 .983 2
 
 Inter-Item Correlation Matrix 
 
  Trial1b Trial2b 
Trial1b 1.000 .967
Trial2b .967 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 4.343 4.326 4.360 .034 1.008 .001 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .966(b) .856 .992 57.308 8.0 8 .000
Average 
Measures .983(c) .923 .996 57.308 8.0 8 .000
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TABLE 28. INTRACLASS CORRELATIONS (1HR POST HYPEREMIC 
DIAMETER) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.941 .942 2
 
 Inter-Item Correlation Matrix 
 
  Trial1c Trial2c 
Trial1c 1.000 .890
Trial2c .890 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 4.380 4.355 4.405 .050 1.011 .001 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .889(b) .588 .974 17.093 8.0 8 .000
Average 
Measures .941(c) .741 .987 17.093 8.0 8 .000
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TABLE 29. INTRACLASS CORRELATIONS (2HR POST HYPEREMIC 
DIAMETER) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.977 .980 2
 
 Inter-Item Correlation Matrix 
 
  Trial1d Trial2d 
Trial1d 1.000 .961
Trial2d .961 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 4.302 4.281 4.323 .042 1.010 .001 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .954(b) .812 .990 42.803 8.0 8 .000
Average 
Measures .977(c) .896 .995 42.803 8.0 8 .000
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TABLE 30. INTRACLASS CORRELATIONS (3HR POST HYPEREMIC 
DIAMETER) 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.966 .968 2
 
 Inter-Item Correlation Matrix 
 
  Trial1e Trial2e 
Trial1e 1.000 .938
Trial2e .938 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 4.322 4.319 4.325 .006 1.001 .000 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .934(b) .737 .985 29.240 8.0 8 .000
Average 
Measures .966(c) .848 .992 29.240 8.0 8 .000
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TABLE 31. INTRACLASS CORRELATIONS (PRE-EXERCISE BASELINE 
VELOCITY) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.711 .716 2
 
 Inter-Item Correlation Matrix 
 
  TRIAL 1 TRIAL 2 
TRIAL 1 1.000 .558
TRIAL 2 .558 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 21.372 20.922 21.822 .900 1.043 .405 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .552(b) -.123 .878 3.462 8.0 8 .049
Average 
Measures .711(c) -.281 .935 3.462 8.0 8 .049
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TABLE 32. INTRACLASS CORRELATIONS (IMMEDIATE BASELINE 
VELOCITY) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.577 .587 2
 
 Inter-Item Correlation Matrix 
 
  TRIAL 1 TRIAL 2 
TRIAL 1 1.000 .415
TRIAL 2 .415 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 27.217 25.200 29.233 4.033 1.160 8.134 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .405(b) -.305 .826 2.361 8.0 8 .123
Average 
Measures .577(c) -.877 .904 2.361 8.0 8 .123
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TABLE 33. INTRACLASS CORRELATIONS (1HR POST BASELINE VELOCITY) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.560 .561 2
 
 Inter-Item Correlation Matrix 
 
  TRIAL 1 TRIAL 2 
TRIAL 1 1.000 .390
TRIAL 2 .390 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 16.711 15.822 17.600 1.778 1.112 1.580 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .389(b) -.322 .820 2.275 8.0 8 .133
Average 
Measures .560(c) -.949 .901 2.275 8.0 8 .133
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TABLE 34. INTRACLASS CORRELATIONS (2HR POST BASELINE VELOCITY) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.543 .585 2
 
 Inter-Item Correlation Matrix 
 
  TRIAL 1 TRIAL 2 
TRIAL 1 1.000 .414
TRIAL 2 .414 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 13.389 13.300 13.478 .178 1.013 .016 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .373(b) -.339 .813 2.190 8.0 8 .144
Average 
Measures .543(c) -1.025 .897 2.190 8.0 8 .144
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TABLE 35. INTRACLASS CORRELATIONS (3HR POST BASELINE VELOCITY) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.577 .644 2
 
 Inter-Item Correlation Matrix 
 
  TRIAL 1 TRIAL 2 
TRIAL 1 1.000 .475
TRIAL 2 .475 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 11.478 11.011 11.944 .933 1.085 .436 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .405(b) -.305 .826 2.362 8.0 8 .123
Average 
Measures .577(c) -.877 .905 2.362 8.0 8 .123
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TABLE 36. INTRACLASS CORRELATIONS (PRE-EXERCISE HYPEREMIC 
VELOCITY) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.613 .613 2
 
 Inter-Item Correlation Matrix 
 
  Trial1a Trial2a 
Trial1a 1.000 .442
Trial2a .442 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 95.006 93.800 96.211 2.411 1.026 2.907 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .442(b) -.264 .839 2.581 8.0 8 .101
Average 
Measures .613(c) -.717 .913 2.581 8.0 8 .101
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TABLE 37. INTRACLASS CORRELATIONS (IMMEDIATE HYPEREMIC 
VELOCITY) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.827 .827 2
 
 Inter-Item Correlation Matrix 
 
  Trial1b Trial2b 
Trial1b 1.000 .705
Trial2b .705 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 89.994 89.522 90.467 .944 1.011 .446 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .705(b) .131 .925 5.769 8.0 8 .011
Average 
Measures .827(c) .231 .961 5.769 8.0 8 .011
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TABLE 38. INTRACLASS CORRELATIONS (1HR POST HYPEREMIC 
VELOCITY) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.767 .816 2
 
 Inter-Item Correlation Matrix 
 
  Trial1c Trial2c 
Trial1c 1.000 .689
Trial2c .689 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 94.028 87.400 100.656 13.256 1.152 87.855 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .623(b) -.015 .900 4.298 8.0 8 .027
Average 
Measures .767(c) -.031 .948 4.298 8.0 8 .027
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TABLE 39. INTRACLASS CORRELATIONS (2HR POST HYPEREMIC 
VELOCITY) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.812 .846 2
 
 Inter-Item Correlation Matrix 
 
  Trial1d Trial2d 
Trial1d 1.000 .734
Trial2d .734 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 85.122 84.378 85.867 1.489 1.018 1.108 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .684(b) .091 .919 5.326 8.0 8 .015
Average 
Measures .812(c) .168 .958 5.326 8.0 8 .015
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TABLE 40. INTRACLASS CORRELATIONS (3HR POST HYPEREMIC 
VELOCITY) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.770 .810 2
 
 Inter-Item Correlation Matrix 
 
  Trial1e Trial2e 
Trial1e 1.000 .680
Trial2e .680 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 83.800 79.733 87.867 8.133 1.102 33.076 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .626(b) -.010 .901 4.341 8.0 8 .027
Average 
Measures .770(c) -.021 .948 4.341 8.0 8 .027
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TABLE 41. INTRACLASS CORRELATIONS (PRE-EXERCISE HYPEREMIC 
LOCAL SHEAR STRESS) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.854 .856 2
 
 Inter-Item Correlation Matrix 
 
  Trial1a Trial2a 
Trial1a 1.000 .748
Trial2a .748 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 6.588 6.522 6.653 .130 1.020 .008 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .745(b) .215 .936 6.856 8.0 8 .007
Average 
Measures .854(c) .353 .967 6.856 8.0 8 .007
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TABLE 42. INTRACLASS CORRELATIONS (IMMEDIATE HYPEREMIC LOCAL 
SHEAR STRESS) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.931 .931 2
 
 Inter-Item Correlation Matrix 
 
  Trial1b Trial2b 
Trial1b 1.000 .871
Trial2b .871 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 6.211 6.156 6.266 .110 1.018 .006 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .871(b) .531 .969 14.472 8.0 8 .001
Average 
Measures .931(c) .694 .984 14.472 8.0 8 .001
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TABLE 43. INTRACLASS CORRELATIONS (1HR POST HYPEREMIC LOCAL 
SHEAR STRESS) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.860 .889 2
 
 Inter-Item Correlation Matrix 
 
  Trial1c Trial2c 
Trial1c 1.000 .800
Trial2c .800 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 6.450 6.020 6.881 .861 1.143 .371 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .755(b) .235 .939 7.161 8.0 8 .006
Average 
Measures .860(c) .381 .969 7.161 8.0 8 .006
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TABLE 44. INTRACLASS CORRELATIONS (2HR POST HYPEREMIC LOCAL 
SHEAR STRESS) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.865 .931 2
 
 Inter-Item Correlation Matrix 
 
  Trial1d Trial2d 
Trial1d 1.000 .871
Trial2d .871 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 6.006 5.903 6.110 .207 1.035 .021 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .762(b) .251 .941 7.401 8.0 8 .005
Average 
Measures .865(c) .401 .970 7.401 8.0 8 .005
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TABLE 45. INTRACLASS CORRELATIONS (3HR POST HYPEREMIC LOCAL 
SHEAR STRESS) 
 
 
 Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items N of Items 
.876 .936 2
 
 Inter-Item Correlation Matrix 
 
  Trial1e Trial2e 
Trial1e 1.000 .879
Trial2e .879 1.000
 
 Summary Item Statistics 
 
  Mean Minimum Maximum Range 
Maximum / 
Minimum Variance N of Items 
Item Means 5.805 5.479 6.131 .652 1.119 .213 2
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(
a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .779(b) .289 .945 8.043 8.0 8 .004
Average 
Measures .876(c) .449 .972 8.043 8.0 8 .004
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TABLE 46. REPRODUCIBILITY CORRELATIONS (ALL FMD COMBINED) 
 
 
    Trial1combo Trial2combo 
Pearson Correlation 1 .579(**)
Sig. (2-tailed)  .000
Trial1combo 
N 45 45
Pearson Correlation .579(**) 1
Sig. (2-tailed) .000  
Trial2combo 
N 45 45
**  Correlation is significant at the 0.01 level (2-tailed). 
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TABLE 47. REPRODUCIBILITY CORRELATIONS (PRE-EXERCISE FMD) 
 
 
    Trial1a Trial2a 
Pearson Correlation 1 .432
Sig. (2-tailed)  .245
Trial1a 
N 9 9
Pearson Correlation .432 1
Sig. (2-tailed) .245  
Trial2a 
N 9 9
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TABLE 48. REPRODUCIBILITY CORRELATIONS (IMMEDIATE FMD) 
  
 
    Trial1b Trial2b 
Pearson Correlation 1 .734(*)
Sig. (2-tailed)  .024
Trial1b 
N 9 9
Pearson Correlation .734(*) 1
Sig. (2-tailed) .024  
Trial2b 
N 9 9
*  Correlation is significant at the 0.05 level (2-tailed). 
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TABLE 49. REPRODUCIBILITY CORRELATIONS (1HR POST FMD)  
 
 
    Trial1c Trial2c 
Pearson Correlation 1 .486
Sig. (2-tailed)  .184
Trial1c 
N 9 9
Pearson Correlation .486 1
Sig. (2-tailed) .184  
Trial2c 
N 9 9
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TABLE 50. REPRODUCIBILITY CORRELATIONS (2HR POST FMD)  
 
 
    Trial1d Trial2d 
Pearson Correlation 1 .573
Sig. (2-tailed)  .107
Trial1d 
N 9 9
Pearson Correlation .573 1
Sig. (2-tailed) .107  
Trial2d 
N 9 9
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TABLE 51. REPRODUCIBILITY CORRELATIONS (3HR POST FMD) 
 
 
    Trial1e Trial2e 
Pearson Correlation 1 .464
Sig. (2-tailed)  .209
Trial1e 
N 9 9
Pearson Correlation .464 1
Sig. (2-tailed) .209  
Trial2e 
N 9 9
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HUMAN SUBJECTS NOTICE OF APPROVAL 
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HUMAN SUBJECTS NOTICE OF CONTINUING REVIEW 
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HUMAN SUBJECTS PROPOSAL 
 
INDIANA UNIVERSITY 
BLOOMINGTON CAMPUS COMMITTEE FOR THE PROTECTION OF HUMAN SUBJECTS 
 
DOCUMENTATION OF REVIEW AND APPROVAL 
of 
Research Project Utilizing Human Subjects 
Study #                           
 
 
TITLE OF PROJECT The Effect of Acute Exercise on Endothelial Function: A Mechanistic 
Approach                                                                                                                                                               
 
PROJECT DURATION - START DATE   November 2005                                           END DATE 
December 2006                                                           
 
PRIN. INVESTIGATOR  Ryan Harris                               SCHOOL/DEPARTMENT   
HPER/Clinical Exercise Physiology                                                 
 
ADDRESS 1025 E. 7th Street HPER 070                             E-MAIL  Harrisra@indiana.edu   
Phone: 812-855-7556                                               
 
RANK:  Faculty          Res. Scientist          Post-Doc          Staff           Student: undergrad          
masters          PhD/EdD_X        
 
If PI’s rank is OTHER than faculty, name of faculty overseeing the research (Sponsor)  
Janet P. Wallace PhD.  
 
SPONSOR'S E-MAIL & CAMPUS ADDRESS   wallacej@indiana.edu, HPER 112, PHONE 855-
6384                             
 
FUNDING AGENCY         Gatorade Sports Science Institute        APPL. DEADLINE _June 
2005_____________ 
 
AGENCY PROJECT #   Student Grant Proposal 2005                                                       New              
 
As the principal investigator, my signature testifies that I pledge to conform to the following: 
 
 As one engaged in investigation utilizing human subjects, I acknowledge the rights and 
welfare of the human subject involved. 
 I acknowledge my responsibility as an investigator to secure the informed consent of the 
subject by explaining the procedures, in so far as possible, and by describing the risks as weighed 
against the potential benefits of the investigation. 
 I assure the Committee that all procedures performed under the project will be conducted in 
accordance with those Federal regulations and University policies which govern research 
involving human subjects.  Any deviation from the project (e.g., change in principal 
investigator, research methodology, subject recruitment procedures, etc.) will be submitted 
to the Committee in the form of an amendment for its approval prior to implementation. 
 
 
PRINCIPAL INVESTIGATOR: 
Ryan Harris___________________________________________                                                                             
(typed/printed name)   (signature  
 
As the faculty sponsor, my signature testifies that I have reviewed this application and that I 
will oversee the research in its entirety, through the termination report. 
  
FACULTY SPONSOR: 
 
___Janet P.Wallace_______________________________________________________                                         
(typed/printed name)   (signature)  
 
 
CAMPUS LEVEL REVIEW 
 
This protocol for the use of human subjects has been reviewed and approved by the Indiana 
University/Bloomington Campus Committee for the Protection of Human Subjects. 
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BLOOMINGTON CAMPUS COMMITTEE for the PROTECTION OF HUMAN SUBJECTS 
 
SUMMARY SAFEGUARD STATEMENT 
 
                           
Project Title (if you wish to use a different title in the consent statement than is 
listed on page 3, explain here): 
 
The Effect of Acute Exercise on Endothelial Function: A Mechanistic Approach 
________________________________________________________________
___________________       
 
                    IF ADDITIONAL SPACE FOR RESPONSES IS DESIRED, THIS 
DOCUMENT MAY BE 
RETYPED ONTO PLAIN PAPER MAINTAINING THE IDENTICAL ORDER AND 
EXACT 
QUESTION WORDING WHILE ADDING EXTRA SPACE WHERE NEEDED. 
 
 Do not type on the reverse side of any form.   
Use type size no smaller than ARIAL 11 or TIMES NEW ROMAN 12 point. 
 
A. Briefly describe, in lay terms, the general nature and purpose of the 
proposed research, and where the study will take place.  If student 
research, indicate whether for a course, thesis, dissertation, or 
independent research.  If the study is only for a course, please review the 
Student Research Policy to ascertain if this project requires HSC review. 
 
     Endothelial cells, located between the circulating blood and the vessel wall, participate 
in multiple essential functions including, regulation of smooth muscle tone, thrombosis 
control, and platelet aggregation control.  A dysfunctional endothelium has been related 
to an increase risk for cardiovascular disease in clinical populations.  Flow-Mediated 
Dilation (FMD) is a non-invasive measurement of endothelial function which reflects the 
overall health and function of the arteries.  Research suggests a single bout of exercise; 
60% VO2max for 45 minutes, increases arterial function approximately 1 hr post 
intervention; however, the mechanisms related to these findings are not fully understood.   
    Inflammation has been found to induce endothelial dysfunction.  TNF-alpha is a pro-
inflammatory biomarker that has been associated with the pathogenesis of cardiovascular 
disease as well as inducing endothelial dysfunction by decreasing the blood flow. 
Exercise has been found to inhibit this inflammatory process; however, the role of TNF-
alpha as a mechanism is unknown. 
     There are 2 phases associated with the proposed investigation.  Each subject will only 
participate in one of the following phases.  The purpose of phase 1 is to describe the 
effect of endothelial function for up to six hours following an acute bout of exercise.  The 
purpose of phase 2 is to investigate the dose-response relationship of exercise on 
endothelial function and investigate TNF-alpha as a proposed mechanism.  It is 
hypothesized that 1) The greater volume of exercise is associated with a larger increase in 
brachial artery reactivity, and 2) TNF-alpha as an inflammatory mediator plays a major 
role in brachial artery reactivity. 
     The proposed study is intended to be my dissertation and will take place in the 
Clinical Exercise Physiology Laboratory in the school of Health Physical Education and 
Recreation.     
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B. Describe the process by which subjects will be recruited (see item F on 
page 2), how many (or estimate) subjects will be involved in the research, 
and how much time will be required of them.  List specific eligibility 
requirements for subjects (or describe screening procedures), including 
those criteria that would exclude otherwise acceptable subjects.  If your 
study uses only male or female subjects, explain why.  For NIH-funded 
research only, address the inclusion of women, minorities and children in 
the research.  Disclose any relationship between researcher and subjects - 
such as, teacher/student; superintendent/principal/teacher; 
employer/employee (see Students as Subjects section in the Policy 
Manual). 
 
Approximately 20-30 moderate risk adults (18-60yrs) will be asked to participate in 
this study with approval from their physician and no financial compensation.  
Moderate risk, suggested by the American College of Sports Medicine, are those men 
who are > 45 years old or women > 55 years old or any individuals who meet the 
threshold for two or more risk factors (ie: hypertension (BP>140/90), 
hypercholesterolemia (TC>200mg/dl), smoking, sedentary, family history of heart 
disease, obesity (BMI>30kg/m2), and impaired fasting glucose(BG 100-125mg/dl)) 
for coronary heart disease.  Majority of the subjects will be recruited from the Adult 
Fitness Program at Indiana University.  Additional subjects will be adult volunteers 
recruited from the University and within the Bloomington community. Participation 
for this study will take approximately 16-20 hours over a period of 4 non consecutive 
days.  Subjects included in the study will be moderate risk identified by risk 
stratification, and will have their physicians approval. Subjects will be excluded if 
they 
• are not between 18 and 60 years of age, 
• do not fall into the moderate risk classification (as described above in section B),  
• cannot exercise at 75% VO2peak for 45 minutes,  
• have a known allergy to heparin,  
• do not have peripheral venous access in the left upper extremity 
• have cardiovascular, pulmonary or metabolic diseases 
• have gallbladder disease 
• have orthopedic problems that limit your exercise 
• take medications that dilate your arteries such as nitroglycerin, prostacyclin, or 
verapamil 
      
Subjects will be instructed to 1) abstain from exercise or any unnecessary physical 
activity for 12 hours, 2) fast for 8 hours, 3) abstain from vitamin supplementation, 
tobacco, and caffeine for 8 hours, all prior to each day of the investigation. 
 
C. Check appropriate box for type of vulnerable subject population involved 
when investigation specifically studies: 
[_] minors (under age 18), [_] fetuses, [_] pregnant women, [_] persons 
with mental disabilities, 
[_] prisoners, [_] persons with physical disabilities, [_] economically or 
educationally disadvantaged, 
[_] other vulnerable population. 
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If any of the above are used, state the necessity for doing so.  Please 
indicate the approximate age range of the minors to be involved. 
 
No Vulnerable subject populations will be used. 
 
 
D. List all procedures to be used on human subjects or describe what subjects 
will do.  If done during regular class time, explain what non-participants will 
do.  If you are taping, explain that here (see item 13 on page 11).  Asterisk 
those you consider experimental.  For those asterisked procedures, 
describe the usual method(s), if any, that were considered and why they 
were not used.  (See item F on page 2 for more information.) 
1. The risk stratification form summarizes information about the subject’s medical 
history, present diseases/disorders, family history of disease, height and weight, 
and current medications along with information that will be obtained from each 
subjects fasting blood draw.  If there is any question regarding any information 
presented in the risk stratification form, the subjects physician may be consulted. 
2. A fasting blood draw performed at the Indiana University Health center will be 
required before any subject can participate in the study.  This test is to help 
determine the risk stratification for exercise.  Each subject will report to the 
Indiana University Health Center (Room 208) and must be fasting for at least 12 
hours prior to this test.  A 20-45 ml sample of venous blood will be drawn by a 
certified technician via sterile techniques for analysis of cholesterol, triglycerides 
and glucose.  This test will take approximately 10-15 minutes. 
3. A maximal graded exercise test will be performed to obtain the appropriate 
exercise treatment levels for each phase of the proposed investigation. This test is 
designed to measure the subjects exercise capacity.  Each subject will walk or jog 
on a motor-driven treadmill beginning at a speed between 2.5-5.0 mph, 0% grade, 
with the grade or slope increasing 2.5% every two minutes until volitional fatigue, 
breathlessness, chest discomfort, and/or any other symptoms which indicate to 
yourself or the technicians that you should stop exercise.  Heart rate via 12-lead 
EKG will be monitored throughout the test.  Blood pressure will be taken before, 
during if walking (every stage), and after the test (recovery).  Expired gases will 
also be collected through a unidirectional flow mouthpiece during the test.  The 
total duration of this test is approximately 45 minutes. 
4. If the subject is participating in phase 1, they will be asked to perform a single 45 
minute walking exercise session at 60% of their exercise capacity (obtained from 
the maximal graded exercise test).  Following this session of exercise, FMD will 
be performed immediately and every hour thereafter for six hours.  They will be 
asked to remain in the laboratory for the six hour recovery period. During this 
time they will be asked to perform sedentary work which may include, using 
computers, doing work, reading, etc. 
Phase 2:  If the subject is participating in phase 2, they will be asked to perform 
three separate walking exercise sessions at 25%, 60%, and 75% of their exercise 
capacity (on three separate days) obtained from the maximal graded exercise test.  
Following this acute bout of exercise, FMD will be performed approximately 
three times based on the findings of phase 1 of this study.   Phase 1 and 2 - 
Expired gases will be measured through a unidirectional flow mouthpiece during 
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the 5th minute of each exercise session to confirm their exercise intensity.  The 
work rate will be adjusted if it is not within ±10% of your target exercise 
intensity.  Expired gases will then be measured again during the 15th minute to 
confirm the new exercise intensity.  Heart rate and blood pressure will be 
monitored throughout each exercise session. 
5. Flow-mediated dilation (a non-invasive procedure) is used to characterize the 
health of the arteries. Each subject will lie on their back for 20 minutes to 
establish a resting state.  After the 20 minute acclimation phase, a water based 
silicon gel will be placed on the ultrasound transducer as an impedance adapter 
for better ultrasound images.  The Sonoace Pico ultra sound system using a 7.0 
MHz linear transducer will then be used to scan the baseline artery of their inner 
arm, 2-10 cm above the elbow.  Once a clear image is obtained, resting blood 
flow velocity and a baseline image of their artery will be captured by the 
ultrasound. After baseline measurements are captured, a second blood pressure 
cuff will be wrapped around the forearm of the right arm and inflated to 250 mm 
Hg to stop blood flow to the lower arm for 5 minutes. Blood flow velocity will be 
recorded 15 seconds after the cuff is deflated and ultrasound images will be 
captured as described above. The health of the artery will be expressed as a 
percentage of the artery expansion with the increased blood flow, compared to the 
resting diameter. The dependent variables will be brachial artery 
diameter(mm) and absolute change in brachial artery diameter(mm).  
6. Phase 2 only:  For the continuous blood draw, a 24 gauge venous catheter will 
be inserted in a vein in the subjects left arm by a clinical exercise physiologist 
who has special IV training and practice.  The catheter will remain there for the 
entire duration of the testing day (approximately 6-8 hrs).  For each measurement 
of FMD performed during phase 2 of the study, the catheter will be flushed with 
normal saline, and a small blood sample (15-20ml) will be collected from the 
inserted catheter and stored for the analysis of TNF-alpha; a biomarker linked to 
inflammation and arterial health.  Any period of time lasting longer than 2 hours 
between sample collections will require the IV to be flushed with a heparin based 
solution to prevent clotting of the catheter. Once the testing day is completed, the 
catheter will be removed by the same trained clinical exercise physiologist.  The 
dependent variable will be plasma concentrations of TNF-alpha (pg/ml).      
       
E. State the potential risks - for example, physical, psychological, financial, 
social, legal or other - connected with the proposed procedures. 
 
Briefly describe how risks to subjects are reasonable in relation to anticipated benefits.  
Describe procedures for protecting against, or minimizing, potential risks.  Assess their 
likely effectiveness.  If you are using an electrical device that is attached directly to 
subjects explain how the subjects will be protected from shock. 
 
The risks associated with the entire study are minimal. 
           
1. There are no risks associated with filling out the risk stratification form. 
2. The risks associated with a fasting blood draw may include fainting, soreness, 
bruising, and/or swelling at the venipuncture site.  This risk is minimized by 
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having the blood drawn by a trained technician while you are in a seated 
position at the IU Health Center. 
3. The risks involved with maximal graded exercise testing can include 
episodes of transient light headaches, chest discomfort, leg cramps, occasional 
irregular heart beats and abnormal blood pressure responses.  The risk of a 
serious event, although rare (sudden death = 1/10,000; heart attack = 4/10,000 
tests; and complications requiring hospitalization = 10/10,000) does exist.  
Reasonable effort will be made to conduct the test in such a way as to 
minimize your discomfort and risk. The mouthpieces will be sanitized with the 
proper disinfecting detergents.  In the unlikely event of an emergency we will 
call Bloomington Hospital Ambulance Service.  The laboratory is equipped to 
respond to such situations and its personnel are trained to administer 
emergency care in the form of Basic Life Support.  Advanced Cardiac Life 
Support will be provided by Bloomington Hospital Ambulance Service.   
4. The risks involved with sub-maximal exercise sessions can include episodes 
of transient light headaches, chest discomfort, leg cramps, occasional irregular 
heart beats, and abnormal blood pressure responses.  The risk of an event, 
although rare, is significantly reduced from exercise testing because of the sub-
maximal intensity (morbidity = 1/887,526 participant hours of exercise and 
mortality = 1/1,124,000 participant hours).  Reasonable effort will be made to 
minimize risk through prior screening and the use of proper warm-up, exercise 
and cool-down technique.  The mouthpiece will be sanitized with the proper 
disinfecting detergents.  In the unlikely event of a heart related emergency we 
will call the Bloomington Hospital Ambulance Service.  The laboratory is 
equipped to respond to such situations and its personnel are trained to 
administer emergency care in the form of Basic Life Support.  Advanced 
Cardiac Life Support will be provided by Bloomington Hospital Ambulance 
Service.      
5. The risks associated with forearm occlusion when measuring FMD may 
include redness of the skin, bruising, numbness, pain, tingling of the fingers 
and discomfort while the cuff is inflated.  The risks associated with 
ultrasound measurements may include skin irritation and pressure around the 
transducer sites. The risks associated with the Ultrasound lubricant gel are 
skin irritation and possible break out of rash.   
6. The risks associated with the blood draw via angiocath may include 
infection, allergic reaction to heparin, irritation and bruising of the skin, pain, 
discomfort, collapsed vein, multiple puncture sites, and fainting. This risk is 
minimized by having the catheter inserted in a supine or seated position.  If a 
mild reaction (ie. local swelling or redness at site) to heparin occurs, oral 
Benadryl® will be provided.  If a serious reaction (ie. rash, swelling of the 
face, anaphylaxis) the emergency protocol will be initiated.  This risk, 
although rare,  is minimized by using proper sterile technique.  There is a 
chance of phlebitis which can cause redness, swelling, moderate discomfort, 
and fever for up to a few days after the catheter is removed. If mild symptoms 
of phlebitis develop, warm compresses, alternating Tylenol® and Advil® will 
be indicated till the symptoms are gone (usually 12-72 hours).  If serious 
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symptoms of phlebitis develop (ie. fever or red streaks up the arm) the subject 
will be instructed to go to prompt care or the ER immediately.  This risk is 
minimized by using proper sterile technique. 
Every effort will be made to minimize these discomforts. 
 
F. Describe methods for preserving confidentiality.  How will data be recorded 
and stored, with or without identifiers?  If identifiers are used describe the 
type: names, job titles, number code, etc.  How long are identifiers kept?  If 
coding system is used, is there a link back to the subject’s ID?  If yes, 
where is the code list stored in relation to data and when is the code list 
destroyed?  How will reports will be written, in aggregate terms, or will 
individual responses be described?  Will subjects be identified in reports 
(see item 5 on page 10)? Describe disposition of tapes/films at the end of 
the study.  If tapes are to be kept, indicate for how long and describe future 
uses of tapes. 
 
     All laboratory data will be collected in the privacy of the Clinical Exercise Physiology 
Laboratory.  All data will be coded and filed with the reference to the subjects’ 
participant number. Codes are stored in the graduate office of the clinical exercise 
physiology lab in a card file separate from the data files.  All data will be stored in files 
locked in the Clinical Exercise Physiology Laboratory.  Any part of the results obtained 
throughout this investigation will be made available to the subjects referring physician if 
desired by the subject.  No subject will be referred to by name in any publication or 
summary of this work. Data collected will be stored and kept by your research 
participation number and may be used for future research studies.  These data will be kept 
indefinitely because they contain medical related information.  The subject is free to 
withdraw from the study at any time. 
 
G. What, if any, benefit is to be gained by the subject?  In the event of 
monetary gain, include all payment arrangements (amount of payment and 
the proposed method of disbursement), including reimbursement of 
expenses.  If class credit will be given, list the amount and the value as it 
relates to the total points needed for an A.  List alternative ways to earn the 
same amount of credit.  If merchandise or a service is given, indicate the 
value.  Explain the amount of partial payment/class credit if the subject 
withdraws prior to completion of the study.  (See policy at 
http://www.indiana.edu/~resrisk/compensation.html) 
 
     The benefits of this study outweigh the risks.  This new non-invasive technique to 
measure the health of the artery may provide further insight on the development and 
treatment of disease.  Using exercise as a non-pharmacological intervention may create a 
safer and more effective treatment in prevention and management of disease.  This study 
is one of many that will aid in discovering the most efficient exercise treatment in 
disease. 
 
H. What information may accrue to science or society in general as a result of 
this work? 
 
     Endothelial function and arterial stiffness are two independent risk factors of 
cardiovascular disease.  Cardiovascular disease is the leading killer in the United States.  
If we can identify risks of cardiovascular disease at an early stage, we can provide the 
  203
most effective dose of exercise as a treatment and possible delay or prevent the disease 
from progressing. 
 
I. Coinvestigators, Cooperating Departments, Cooperating Institutions.  If 
there are multiple investigators, please indicate only one person on the 
Documentation of Review and Approval (page 3) as the principal 
investigator; others should be designated as coinvestigators here.  
Coinvestigators, not signing on page 3, should sign here, pledging to 
conform to the sentences on page 3.  If you anticipate that another 
department or institution may be involved in this research, list that here.   If 
you are working with another institution, please include a letter of 
cooperation from that institution. 
 Please provide the person’s name and e-mail address. 
 
 
A. Co investigators will include: 
 
a. Janet P. Wallace, PhD.              
Email: wallacej@indiana.edu                                                                
 
 
 
b. Larry D. Rink, MD 
Email:  lrink@ima-md.com   
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INFORMED CONSENT (Inactive) 
 
INDIANA UNIVERSITY - BLOOMINGTON  
Informed Consent Statement 
 
The Interaction of TNF-α, IL-6, and Acute Exercise on Endothelial Function 
 
     You are invited to participate in a research project under the supervision of Janet P. 
Wallace, Ph.D., Ryan Harris, M.S., and Larry Rink, M.D., at Indiana University. The 
purpose of this study is a) to investigate how the exercise intensity is related to the health 
of your arteries, and b) to investigate whether the exercise effects are related to the 
biomarker TNF-alpha, a marker of inflammation. 
 
RESEARCH DESIGN INFORMATION 
     There will be approximately 15-20 
subjects recruited for this investigation.  
Participation of this study will required you 
to 1) fill out a risk stratification form, 2) 
have fasting blood taken at the IU health 
center, and 3) perform a maximal graded 
exercise test on a separate day to determine 
the appropriate exercise intensity (25%, 
50%, or 75% VO2peak).   
     Flow-Mediated Dilation and TNF-alpha 
will be taken at baseline and post exercise 
sessions.  Each subject will take 
approximately 2-3 weeks for completion of 
this study. 
 
Note: Some answers to the questionnaire, results from the initial blood draw, and 
preliminary ultrasound screening may exclude you from the study. 
 
SUBJECT PREPARATION / INCLUSION/EXCLUSION CRITERIA 
     To participate in the study you must: 
• Be of moderate risk described by ACSM guidelines 
• Be a male over the age of 45 years old 
• Have a Body Mass Index (BMI) greater than 25 kg/m2 
• Be sedentary defined by the surgeon general 
• Have permission from your physician to participate in this investigation 
• Have fasted for the past 12 hours 
• Not have any tobacco products at least 8hrs prior to each treatment day 
• Not exercise for at least 12hrs prior to each treatment day 
• Not have any caffeine at least 8hrs prior to each treatment day 
• Not have any vitamin supplementation for at least 8hrs prior to each treatment day 
• Not have any trace of medications that dilate your arteries in your bodies system 
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o If you are on any medications that dilate your arteries and/or cannot be 
tested within the preparation criteria listed above you will be excluded 
from the study 
 
 
You will be excluded from the study if you: 
• Are not 45 years of age or older, 
• Do not fall into the moderate risk classification (ACSM),  
• Cannot exercise at 75% VO2peak for 45 minutes,  
• Have a known allergy to heparin,  
• Do not have peripheral venous access in the left upper extremity 
• Have cardiovascular, pulmonary or metabolic diseases 
• Have orthopedic problems that limit your exercise 
• Take medications that dilate your arteries such as nitroglycerin or verapamil 
• Take Aspirin and cannot discontinue use 3 days prior to each treatment 
• Take any non-steroidal anti-inflammatory and cannot discontinue use 1 day prior 
to each treatment 
 
RISK STRATIFICATION FORM 
     The risk stratification form summarizes information about your medical history, 
present diseases/disorders, family history of disease, height and weight, and current 
medications along with information that will be obtained from your fasting blood draw.  
If there is any question regarding any information presented in the risk stratification form, 
your physician may be consulted. 
 
FASTING BLOOD DRAW 
     This test is to determine your risk stratification for exercise.  You will report to the 
Indiana University Health Center (Room 208).  You must be fasting for at least 12 hours 
prior to this test.  A 20-45 ml sample of venous blood will be drawn by a certified 
technician via sterile techniques for analysis of cholesterol, triglycerides and glucose.  
This test will take approximately 10-15 minutes. 
 
MAXIMAL GRADED EXERCISE TEST 
     This test is designed to measure your exercise capacity.  In the presence of a 
physician, you will walk or jog on a motor-driven treadmill beginning at a speed between 
2.5-5.0 mph, 0% grade, with the grade or slope increasing 2.5% every two minutes until 
volitional fatigue, breathlessness, chest discomfort, and/or any other symptoms which 
indicate to yourself or the technicians that you should stop exercise.  Heart rate, 12-lead 
EKG will be monitored throughout the test.  Blood pressure will be taken before, during 
if walking (every stage), and after the test (recovery).  Expired gases will also be 
collected through the mouthpiece during the test to measure fitness and identify the 
appropriate exercise intensity.  The total duration of this test is approximately 45 minutes.  
There is a one hour recovery period following maximal exercise testing during which you 
should not subject yourself to additional stress such as a very hot or very cold shower, 
smoking, heavy food intake, or other exercise.   
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ARTERIAL HEALTH or FLOW MEDIATED DILATION (FMD) 
     How well your artery expands with changes in blood flow is used to characterize the 
health of your arteries. Three EKG electrodes will be positioned on your chest. Following 
EKG placement, you will be instructed to lie on your back (connected to the EKG 
machine) in a dark, climate controlled room (22-24°C or 72-75 F) with your right arm 
extended laterally to establish a resting state.  After the 20 minute resting phase, a water 
based silicon gel will be placed on the ultrasound transducer as an impedance adapter for 
better ultrasound images.  The Sonoace Pico ultra sound system using a 7.0 MHz linear 
transducer will then be used to scan the resting artery of your inner arm, 2-10 cm above 
your elbow.  Once a clear image is obtained, resting blood flow velocity and a baseline 
image of your artery will be captured by the ultrasound. After baseline measurements are 
captured, a blood flow cuff will be wrapped around the forearm of the right arm and 
inflated to 250 mm Hg to stop blood flow to your lower arm for 5 minutes. Blood flow 
velocity will be recorded for 10 seconds after the cuff is deflated and ultrasound images 
will be captured as described above for the remaining duration (~2 minutes). The health 
of your artery will be expressed as a percentage of the artery expansion with the 
increased blood flow, compared to the resting diameter. 
 
EXERCISE INTERVENTIONS (25%, 50%, and 75% of Exercise Capacity)   
     You will be asked to perform three separate walking exercise sessions at 25%, 50%, 
and 75% of your exercise capacity (on three separate days) obtained from the maximal 
graded exercise test.  Following this single bout of exercise, FMD will be performed 
immediately and at one, two and three hours post exercise.  
     Expired gases will be measured through a mouthpiece during the 5th minute of each 
exercise session to confirm your exercise intensity.  The work rate will be adjusted if it is 
not within ±10% of your target exercise intensity.  Expired gases will then be measured 
again during the 15th minute of exercise to confirm the new exercise intensity.  Heart rate 
and blood pressure will be monitored throughout each exercise session.  
 
SERIAL BLOOD DRAWS via ANGIOCATH 
     At the beginning of the study day, a 22-24 gauge venous catheter will be inserted in a 
vein in your left arm by a trained exercise physiologist.  The catheter will remain in your 
arm for the entire duration of the testing day (approximately 6-8 hrs).  For each 
measurement of FMD performed during the study, the catheter will be flushed with 
normal saline, and a small blood sample (10-20ml) will be collected from the inserted 
catheter and stored for the analysis of TNF-alpha and IL-6; biomarkers linked to 
inflammation and arterial health.  Upon completion of the testing day, the trained 
exercise physiologist will remove the catheter from your arm. 
 
RISKS 
     The discomforts and potential risks associated with this study are minimal. 
 
     Risk Stratification Form:  There are no risks associated with the questionnaire. 
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     Fasting Venous Blood Draw:  The risks associated with this test may include 
fainting, soreness, bruising, and/or swelling at the venipuncture site.  This risk is 
minimized by having the blood drawn by a trained technician while you are in a seated 
position at the IU Health Center. 
     
     Maximal Graded Exercise Test:  The discomforts involved with maximal graded 
exercise testing can include episodes of transient light headaches, chest discomfort, leg 
cramps, occasional irregular heart beats and abnormal blood pressure responses.  The risk 
of a serious event, although rare (sudden death = 1/10,000; heart attack = 4/10,000 tests; 
and complications requiring hospitalization = 10/10,000) does exist.  Reasonable effort 
will be made to conduct the test in such a way as to minimize your discomfort and risk. 
The mouthpiece will be sanitized with the proper detergents.  In the unlikely event of an 
emergency we will call Bloomington Hospital Ambulance Service.  Our laboratory is 
equipped to respond to certain situations and our personnel are trained to administer 
emergency care in the form of Basic Life Support.  Advanced Cardiac Life Support will 
be provided by Bloomington Hospital Ambulance Service.   
 
     Flow-Mediated Dilation:  The risks associated with the placement of EKG 
electrodes may include redness and/or itching at the electrode sites. The risks associated 
with forearm occlusion when measuring FMD may include redness of the skin, bruising, 
numbness, pain, tingling of the fingers and discomfort while the cuff is inflated.  The 
risks associated with ultrasound measurements may include skin irritation and pressure 
around the transducer sites. The risks associated with the Ultrasound lubricant gel are 
skin irritation and possible break out of rash.   
      
     Walking Exercise Intervention:  The discomforts involved with exercise sessions 
can include episodes of transient light headaches, chest discomfort, leg cramps, 
occasional irregular heart beats, and abnormal blood pressure responses.  The risk of an 
event, although rare, is significantly reduced from exercise testing because of the sub-
maximal intensity (morbidity = 1/887,526 participant hours of exercise and mortality = 
1/1,124,000 participant hours).  Reasonable effort will be made to minimize risk through 
prior screening and the use of proper warm-up, exercise and cool-down technique.  The 
mouthpiece will be sanitized with the proper detergents.  In the unlikely event of a heart 
related emergency we will call the Bloomington Hospital Ambulance Service.  The 
laboratory is equipped to respond to such situations and its personnel are trained to 
administer emergency care in the form of Basic Life Support.  Advanced Cardiac Life 
Support will be provided by Bloomington Hospital Ambulance Service. 
     
Continuous Blood Draw via Angiocath:  The risks associated with the blood draw via 
angiocath may include infection, allergic reaction to heparin, irritation and bruising of the 
skin, pain, discomfort, collapsed vein, multiple puncture sites, and fainting. This risk is 
minimized by having the catheter inserted in a supine or seated position.  If a mild 
reaction (ie. local swelling or redness at site) to heparin occurs, oral Benadryl® will be 
provided.  If a serious reaction (ie. rash, swelling of the face, anaphylaxis) the emergency 
protocol will be initiated.  This risk, although rare, is minimized by using proper sterile 
technique.  There is a chance of phlebitis which can cause redness, swelling, moderate 
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discomfort, and fever for up to a few days after the catheter is removed. If mild 
symptoms of phlebitis develop, warm compresses, alternating Tylenol® and Advil® will 
be indicated till the symptoms are gone (usually 12-72 hours).  If serious symptoms of 
phlebitis develop (ie. fever or red streaks up the arm) the subject will be instructed to 
seek medical care immediately.  This risk is minimized by using proper sterile technique. 
 
Every effort will be made to minimize these risks. 
 
BENEFITS 
       This new non-invasive technique to measure the health of the artery may provide 
further insight on the development and treatment of disease.  Using exercise as a non-
pharmacological intervention may create a safer and more effective treatment in 
prevention and management of disease.  This study is one of many that will aid in 
discovering the most efficient exercise treatment in disease. You will receive information 
on your maximal exercise capacity, fasting blood work, and most importantly how well 
your arteries respond to different intensities of single session exercise.  
 
CONFIDENTIALITY 
     All laboratory data will be collected in the privacy of the Clinical Exercise Physiology 
Laboratory.  All data will be coded and filed with the reference to the subjects’ 
participant number. Codes are stored in the graduate office of the clinical exercise 
physiology lab in a card file separate from the data files.  All data will be stored in files 
locked in the Clinical Exercise Physiology Laboratory.  Any part of the results obtained 
throughout this investigation will be made available to your physician if you desire.  No 
subject will be referred to by name in any publication or summary of this work.  Data 
collected will be stored and kept by your research participation number and may be used 
for future research studies.  These data will be kept indefinitely because they contain 
medical related information.  You are free to withdraw from the study at any time. 
 
CONTACT 
     If you have any questions at any time regarding this study or the procedures, (or you 
experience adverse effects as a result of participating in the study) you may contact: 
 
Ryan Harris HPER 070 Indiana University, Bloomington, IN 47405 - 855-7556 
 
Dr Wallace HPER 112G Indiana University, Bloomington, IN 47405 - 855-6384 
 
Dr Rink HPER 070 Indiana University, Bloomington, IN 47405 - 855-7556 
  
     If you feel that you have not been treated according to the descriptions in this form, or 
your rights as a participant in research have been violated during the course of this 
project, you may contact the office for Human Subjects Committee, Indiana University, 
Carmichael Center L03, 530E. Kirkwood Ave., Bloomington, IN 47408 or call 812-855-
3067, email: iub_hsc@indiana.edu. 
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PARTICIPATION 
     You are free to decline to answer specific items or questions in interviews or on 
questionnaires, and are free to withdraw from the study at any time.  If you do withdraw 
from the study before data collection is completed, your data will be returned to you or 
destroyed upon your request. 
 
PARTICIPATION IN RELIABILITY TEST (check one) 
     Approximately 10 subjects are needed to repeat the 50% exercise intensity treatment 
day to evaluate reproducibility of the results.  Willingness to participate in this part of the 
study will be solicited during initial consent.   
 
_____ I am interested in repeating one treatment as part of a reliability test. 
 
_____ I am not interested in repeating one treatment as part of a reliability test. 
 
 
CONSENT 
     I certify to the best of my knowledge and belief, I have no physical or mental illness 
or weakness that would increase my risk of participation in this study.      
     I have read this form and received a copy of it.  I have had all my questions answered 
to my satisfaction.  I agree to take part in this study. 
 
 
Subjects Signature_________________________________   Date_________________ 
 
Investigators Signature______________________________  Date_________________ 
 
 
Consent Form Updated: July 26, 2006 
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INFORMED CONSENT (Active) 
 
INDIANA UNIVERSITY - BLOOMINGTON  
Informed Consent Statement 
 
The Interaction of TNF-α, IL-6, and Acute Exercise on Endothelial Function 
 
     You are invited to participate in a research project under the supervision of Janet P. 
Wallace, Ph.D., Ryan Harris, M.S., and Larry Rink, M.D., at Indiana University. The 
purpose of this study is a) to investigate how the exercise intensity is related to the health 
of your arteries, and b) to investigate whether the exercise effects are related to the 
biomarker TNF-alpha, a marker of inflammation. 
 
RESEARCH DESIGN INFORMATION 
     There will be approximately 15-20 
subjects recruited for this investigation.  
Participation of this study will required 
you to 1) fill out a risk stratification form, 
2) have fasting blood taken at the IU 
health center, and 3) perform a maximal 
graded exercise test on a separate day to 
determine the appropriate exercise 
intensity (25%, 50%, or 75% VO2peak).   
     Flow-Mediated Dilation and TNF-
alpha will be taken at baseline and post 
exercise sessions.  Each subject will take 
approximately 2-3 weeks for completion 
of this study. 
 
Note: Some answers to the questionnaire, results from the initial blood draw, and 
preliminary ultrasound screening may exclude you from the study. 
 
SUBJECT PREPARATION / INCLUSION/EXCLUSION CRITERIA 
     To participate in the study you must: 
• Be of moderate risk described by ACSM guidelines 
• Be a male over the age of 45 years old 
• Have a Body Mass Index (BMI) more than 25 kg/m2 
• Be active defined by the surgeon general 
• Have permission from your physician to participate in this investigation 
• Have fasted for the past 12 hours 
• Not have any tobacco products at least 8hrs prior to each treatment day 
• Not exercise for at least 12hrs prior to each treatment day 
• Not have any caffeine at least 8hrs prior to each treatment day 
• Not have any vitamin supplementation for at least 8hrs prior to each treatment day 
• Not have any trace of medications that dilate your arteries in your bodies system 
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o If you are on any medications that dilate your arteries and/or cannot be 
tested within the preparation criteria listed above you will be excluded 
from the study 
 
 
You will be excluded from the study if you: 
• Are not 45 years of age or older, 
• Do not fall into the moderate risk classification (ACSM),  
• Cannot exercise at 75% VO2peak for 45 minutes,  
• Have a known allergy to heparin,  
• Do not have peripheral venous access in the left upper extremity 
• Have cardiovascular, pulmonary or metabolic diseases 
• Have orthopedic problems that limit your exercise 
• Take medications that dilate your arteries such as nitroglycerin or verapamil 
• Take Aspirin and cannot discontinue use 3 days prior to each treatment 
• Take any non-steroidal anti-inflammatory and cannot discontinue use 1 day prior 
to each treatment 
 
RISK STRATIFICATION FORM 
     The risk stratification form summarizes information about your medical history, 
present diseases/disorders, family history of disease, height and weight, and current 
medications along with information that will be obtained from your fasting blood draw.  
If there is any question regarding any information presented in the risk stratification form, 
your physician may be consulted. 
 
FASTING BLOOD DRAW 
     This test is to determine your risk stratification for exercise.  You will report to the 
Indiana University Health Center (Room 208).  You must be fasting for at least 12 hours 
prior to this test.  A 20-45 ml sample of venous blood will be drawn by a certified 
technician via sterile techniques for analysis of cholesterol, triglycerides and glucose.  
This test will take approximately 10-15 minutes. 
 
MAXIMAL GRADED EXERCISE TEST 
     This test is designed to measure your exercise capacity.  In the presence of a 
physician, you will walk or jog on a motor-driven treadmill beginning at a speed between 
2.5-5.0 mph, 0% grade, with the grade or slope increasing 2.5% every two minutes until 
volitional fatigue, breathlessness, chest discomfort, and/or any other symptoms which 
indicate to yourself or the technicians that you should stop exercise.  Heart rate, 12-lead 
EKG will be monitored throughout the test.  Blood pressure will be taken before, during 
if walking (every stage), and after the test (recovery).  Expired gases will also be 
collected through the mouthpiece during the test to measure fitness and identify the 
appropriate exercise intensity.  The total duration of this test is approximately 45 minutes.  
There is a one hour recovery period following maximal exercise testing during which you 
should not subject yourself to additional stress such as a very hot or very cold shower, 
smoking, heavy food intake, or other exercise.   
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ARTERIAL HEALTH or FLOW MEDIATED DILATION (FMD) 
     How well your artery expands with changes in blood flow is used to characterize the 
health of your arteries. Three EKG electrodes will be positioned on your chest. Following 
EKG placement, you will be instructed to lie on your back (connected to the EKG 
machine) in a dark, climate controlled room (22-24°C or 72-75 F) with your right arm 
extended laterally to establish a resting state.  After the 20 minute resting phase, a water 
based silicon gel will be placed on the ultrasound transducer as an impedance adapter for 
better ultrasound images.  The Sonoace Pico ultra sound system using a 7.0 MHz linear 
transducer will then be used to scan the resting artery of your inner arm, 2-10 cm above 
your elbow.  Once a clear image is obtained, resting blood flow velocity and a baseline 
image of your artery will be captured by the ultrasound. After baseline measurements are 
captured, a blood flow cuff will be wrapped around the forearm of the right arm and 
inflated to 250 mm Hg to stop blood flow to your lower arm for 5 minutes. Blood flow 
velocity will be recorded for 10 seconds after the cuff is deflated and ultrasound images 
will be captured as described above for the remaining duration (~2 minutes). The health 
of your artery will be expressed as a percentage of the artery expansion with the 
increased blood flow, compared to the resting diameter. 
 
EXERCISE INTERVENTIONS (25%, 50%, and 75% of Exercise Capacity)   
     You will be asked to perform three separate walking exercise sessions at 25%, 50%, 
and 75% of your exercise capacity (on three separate days) obtained from the maximal 
graded exercise test.  Following this single bout of exercise, FMD will be performed 
immediately and at one, two and three hours post exercise.  
     Expired gases will be measured through a mouthpiece during the 5th minute of each 
exercise session to confirm your exercise intensity.  The work rate will be adjusted if it is 
not within ±10% of your target exercise intensity.  Expired gases will then be measured 
again during the 15th minute of exercise to confirm the new exercise intensity.  Heart rate 
and blood pressure will be monitored throughout each exercise session.  
 
SERIAL BLOOD DRAWS via ANGIOCATH 
     At the beginning of the study day, a 22-24 gauge venous catheter will be inserted in a 
vein in your left arm by a trained exercise physiologist.  The catheter will remain in your 
arm for the entire duration of the testing day (approximately 6-8 hrs).  For each 
measurement of FMD performed during the study, the catheter will be flushed with 
normal saline, and a small blood sample (10-20ml) will be collected from the inserted 
catheter and stored for the analysis of TNF-alpha and IL-6; biomarkers linked to 
inflammation and arterial health.  Upon completion of the testing day, the trained 
exercise physiologist will remove the catheter from your arm. 
 
RISKS 
     The discomforts and potential risks associated with this study are minimal. 
 
     Risk Stratification Form:  There are no risks associated with the questionnaire. 
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     Fasting Venous Blood Draw:  The risks associated with this test may include 
fainting, soreness, bruising, and/or swelling at the venipuncture site.  This risk is 
minimized by having the blood drawn by a trained technician while you are in a seated 
position at the IU Health Center. 
         Maximal Graded Exercise Test:  The discomforts involved with maximal graded 
exercise testing can include episodes of transient light headaches, chest discomfort, leg 
cramps, occasional irregular heart beats and abnormal blood pressure responses.  The risk 
of a serious event, although rare (sudden death = 1/10,000; heart attack = 4/10,000 tests; 
and complications requiring hospitalization = 10/10,000) does exist.  Reasonable effort 
will be made to conduct the test in such a way as to minimize your discomfort and risk. 
The mouthpiece will be sanitized with the proper detergents.  In the unlikely event of an 
emergency we will call Bloomington Hospital Ambulance Service.  Our laboratory is 
equipped to respond to certain situations and our personnel are trained to administer 
emergency care in the form of Basic Life Support.  Advanced Cardiac Life Support will 
be provided by Bloomington Hospital Ambulance Service.   
 
     Flow-Mediated Dilation:  The risks associated with the placement of EKG 
electrodes may include redness and/or itching at the electrode sites. The risks associated 
with forearm occlusion when measuring FMD may include redness of the skin, bruising, 
numbness, pain, tingling of the fingers and discomfort while the cuff is inflated.  The 
risks associated with ultrasound measurements may include skin irritation and pressure 
around the transducer sites. The risks associated with the Ultrasound lubricant gel are 
skin irritation and possible break out of rash.   
      
     Walking Exercise Intervention:  The discomforts involved with exercise sessions 
can include episodes of transient light headaches, chest discomfort, leg cramps, 
occasional irregular heart beats, and abnormal blood pressure responses.  The risk of an 
event, although rare, is significantly reduced from exercise testing because of the sub-
maximal intensity (morbidity = 1/887,526 participant hours of exercise and mortality = 
1/1,124,000 participant hours).  Reasonable effort will be made to minimize risk through 
prior screening and the use of proper warm-up, exercise and cool-down technique.  The 
mouthpiece will be sanitized with the proper detergents.  In the unlikely event of a heart 
related emergency we will call the Bloomington Hospital Ambulance Service.  The 
laboratory is equipped to respond to such situations and its personnel are trained to 
administer emergency care in the form of Basic Life Support.  Advanced Cardiac Life 
Support will be provided by Bloomington Hospital Ambulance Service. 
     
Continuous Blood Draw via Angiocath:  The risks associated with the blood draw via 
angiocath may include infection, allergic reaction to heparin, irritation and bruising of the 
skin, pain, discomfort, collapsed vein, multiple puncture sites, and fainting. This risk is 
minimized by having the catheter inserted in a supine or seated position.  If a mild 
reaction (ie. local swelling or redness at site) to heparin occurs, oral Benadryl® will be 
provided.  If a serious reaction (ie. rash, swelling of the face, anaphylaxis) the emergency 
protocol will be initiated.  This risk, although rare, is minimized by using proper sterile 
technique.  There is a chance of phlebitis which can cause redness, swelling, moderate 
discomfort, and fever for up to a few days after the catheter is removed. If mild 
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symptoms of phlebitis develop, warm compresses, alternating Tylenol® and Advil® will 
be indicated till the symptoms are gone (usually 12-72 hours).  If serious symptoms of 
phlebitis develop (ie. fever or red streaks up the arm) the subject will be instructed to 
seek medical care immediately.  This risk is minimized by using proper sterile technique. 
 
Every effort will be made to minimize these risks. 
 
BENEFITS 
       This new non-invasive technique to measure the health of the artery may provide 
further insight on the development and treatment of disease.  Using exercise as a non-
pharmacological intervention may create a safer and more effective treatment in 
prevention and management of disease.  This study is one of many that will aid in 
discovering the most efficient exercise treatment in disease. You will receive information 
on your maximal exercise capacity, fasting blood work, and most importantly how well 
your arteries respond to different intensities of single session exercise.  
 
CONFIDENTIALITY 
     All laboratory data will be collected in the privacy of the Clinical Exercise Physiology 
Laboratory.  All data will be coded and filed with the reference to the subjects’ 
participant number. Codes are stored in the graduate office of the clinical exercise 
physiology lab in a card file separate from the data files.  All data will be stored in files 
locked in the Clinical Exercise Physiology Laboratory.  Any part of the results obtained 
throughout this investigation will be made available to your physician if you desire.  No 
subject will be referred to by name in any publication or summary of this work.  Data 
collected will be stored and kept by your research participation number and may be used 
for future research studies.  These data will be kept indefinitely because they contain 
medical related information.  You are free to withdraw from the study at any time. 
 
CONTACT 
     If you have any questions at any time regarding this study or the procedures, (or you 
experience adverse effects as a result of participating in the study) you may contact: 
 
Ryan Harris HPER 070 Indiana University, Bloomington, IN 47405 - 855-7556 
 
Dr Wallace HPER 112G Indiana University, Bloomington, IN 47405 - 855-6384 
 
Dr Rink HPER 070 Indiana University, Bloomington, IN 47405 - 855-7556 
  
     If you feel that you have not been treated according to the descriptions in this form, or 
your rights as a participant in research have been violated during the course of this 
project, you may contact the office for Human Subjects Committee, Indiana University, 
Carmichael Center L03, 530E. Kirkwood Ave., Bloomington, IN 47408 or call 812-855-
3067, email: iub_hsc@indiana.edu. 
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PARTICIPATION 
     You are free to decline to answer specific items or questions in interviews or on 
questionnaires, and are free to withdraw from the study at any time.  If you do withdraw 
from the study before data collection is completed, your data will be returned to you or 
destroyed upon your request. 
 
PARTICIPATION IN RELIABILITY TEST (check one) 
     Approximately 10 subjects are needed to repeat the 50% exercise intensity treatment 
day to evaluate reproducibility of the results.  Willingness to participate in this part of the 
study will be solicited during initial consent.   
 
_____ I am interested in repeating one treatment as part of a reliability test. 
 
_____ I am not interested in repeating one treatment as part of a reliability test. 
 
 
CONSENT 
     I certify to the best of my knowledge and belief, I have no physical or mental illness 
or weakness that would increase my risk of participation in this study.      
     I have read this form and received a copy of it.  I have had all my questions answered 
to my satisfaction.  I agree to take part in this study. 
 
 
Subjects Signature_________________________________   Date_________________ 
 
Investigators Signature______________________________  Date_________________ 
 
 
Consent Form Updated: August 28, 2006 
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HUMAN SUBJECTS AMMENDMENT 4/5/2006 
 
This study amendment is being submitted to modify: 
• The number of subjects being recruited for this investigation 
• Additional inclusion/exclusion criteria for this investigation 
• An additional arterial health measurement and subsequent blood draw 
• And, the analysis of another biomarker. 
 
After analysis of the literature and pilot work from our laboratory, the required subjects 
needed to find significance will be approximately 15-20.  This modification does not 
affect the risk: benefit for the subjects being investigated. 
 
In order to control for certain parameters in measuring arterial health and the biomarkers, 
more strict criteria for including and excluding subject will be implemented.  The 
complete list of inclusion/exclusion criteria is highlighted in the attached informed 
consent.  This modification does not affect the risk: benefit for the subjects being 
investigated and will hopefully create more reliable data. 
 
One additional measurement of arterial health and subsequent blood draw will be added 
immediately following exercise.  This additional blood collection (10-20ml) is still within 
appropriate collection amounts within the investigation time studied.  This modification 
does not affect the risk: benefit for the subjects being investigated and will provide further 
insight to answering the scientific question being asked. 
 
Following collection and storage of the blood, an additional biomarker will be analyzed.  
This modification does not affect the risk: benefit for the subjects being investigated. 
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HUMAN SUBJECTS AMMENDMENT 4/17/2006 
 
This study amendment is being submitted to modify: 
• The procedure utilized to measure endothelial function.  
 
 
The procedure will be similar as previously described, yet include the following: 
• Placement and connection of 3 EKG electrodes during the Flow-mediated Dilation 
procedure. 
• Utilization of a specific blood flow cuff as a replacement for the standard blood 
pressure cuff used to occlude the artery. 
   
The risks associated with the placement of EKG electrodes may include redness and/or 
itching at the electrode sites; however, these modifications do not affect the overall risk: 
benefit for the subjects being investigated. 
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HUMAN SUBJECTS AMMENDMENT 5/5/2006 
 
This study amendment is being submitted to modify: 
• The procedure utilized to measure endothelial function.  
 
 
The procedure will be similar as previously described, yet include the following: 
• Placement and connection of 3 EKG electrodes during the Flow-mediated Dilation 
procedure (FMD). 
• Utilization of a specific blood flow cuff as a replacement for the standard blood 
pressure cuff used to occlude the artery. 
   
The benefit of incorporating EKG will decrease the subjective error associated with the 
FMD procedure. 
 
The risks associated with the placement of EKG electrodes may include redness and/or 
itching at the electrode sites; however, these modifications do not affect the overall risk: 
benefit for the subjects being investigated. 
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HUMAN SUBJECTS AMMENDMENT 5/17/2006 
 
This study amendment is being submitted to modify: 
• The inclusion criteria for the moderate risk population being investigated, and 
• To include the option of repeating one of the treatment days to evaluate 
reproducibility. 
 
The modification to the inclusion criteria is being done to identify a more specific 
moderate risk population.  The inclusion criteria being added are: 
• Be a male over the age of 45 years old 
• Have a Body Mass Index (BMI) greater than 25 kg/m2 
• Be sedentary defined by the surgeon general 
 
The repetition of one treatment day will help answer an important research question that 
will be necessary to incorporate for external funding opportunities.  
 
The benefit of identifying a more specific subject population will help when inferring the 
results to the specific group being investigated. A more diverse subject population may 
introduce too many demographic confounding variables. 
 
There are no risks associated with the new addition of the inclusion criteria and there are 
no additional risks associated with participating in an extra treatment day. 
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HUMAN SUBJECTS AMMENDMENT 6/2/2006 
 
This study amendment is being submitted to modify the statement regarding prostacyclin 
inhibitors to be more specific and the addition of a Public Service Announcement: 
• Alternative pharmacology that needs to be controlled for throughout the duration 
of the study 
 
• The modification to exclude the use of aspirin and non-steroidal anti inflammatory 
agents (ibuprofen, Advil, etc.) for the days prior to the treatments will be 
implemented to control for vascular and inflammatory effects. 
 
• The PSA is attached and will be used to aid in subject recruitment 
 
 
There are no risks associated with the new addition of the inclusion criteria, as these 
agents used in the studied population are for prophylactic affects and will be approved by 
each subject’s physician if discontinued use is necessary. 
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HUMAN SUBJECTS AMMENDMENT 7/26/2006 
 
This study amendment is being submitted to modify the inclusion criteria to include: 
• Have fasted for the past 12 hours 
 
 
There are no risks associated with the new addition of the inclusion criteria.  To control 
for a meal effect on arterial health, subjects need to be fasting. 
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HUMAN SUBJECTS AMMENDMENT 8/28/2006 
 
This study amendment is being submitted to modify the population being investigated in 
addition to the overweight/sedentary group currently being investigated.  The new 
population will include: 
• Overweight/active Men 
 
 
 
There are no risks associated with the new addition of the inclusion criteria.   
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BIOHAZARD SAFETY APPROVAL 
 
    
225 
BIOHAZARD SAFETY PROPOSAL 
 
Study No.                
 
 
INSTITUTIONAL BIOSAFETY REPORTING AND APPROVAL FORM 
 Indiana University 
 
 This form must be submitted for ALL activities (e.g., 
research, teaching) involving recombinant DNA (rDNA), 
infectious agents, TAT proteins, toxins, prions, and/or 
human tissue and fluids use. 
 
Submit the original and two copies to:  Beth Reeves, 
Biosafety Officer, Environmental Health and Safety, 2735 E 
10th St Room 160, Indiana University 47408.  Call 855-9333, 
or e-mail bereeves@indiana.edu, for additional forms and 
information. (Keep a copy for your records.) 
 
 
I. CAMPUS Bloomington  
SCHOOL/DEPARTMENT___Kinesiology_____________                        
PRIN. INVEST/INSTR___Janet P. Wallace, Ph.D._________________ 
ID# (IU ID# or if you choose your S.S.#) 2 0000 001 019 
179______             
CO-PRIN.INVEST/INSTR___Julie Frey, M.S. ___ 
ID# (IU ID# or if you choose your S.S.#) __0000 881937______ 
CO-PRIN.INVEST/INSTR___ Alyce Fly, Ph.D. __________ 
ID# (IU ID# or if you choose your S.S.#) _361-44-6085____ 
CO-PRIN.INVEST/INSTR___ Larry Rink, M.D.  
ID# (IU ID# or if you choose your S.S.#) ___314-42-2953 
CO-PRIN.INVEST/INSTR___ Tim Mickleborough, Ph.D.__________ 
ID# (IU ID# or if you choose your S.S.#) __2 0593 899 857 553__ 
 
Campus Address:  HPER 112-G            Office Phone:_5-6384  
Lab Phone:     5-5776        Home Phone:__334-8217___  
E-mail address:___wallacej@indiana.edu__________________                 
RANK: Faculty x     Res. Scientist    Post-Doc         Staff          
StudentRyan Harris ID#0001860960 Faculty advisor Janet P. Wallace           
Citizenship:PI   USA        Co-PI   USA  Student(s)___ USA  
 
PROJECT TITLE:  Can exercise and physical activity counteract the 
effects of a high fat meal on endothelial function? 
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TITLE OF GRANT UNDER WHICH PROJECT WILL BE CONDUCTED (if 
different than project title) 
 
1. American Heart Association:  Can exercise and physical activity 
counteract the effects of a high fat meal on endothelial function? 
2. American Diabetes Association:  Can exercise and physical activity 
counteract the effects of a high fat meal on endothelial function in 
diabetes? 
3. NIH: Can exercise and physical activity counteract the effects of a 
high fat meal on endothelial function in obesity? 
 
If this activity involves other campuses, please indicate 
which ones: 
 
FUNDING SOURCE AHA, ADA, NIH APPLICATION DEADLINE Jan & Feb 
2006           
Proposed Start Date:July 06; pilot data Fall 05 or renewal date              
PROJECT TYPE:  Research  x  Project#     New      Renewal         
Teaching  x  Course # K602  New    Renewal   
Teaching is for the pilot work; supervised by Drs. Fly & 
Mickleborough and Julie Frey    
 
LOCATION: List the building and room number of each 
laboratory in which any part of the experiments will be 
conducted HPER Rooms 070 (collection) and 005 & 078 (analysis & storage) 
 
If grant proposal, list grant numbers and all agencies _1) 
American Heart Association (January 2006), 2) American Diabetes 
Association (January 2006), and 3) NHLBI of NIH (February 2006)__  
TERM OF PROJECT:  START Fall 2005     END __June 2011________            
If this application requires BL-2 or higher containment 
circle "yes" or "no": 
 
YES  NO The facilities used in these activities have been 
previously inspected by the IBC and meet 
appropriate biological laboratory safety 
standards. 005 (Dr. Fly), 070 (Dr. Wallace) and 078 (Dr. 
Mickleborough) have been previously approved for biosafety 
standards 
Indicate (check) agents or materials used and follow 
instructions: 
 
     Recombinant DNA.  Fill out sections even if 
exempt: Complete  sections  A,B,C & D as required. 
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     Infectious agents, toxins, TAT proteins, or prions 
(pathogenic to humans, animals or plants)  Fill 
out section E 
  x  Human tissues or fluids.  Fill out section F  
_____Use and/or possession of select agents according 
to the Patriot  Act ( 
http://www.indiana.edu/~resrisk/patriotactsummary.pdf 
).   Fill out section G 
COMPLETION AND SIGNING OF THIS FORM ARE THE 
RESPONSIBILITY OF THE PRINCIPAL INVESTIGATOR OR 
FACULTY MEMBER IN CHARGE. 
 
In signing this form, I agree to abide by all university and 
federal guidelines and regulations regarding recombinant 
DNA, infectious agent, TAT protein and/or human tissues and 
fluids work.   
 
Principal Investigator is responsible for all liabilities 
related to use of his/her materials. 
 
 
_______________________________________6 October 2005______ 
Principal Investigator (and Faculty Advisor)    Date 
                Signature 
 
A. Experiments that require RAC or ORDA review; NIH and 
IBC approval.  Circle "Yes" or "No": 
 
YES NO 1. Deliberate formation of rDNAs containing 
genes for biosynthesis of toxic molecules. 
YES NO 2. Deliberate release into the environment of 
any organism containing rDNA. 
YES NO 3. Deliberate transfer of drug resistance trait 
to microorganisms such that drug control 
might be compromised. 
YES NO 4. Deliberate transfer of rDNA into human 
subjects. 
 
 
B.  Experiments that require IBC approval before initiation.  
Circle "Yes" or "No": 
 
YES NO 1. Use of other than a Class 1 agent as host-
vector system (see Appendix B of NIH 
Guidelines, 1995). 
YES NO 2. Will you use a Class 2,3, or 4 viral vector?  
If so, will: 
(YES NO) a.  Greater than 2/3's of genome be 
used? 
(YES NO) b.  helper virus be used? 
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(YES NO) c.  your experiment enhance 
pathogenicity (e.g., 
   insertion of oncogene, extend 
host range)? 
YES NO 3. Will whole animals or plants be used as 
hosts? 
YES NO 4. Will experiments involve more than 10 liters 
of culture? 
YES NO 5. Will a deliberate attempt be made to obtain 
expression of a 
 foreign gene? 
If so, what protein/RNA will be produced?               
                                                       
YES NO 6. Will TAT proteins be purchased, synthesized 
or expressed? 
YES NO 7. Will a toxin be used? 
YES NO 8. Will prions be used? 
 
ALL "YES" ANSWERS ABOVE MUST BE EXPLAINED IN SECTION 
BELOW. 
 
 
C. rDNA Constructs: 
 
1. Host organism:                                              
 
2. List the vector(s) name and type (e.g.,  -gt11, 
retroviral pLNL), and append a DNA map of any 
novel vectors listing components with their 
sizes). 
3. Source organism of DNA to be cloned (e.g., human 
T-Cell cDNA library, HIV gag gene): 
 
                                                            
 
4. If the DNA is microbial, circle the appropriate 
class as given in Appendix B [Current federal 
guidelines: 
http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.h
tm ] 
1   2   3   4   5  N/A        
 
5. Function of products (protein or RNA) of the 
cloned DNA:         
                                                            
 
6. For oncogenic viruses, circle appropriate level 
(Appendix B [and all federal guidelines and 
Biosafety Manual]: 
 
Low Risk  Moderate 
Risk  N/A         
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7. Circle containment level specified by the current 
Federal Guidelines 
(http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.
htm )and the Biosafety Manual:  
 
Exempt 
 
BL1 
 
BL2 
 
BL3 
 
BL4 
 
*Note:  All human tissue/body fluid samples 
require BL2.* 
 
 
D. Include a succinct description of your project on a 
separate page and explain WHAT, WHY, and HOW rDNA will 
be used in the project.  This CANNOT be replaced with a 
grant proposal or reprint. 
 
E. Description of proposed research involving infectious 
agents, toxins, TAT proteins, or prions. 
 
a. Submit a succinct statement of your project on a separate page.  Explain 
why and how infectious agent(s), toxins, TAT proteins, or prions will be used in the 
project.  This CANNOT be replaced with a grant proposal or a reprint. 
b. List the infectious agent(s), toxins, TAT proteins, or 
prions:                              
c. Circle level of research according to the federal 
guidelines and Biosafety in Microbiological and 
Biomedical Laboratories 
(http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.
htm ).(BL-1, BL-2, BL-3, BL-4) 
 
F. Human Tissues and Fluids Usage.  Submit to the IBC a 
statement of that intent and include an outline 
(abstract) of the proposed activity, and sufficient 
information that will clarify to the reader that the 
guidelines involving human tissue and fluids are 
understood and that the submitting individual is able 
and intends to adhere to those guidelines. 
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The purpose of this study is to determine if prior exercise or physical 
activity prevents the postprandial 
attenuation in brachial artery FMD produced 
by ingestion of a high fat meal and to 
provide insight into the underlying 
physiological mechanisms.   
 
The design is illustrated in Figure 1.   
Three different activity sessions and one 
control session will be presented before the 
consumption of a high-fat meal in a 
randomized cross over design.  The duration 
of the physical activity will be from 7:00 am 
to noon.  The single long session of exercise 
will begin at 11:20 am and end at noon.  The 
four short 10 minute bouts of exercise will 
begin at 8:40 am, 9:40 am, 10:40 am and 
11:40 am; also ending at noon.  FMD will be 
measured 1) at baseline at 6:30 am, 2) 
before the high-fat meal, 3) every hour, for 
five hours following the high fat meal, 
beginning one hour after the high-fat meal,   
and 4) at 6:30 am the next day. Oxidative 
and inflammatory biomarkers that will be 
measured in our proposed study will include 
1) Interleuklin-6 (IL-6), 2) nuclear factor κB (NF ιB), 3) Tumor Necrosis 
Factor (TNF ∀), and 3) 8-epi-prostaglandin F2∀ (8-PG F2∀).    IL-6, NF κB, 
TNF ∀, and 8-PG F2∀  will be measured following every FMD measurement, 
except for the 6:00 am next day measurement period.   
Biomarkers:  Seven blood draws and urine samples will be collected; baseline, 
pre-, and hourly for five hours post the high-fat meal.  Each blood sample will 
be analyzed for concentrations of IL-6, TNF ∀, and NF κB.  The urine 
samples will be analyzed for 8-PG F2∀.   
Blood Collection:  a 24 gauge venous catheter equipped with a PRN adapter 
will be inserted in a vein in the subjects left arm by a clinical exercise 
physiologist who has special IV training and practice.  The catheter will 
remain there for the entire duration of the testing day (approximately 12 
Figure 1.  Study Design.  FMD 
indicates the measurement intervals 
for flow-mediated dilation.  Marker 
indicates the measurement interval for 
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hrs).  For each measurement, the catheter will be flushed with normal saline, 
and a small blood sample (10-20 ml) will be collected from the inserted 
catheter and immediately transferred into ethylendedinaminetetraacetic 
(EDTA) vacutainer tubes (Vacutainer, Becton and Dickinson, Meylan, France).  
Any period of time lasting longer than 2 hours between sample collections will 
require the IV to be flushed with a heparin based solution to prevent clotting 
of the catheter. Once the testing day is completed, the catheter will be 
removed by the same trained clinical exercise physiologist.   
Insertion of the antiocath and blood collection will be performed in 
HPER 070K and be taken to the biochemistry lab down the hall (HPER 005 & 
078) for preparation, storage and analysis.  Sterile techniques, standard 
microbiological practices, and universal precautions will be practiced at all 
times.  Latex gloves will be worn during the insertion of the antiocath, the 
collection of blood, during the analysis of blood, and during any clean-up 
procedures.  Needles (re-sheathe with syringe) will be discarded in sharps 
containers and alcohol wipes, gauze pads, other angiocath supplies as well as 
blood analysis supplies such as pipette tips tubes, etc will be discarded in 
biohazard waste bags.  Full biohazard waste bags and sharps containers will 
be disposed of through the Institutional Biosafety and BioHazard Office.  
Spills, should they occur, will be absorbed with paper towels and discarded in 
the biohazard waste bags.   A 1:10 Chlorox solution (less than 24 hours old) 
will set in the spill area for 20 minutes.  The items used to clean will be 
discarded in the biohazard waste bags. 
On two testing occasions, subjects will be leaving the lab and returning 
to their daily routine or performing physical activity with the angiocath in 
place.  Upon departure from the CEP laboratory with the angiocath inserted, 
Tegaderm® (a see through type tape) will be placed over the entire 
venipuncture area to seal and prevent the IV area from contamination.  
Coban® will then be wrapped around the arm to ensure stability of the 
angiocath.  If the IV is placed in the hand, the same procedure described 
above will take place and the Coban® will be used whenever possible (i.e. 
depending on the site of the needle incertion).  Instead, latex gloves will be 
given to the subject in to cover the access site, in case they want to wash 
their other hand. 
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 A locked traveling kit1 will be used if any of these subjects report 
having trouble with their angiocath and are in need of help while they are not 
in the lab.  The clinical exercise physiologist will be paged to respond to any 
situation.  The traveling kit will contain 1) latex gloves, 2) angtiocath kits, 3) 
sterile drapery, 4) gauze and alcohol wipes, 5) paper towels for cleaning 
spills, 6) Clorox solution, 7) lab coat, 8) biohazard bags, and 9) sharps 
container. 
Urine Collection:  Urine will be collected in sterile urine cups, by the subject 
in the privacy of the rest room (men’s room is HPER 089 and women’s room is 
HPER 087).  The sample will be left on the rest room sink for the 
investigator to pick-up immediately.  The sample will be then taken to the 
biochem labs (HPER 005 & 078) around the corner for preparation.  Latex 
gloves will be worn during the handling and analysis of all urine samples.  Used 
urine cups and related materials will be discarded in biohazard waste bags.  
Full biohazard waste bags will be disposed of through the Institutional 
Biosafety and BioHazard Office.  Spills, should they occur, will be absorbed 
in paper towels and discarded in the biohazard waste bags.  The spill area will 
be cleaned with Clorox solution of 1:10 and the items used to clean will be 
discarded in the biohazard waste bags. 
Biosafety Level 2 Precautions:  Work with human fluids is considered to be 
biosafety level 2.  Appropriate precautions for Level 2 include: 
1. Laboratory coats will be worn. 
2. Latex gloves will be worn. 
3. Protective eyewear will be worn. 
4. Laboratory areas have vinyl flooring 
5. Sinks are located in HPER 005, 070K, 078, 087 and 089 
6. Bench tops in 070 and 078 are impervious to water and are resistant 
to moderate heat and organic solvents, acids, alkalis, and chemicals 
used to decontaminate the work surface 
7. Laboratory cot and blood drawing chair are used to insert the 
angiocath and draw blood.  These furniture are capable of supporting 
subjects and are accessible for cleaning. 
8. There are no windows in laboratories in 070K, 078.  The windows in 
HPER 005 open to the exterior and are fitted with fly screens. 
                                                 
1 Only the doctoral student (Ryan Harris) who uses the traveling kit and the lab director 
(Janet P. Wallace) will have keys to the traveling kit. 
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9. Any time urine or blood samples are transported from one site to 
another, they will first be placed in a plastic sealed container, labeled 
with biohazard symbol, outside of container.  The container will be 
disinfected, and the transporter will wash their hands before 
transport.  
10. Standard microbiological practices will be used 
a. Restriction to the laboratories will be made during blood and 
urine collection and analyses 
b. Laboratory personnel will wash their hands after handling 
materials, removing gloves, and before leaving the laboratory. 
c. No eating or drinking is allowed in the laboratories.  No food will 
be stored in any refrigerators used to store samples. 
d. Mouth pipetting will not be practiced. 
e. Work surfaces will be decontaminated after each use. 
f. All waste will be sent to Institutional Biosafety and BioHazard 
Office for disposal. 
11. Eyewash stations are in HPER 005, 070E and 078. 
12. Laboratory personnel will have the opportunity to receive the 
appropriate  immunizations 
13. Laboratory personnel will take the biosafety course each year. 
14. Needles and syringes will be restricted to the laboratory 070K and 
the locked traveling kit. 
15. disposable syringes will be used to collect blood samples through the 
angiocath.  Once the blood sample is transferred to the EDTA tube, 
the needles will be removed and place in the sharps container. 
16. Broken glassware will be handled using tongs and wearing latex gloves 
17. Spills and accidents that result in overt exposures to infectious 
materials will be immediately reported to the laboratory director who 
will report to the Institutional Biosafety and BioHazard Office.  
Medical evaluation will be made on those who were exposed.  
Documentation will be kept. 
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APPENDIX G – SUBJECT RECRUITMENT AND DATA COLLECTION 
FORMS 
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PUBLIC SERVICE ANNOUNCEMENT 
 
Are you a Man 45 years of age or older?  Do you not exercise as much as you would like? 
 
Indiana University Clinical Exercise Physiology Laboratory seeks volunteers for exercise 
and arterial health study 
 
The Indiana University Clinical Exercise Physiology Lab is currently seeking Men who 
are 45 years old or older who don’t exercise as much as they would like.  The purpose of 
the study is to investigate three bouts of different intensity exercise and how your arterial 
health responds to each bout. Each participant will receive free exercise testing, blood 
work, and exercise prescription.  Prior physician approval is required to participate. 
 
For more information on this study # 05-10379 contact Ryan Harris at the Indiana 
University Clinical Exercise Physiology Laboratory, 812-855-7556 or 
Harrisra@indiana.edu. 
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TELEPHONE SCRIPT 
 
Hello, my name is ________________ and I am one of the study coordinators of the 
arterial stiffness and exercise study at Indiana University. 
 
Thank you for your interest in this study.  
 
The purpose of this study is to describe the how your arteries respond for up to six hours 
following a single bout of exercise, and to investigate if the intensity of the exercise is 
related to how well your arteries respond and possibly identify a specific biomarker 
(TNF-alpha) that plays an important role in how your arteries respond.  
 
Are you still interested in participating? 
 
If the answer is NO: 
 
Thank you very much for calling.  If you know of anyone who might be interested, please 
give them our phone number.  
 
If the answer is YES: 
 
To be eligible for this study you must be between 18 and 60 years of age, and must not: 
 
• Have had a heart attack, lung disease or diabetes 
• Have gallbladder disease 
• Have bone and joint problems that limit your exercise 
• Take medications that dilate your arteries such as nitroglycerin, prostacyclin, 
or verapamil 
• Have an allergy to heparin 
 
Do you meet these criteria? 
 
If the answer is NO: 
 
I am sorry; we need to control for these variables.  Thank you for your time.  If you know 
of anyone who might be interested, please give them our phone number. 
 
If the answer is YES: 
 
 
To participate, you also need to: 
 
• Not exercise or perform strenuous physical activity at least 12 hours before 
each testing session. 
• Not have any caffeine at least 8 hours before each testing session. 
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• Not have Vitamin C at least 8 hours before each testing session. 
• Not have tobacco products at least 8 hours before each testing session. 
• Fast for 8 hours before each of the testing sessions. 
Will you be able to follow these instructions? 
 
If the answer is NO: 
 
I am sorry; we need to control for these variables.  Thank you for your time.  If you know 
of anyone who might be interested, please give them our phone number. 
 
If the answer is YES: 
 
You meet all the initial requirements to be eligible for the study. 
 
Are you interested to come into the lab and go over all of the specifics (ie. fasting blood 
draw, initial risk stratification form, etc)?  We need to get some initial information that 
may determine you are ineligible to participate in the study 
 
If the answer is NO: 
 
Thank you very much for calling.  If you know of anyone who might be interested, please 
give them our phone number.  
 
If the answer is YES: 
 
We need to schedule an appointment to go over the informed consent during which I will 
be able to describe all the procedures of the study in detail. 
 
[Scheduling part]  
 
Thank you very much for your time.  I look forward to meeting you on that day.  
 
Have a great day! 
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HERALD TIMES ADVERTISEMENTS 
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HUMAN SUBJECTS RECRUITMENT FLYER 
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MEDICAL RELEASE FORM 
 
Physical Examination and Medical History 
 
Name of Patient_________________________________ DOB__________ 
Medical History 
Does the above patient have or ever had the following conditions? (Please 
check the appropriate column). No 
Yes Comments
Acute myocardial infarction    
Angina (please comment)    
Congestive Heart Failure (CHF)    
Cardiomyopathy (IHSS) or Valvular heart disease (specify)    
Suspected or known aneurysm    
Embolism or thrombophlebitis    
ECG abnormalities (specify type)    
Active or suspected myocarditis or pericarditis    
Serious systemic disorder (ie: Mononucleosis, Hepatitis)    
Pulmonary disorders (ie: COPD, asthma, hypertension)    
Diabetes (specify type and severity)    
Uncontrolled metabolic disease (ie: Myxedema, Thyrotoxicosis)    
Electrolyte abnormalities (specify type)    
Prescribed medications (specify type)    
Neuromuscular, musculoskeletal, or rheumatoid disorders 
which would make exercise difficult    
Significant emotional distress    
Physical Examination 
Blood Pressure______________mmHg 
Heart Sounds (please check if present): 
Lifts_____ Heaves_____Clicks_____ Thrills_____Murmurs_____(location  
Lung Sounds (please describe auscultation): 
Clear_____ Wheezes_____ Rales_____ 
Quality of peripheral pulses (please check): 
Absent_____ 1/4_____ 2/4_____ 3/4_____ 4/4_____ 
Edema (please quantify if present):_____________ 
To your knowledge, can this individual perform an exercise stress test? 
     *If no, please comment.___________________________________________________________ 
 
Yes No 
This individual is capable of participating in a maximal_____or moderate_____exercise program 
under the guidance of a certified exercise specialist. 
 
Date of Health Examination________________________ (must be valid within the past six month) 
Signed___________________________________M.D._________________________________Date_______________ 
    
241 
HIPPA AUTHORIZATION FORM 
 
AUTHORIZATION FOR THE RELEASE OF HEALTH INFORMATION FOR 
RESEARCH 
 
______________________________________________________________________ 
(Name)       (Date of Birth) 
 
This authorization relates to: 
 
Project:   The interaction of TNF-a, IL-6, and Endothelial Function on Acute 
Exercise Intensity 
IRB Protocol #:  05-10379 
Principal Investigator: Ryan Harris, MS 
 
I understand that the law generally protects my medical records and other health 
information from use without my permission.  The type of information that is protected 
includes:  my address and phone number, laboratory tests, medical history, and X-rays 
reports. 
 
I understand that if I wish to take part in the research project name(s) above, the 
researchers will need to see the results of any physical examination(s) conducted for me 
by my doctor(s) and/or any clinic(s) or hospital(s).   
 
Therefore, to allow me to participate in this research study, I give permission for 
_______________________________________ [name the doctor(s), clinic(s), and/or 
hospital(s)] to release the results of all physical examinations they have conducted on or 
about me, to:  
 
1. The Indiana University CEP research team, headed by Janet P. Wallace, PhD,  
2. The Medical Director, Dr. Larry Rink,  
 
 
By signing this authorization, I understand and agree that I am giving permission for 
protected health information indicated above to be used for the purposes of conducting 
the above study. 
 
I understand that the researchers also would like to access, for the purpose of 
conducting the study, additional medical records concerning hospitalization or treatment, 
including, but not limited to, information regarding treatment for alcohol/substance 
abuse, human immunodeficiency virus (HIV), or for psychiatric treatment of counseling.   
I understand that I have the right to specifically request that the above records NOT be 
released from my health care providers to the research team.  I understand that, if I limit 
access to any of the records listed above, I may not be able to be in this research study.   
 
I do not authorize release of the following records to the research team:   
 
____Mental Health Records  _____Sexually Transmitted Disease 
____Psychotherapy Notes  _____Alcohol/Substance Abuse 
____HIV (AIDS)   _____           Other:_______________
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I understand that: 
 
 1. this authorization is valid for the duration of the study, including the analysis and 
publication or distribution of study results, unless I cancel the authorization as provided 
below.   
 2. efforts will be made to ensure that my protected health information will not be 
shared with other people outside the research study personnel indicated above.  
However, I recognize that my protected health information may be disclosed to others as 
required by law and/or to individuals or organizations that oversee the conduct of 
research studies, and these individuals may not be held to the same legal privacy 
standards as are doctors and hospitals.  I understand, therefore, that the researchers 
cannot guarantee absolute confidentiality and privacy of my protected health information. 
 
I understand that I have the right: 
 
1. To refuse to sign this form.  Not signing this form will not affect my regular health 
care including treatment, payment, or enrollment in a health plan or eligibility for health 
care benefits.  However, not signing the form will prevent me from participating in the 
research study above. 
2. To cancel this release of authorization at any time.   If I choose to cancel this 
authorization, I must notify Dr. Janet P. Wallace and Ryan Harris, MS at the Adult 
Fitness Program, HPER 070, Indiana University, Bloomington IN 47405; fax: 812 855-
9417 in writing that I request a cancellation of this authorization.  Even if I cancel this 
release of information authorization, the Research Team may still use information about 
me that was collected as part of the research project between the date I signed the 
current form, and the date I cancel the authorization.  This is to protect the quality of the 
research results. 
3. To receive a copy of this form. 
I have had the opportunity to review and ask questions regarding this authorization form.   
By signing this authorization form, I am confirming that it reflects my wishes. 
____________________________________________________________________ 
(Printed name of Individual/Legal Representative) 
 
____________________________________________________________________ 
(Signature of Individual/Legal Representative)    (Date) 
 
*If signed by a legal representative: state the relationship and identify below the authority 
to act on behalf of the individual’s behalf. 
Individual is a :    ___Minor  ____Incompetent   ___Disabled ____Deceased 
Legal Authority:  ___Custodial Parent ___Legal Guardian ___Executor of Estate of 
Deceased ___Power of Health care Attorney     ___Authorization of Legal 
Representative   ___Other:________________________ 
 
Please return the form to: 
Ryan Harris, MS or Janet P Wallace, PhD 
Clinical Exercise Physiology Laboratory- HPER 070 
Indiana University  
Bloomington, IN 47405-4801 
Phone (812) 855-7556 
Fax (812) 855-8179 
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RISK STRATIFICATION FORM 
 
Name___________________________  Date ____________  DOB________ Age_____ 
 
Home Address___________________________________     Phone_________________ 
 
Email Address________________________ Phone (WORK / CELL) _________________ 
 
Emergency Contact:  Name___________  Relationship___________ Phone___________ 
 
Have you ever been told you have had a heart attack?  _____Yes _____No   
If yes, explain____________________________________________________ 
Have you ever been told you have lung disease?     _____Yes _____No 
 If yes, explain________________________________________________________ 
Have you ever been told you have diabetes?                  _____Yes _____No 
 If yes, explain________________________________________________________ 
  
MEDICATIONS 
Please list all medications currently taking: 
 
Medication Reason Dose 
   
   
   
   
   
 
FAMILY HISTORY OF HEART DISEASE/STROKE/DIABETES 
Indicate immediate family members (parents, siblings, aunt, uncles) who have diagnosed 
coronary heart disease/stroke and/or who have died from heart disease/stroke. 
Check all that apply.  Indicate age at diagnosis as appropriate. 
 
       Heart Attack       Stroke                   Diabetes  
Father    ____   ____   ____   
Mother    ____   ____   ____   
Brother    ____   ____   ____   
Sister    ____   ____   ____   
Daughter    ____   ____   ____  
 
Do you smoke?            _____Yes _____No 
 
 
(Over) 
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Do you exercise?          _____Yes _____No 
Type of Exercise _______________________________ 
How Often?  _______________days/week 
How Long?  _______________min/session 
How Hard?      Low      Moderate    Hard 
 
------------------------------------------------------------------------------------------------------------ 
For Clinical Use Only: 
   
WEIGHT 
Height________(in)    Weight ________(lbs)    Calculated BMI ________   
  
BLOOD PRESSURE 
Screening Blood Pressures _______/________ mm Hg (average) 
 
Day 1 Date__________             Day 2 Date__________ 
_______/________ mm Hg       _______/________ mm Hg 
         _______/________ mm Hg _______/________ mm Hg 
         _______/________ mm Hg _______/________ mm Hg 
 
CHOLESTEROL  Date__________ 
Total Cholesterol Current_______ mg/dL   
LDL Cholesterol Current_______ mg/dL   
HDL Cholesterol Current_______ mg/dL   
Triglycerides Current_______ mg/dL   
 
BLOOD GLUCOSE  Date__________        Glucose  Current_______ 
mg/dL   
 
 
 
 
For Office use only:  
 
Risk Stratification:        Unknown          Low         Moderate      High 
 
Physical Required:    Vigorous Exercise    Moderate Exercise     Vigorous Exercise 
 
Physician Supervision:   Maximal Testing    Maximal Testing    Submax Testing 
 
 
Evaluator: _______________________________  Date:___________________ 
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MAXIMAL EXERCISE TEST DATA FORM 
             
I.D.#________Name_______________ Date______________ Age________ Sex______ 
 
DOB _________________    Physician______________   Do you smoke:  Yes_____   No_____     
 
Weight  _______ lb.   ______ kg.      Height ___in. ____ cm.    Fasting:  Yes______   No______         
 
Rest BP (mm Hg) #1______/______-________ #2 ______/______-______  #3________/_____ 
 
Recent illness, Chest Discomfort, or Arrhythmias, etc. 
_____________________________________________________________________________ 
 
Current Medications 
_____________________________________________________________________________ 
 
_____________________________________________________________________________ 
 
Rest EKG___________________________________   Axis__________*  P-R __________ sec. 
 
MD comments/Conclusions______________________________________________________ 
 
Previous test : 
Date Speed Final 
grade 
Time Peak 
HR 
Peak VO2 EKG 
       
 
Time 
(min) 
Grade (%) 
Load 
(rpm) 
Rate 
(mph) 
(kpm/min) 
Heart 
Rate 
(beats/min)     
Blood Pressure 
mmHg 
Phase: 1/4-5 
RPE Ectopy 
         
 
Comments 
baseline                /               -    
0-2                /               -    
2-4                /               -     
4-6                /               -    
                /               -    
                /               -    
                /               -    
                /               -    
peak                /               -    
                /               -    
                /               -    
                /               -    
                /               -    
                /               -    
                /               -    
                /               -    
                /               -    
                /               -    
                /               -    
                /               -    
                /               -    
 
 
Reason for termination___________________________________________________________ 
 
   
246 
EXERCISE VARIABLES DATA COLLECTION FORM 
 
Subject #       Date     
        
VO2peak   ml/kg/min Target VO2 25% 50% 75% 
    (ml/kg/min)       
    ± 5%       
        
Resting BP   /        
        
        
Time (min) 
               HR 
(bpm)        BP (SBP/DBP) 
RPE (6-
20)  VO2 (ml/kg/min)
5         /       
10         /       
15         /       
20         /       
25         /       
30         /       
35         /       
40         /       
45         /       
        
        
        
Completed Exercise     minutes    
        
        
   Exercise Technician       
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FMD AND BIOMARKER DATA RECORD FORM 
 
         
Subject 
#      Date       
         
         
         
Visit # 1 2 3       
         
         
         
         
         
   Baseline   Hyperemia     Biomarkers   
Time   
Diameter 
(mm) 
Velocity 
(cm/s) 
Diameter 
(mm) 
Velocity 
(cm/s) 
FMD 
(%) IL-6 (pg/ml) 
TNF-a 
(pg/ml) 
  Baseline         #DIV/0!     
  Immediately         #DIV/0!     
  1 hr post         #DIV/0!     
  2 hr post         #DIV/0!     
  3 hr post         #DIV/0!     
         
         
         
         
     Sonographer       
         
         
         
     
Measured 
By       
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INTRODUCTION 
 
     The endothelium is a thin monolayer of cells that lines the walls of all the vessels in 
the body.  Endothelial cells participate in multiple essential functions, including 
regulation of the vascular smooth muscle tone, control of thrombosis, inhibition of 
leukocyte and platelet adhesion, and promotion of intra-arterial permeability (4, 27, 36).  
A dysfunctional endothelium allows for adverse affects to the body’s vasculature and has 
been associated with an increase risk for cardiovascular disease in many different clinical 
populations (9, 14, 19).  
     Within the past decade, the effects of exercise on endothelial function have received 
vast amounts of attention.  Flow-Mediated Dilation (FMD) is a non-invasive 
measurement of endothelial function, which reflects the overall health and function of the 
arteries.  There is substantial evidence suggesting that chronic exercise enhances 
endothelial function in healthy and clinical populations (12, 16); however, there is limited 
research investigating the effects of acute exercise on endothelial function. Harvey and 
colleagues (15) found that a single bout of exercise, at 60% VO2max for 45 minutes, 
increases endothelial function approximately one hour post exercise with no additional 
endothelial function measurements taken.   
     The physiological mechanisms associated with the improvement in endothelial 
function are not fully understood (3).  Furthermore, the FMD response beyond one hour 
of exercise cessation has not been investigated.  Providing additional information past 
one hour post exercise may also provide valuable information to the possible mechanism 
influencing FMD following acute exercise.      
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     The dose response of exercise can be divided into four different elements: mode, 
intensity, frequency, and duration.  Each element may contribute in different ways in 
identifying possible exercise induced mechanisms associated with the improvement of 
endothelial function.  For example, a strong association exists between training intensity, 
degree of oxidative stress, and inflammation (11, 17), all of which can impact FMD 
adversely.  There has only been one study to investigate FMD following three different 
intensities (25%, 50%, and 75% VO2max) of chronic exercise in humans (13).  The 
findings of this investigation suggest that chronic cycling at moderate intensity (50% 
VO2max) improves endothelial function, whereas cycling at low intensity (25% VO2max) 
and high intensity (75% VO2max) elicits no effect.  Goto and colleagues (13) suggest that 
the increase in oxidative stress following high intensity exercise training impacted the 
FMD result, whereas moderate intensity exercise generated no change in oxidative stress.  
Furthermore, the 25% VO2max may not provide a sufficient stimulus to influence 
oxidative stress or subsequent FMD.  It is well known that the increase in oxygen uptake 
during acute exercise produces an increase in oxidative stress (OS) (37), which may 
appear to contradict the increase in FMD following exercise.  In addition, evidence 
supports a strong correlation between oxidative stress and inflammation (23). 
     Inflammation has been found to increase cell surface adhesion and induce endothelial 
dysfunction (33).  TNF-α is a pro-inflammatory cytokine that is elevated in patients with 
attenuated endothelial function (5, 18) and has been associated with the inflammatory 
pathogenesis of cardiovascular disease (33).  There is evidence to support TNF-α’s direct 
affect in producing endothelial dysfunction. Bhagat and colleagues (1) infused TNF-α 
into the arteries of healthy subjects and observed a transient decrease in microvascular 
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endothelial function.  In addition, chronic endurance exercise has been found to attenuate 
TNF-alpha concentrations and reduce the acute inflammatory response (8).  TNF-alpha is 
postulated to be the first responder (8) of the cytokine family to mediate OS induced by 
chronic exercise (2); however, the response of plasma TNF-alpha following acute 
exercise and its influence on FMD has not been investigated.  Furthermore, IL-6 another 
proinflammatory cytokine, is typically the last inflammatory cytokine to respond (8).  
Until recently, IL-6 has been classified as both a pro- and anti-inflammatory cytokine; 
however, the current view accepts the primary role as having anti-inflammatory effects 
(26).  Elevations in IL-6 concentrations may be due to increases in immune activity (29), 
unrelated inflammation (6, 29), catecholamine production (30), and exercise (20).  
Interleukin-6 acts to stimulate the hypothalamus-pituitary axis in response to 
inflammation, promotes osteoclastogenesis, and influences intermediary metabolism (20).    
The exercise-induced increase in IL-6 concentrations had been suggested to be a 
consequence of  an immune response do to local damage in the working muscle (22), 
until recently debated.   
     Starkie and colleagues (31) have demonstrated that the immune cells are not the 
source of the increase in plasma IL-6 during exercise.  Furthermore, Febbraio and 
colleagues (10) suggest the production of IL-6 in response to exercise is not an exercise 
induced immune response, it’s a direct release from the muscle contraction itself.  They 
refer to IL-6 as a myokine, a cytokine released from the skeletal muscle itself.  The 
investigations from Pedersen and colleagues (25) support this phenomenon by suggesting 
that IL-6 is linked more so with metabolism (exercise) than it is with inflammation. 
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Furthermore, the production of IL-6 during exercise is related to the intensity and 
duration of the exercise (26). 
     Ullum and colleagues (35) report an increase in IL-6 in response to one-hour of cycle 
ergometry at 75% of maximal oxygen intake.  In addition a 3 hour combination of cycle 
ergometry and treadmill running at 60-65% VO2max  increased IL-6 concentration greater 
than 18 fold compared to baseline values (21).   Increases in IL-6 in response to cycling, 
treadmill, rowing, and eccentric exercise have all been reported (28).  In addition, there 
appears to be a dose response relationship of amount of plasma IL-6 observed and 
exercise intensity (40% - 90%) with the greatest increase occurring at a relative intensity 
of ~75% (28).  
     There is conclusive evidence that IL-6 is released in response to all types, modes, and 
durations of exercise; however, the remaining unanswered question of why it is released 
is debated. During exercise there may be an increase in IL-6 from muscle to increase 
lipolysis and fat oxidation, but Pedersen and colleagues (25) report that IL-6 is not the 
sole mediator of these outcomes.  IL-6 has also been shown to impair TNF-a expression 
in cardiac muscle (32) and skeletal muscle (26); consequently, the augmentation of 
endothelial function associated with acute and chronic exercise may be associated with 
the IL-6 mediated TNF-a suppression.   
     It is unclear if the elevated concentrations of IL-6 in response to exercise directly 
influence the endothelial response. The increase in concentrations of IL-6 in response to 
exercise may be a factor in controlling the pro-inflammatory response, thus limiting the 
TNF-α response, resulting in an improvement of endothelial function.  Furthermore, the 
transient increase in oxidative stress observed following acute exercise does not explain 
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the increase in FMD.  In addition, there appears to be no change in superoxide dismutase 
(34), total antioxidant status (37), or muscle antioxidant capacity (24) following acute 
exercise which would counteract the increase in OS and explain the augmentation of 
FMD.  Nevertheless, IL-6 alone may not be the sole contributor that influences FMD 
following acute exercise.  TNF-alpha may be the connecting link associated with the 
improvement in FMD.  The mechanisms associated with the increase in endothelial 
function following acute exercise are unclear.  The response of TNF-alpha following 
different acute exercise intensities may provide a link to the possible mechanisms 
associated with the FMD response following acute exercise. 
PURPOSE 
 
    There are three purposes to this investigation; 1) to investigate the direct effect of the 
dose-response relationship of acute exercise on endothelial function, 2) to identify TNF-
alpha and IL-6 as a possible link in the physiological mechanism in which endothelial 
function following acute exercise is augmented, and 3) to investigate the three hour time 
course of endothelial function and concentrations of TNF-alpha and IL-6 following acute 
exercise. 
HYPOTHESES 
 
Endothelial Function 
     It is hypothesized that: 
 
• Exercise at 50% of VO2peak will elicit the greatest endothelial response compared 
to 25% VO2peak and 75% VO2peak 
• Exercise at 25% intensity will elicit no change in endothelial function 
• Exercise at 75% intensity will attenuate endothelial function 
• FMD will be augmented for the three hour time period studied following the 50% 
intensity treatment of acute exercise. 
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Biomarkers 
     It is hypothesized that: 
 
• There will be an intensity associated increase in concentrations of IL-6 with acute 
exercise. 
• There will be an intensity associated decrease in TNF-alpha with acute exercise. 
• There will be an inverse relationship between concentrations of IL-6 and TNF-
alpha that is dose dependent. 
• Concentrations of IL-6 and TNF-alpha will be significant predictors of 
endothelial function. 
 
 DESIGN 
 
     In a randomized crossover 
design (figure 1), each subject will 
perform three different exercise 
interventions on three separate 
days within a two week period.  
For each intervention, Flow-
Mediated Dilation (FMD) and 
subsequent blood samples will be 
taken at baseline, immediately 
following acute exercise, and every hour for three hours following the exercise 
intervention.  FMD and blood samples will be used for the measurement and analysis of 
endothelial function and concentrations of IL-6 and TNF-alpha, respectively. 
SUBJECTS 
 
     Approximately 15-20 moderate risk adults (18-60 yrs) will participate in the proposed 
investigation.  Moderate risk, defined by the American College of Sports Medicine, are 
those men who are > 45 years old or women > 55 years old or any individuals who meet 
the threshold for two or more risk factors (ie: hypertension (BP >140/90), 
Figure 1. General Design 
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hypercholesterolemia (TC >200mg/dl), smoking, sedentary lifestyle, family history of 
heart disease, obesity (BMI >30kg/m2), and impaired fasting glucose (BG >100mg/dl)) 
for coronary heart disease.   
Subject Number 
     The sample size is a conservative number to obtain significance in measuring 
endothelial function, TNF-alpha, and IL-6 based on published data (15, 20, 21) and pilot 
data from our laboratory. 
Inclusion/Exclusion Criteria 
     Subject preparation, and FMD technique will follow the guidelines for ultrasound 
assessment of endothelial function (7). Inclusion into the study will require the subjects 
to: 
• Be of moderate risk described by ACSM guidelines 
• Have permission from their physician to participate in this investigation 
• Not have any tobacco products at least 8hrs prior to each treatment day 
• Not exercise for at least 12hrs prior to each treatment day 
• Not have any caffeine at least 8hrs prior to each treatment day 
• Not have any vitamin supplementation for at least 8hrs prior to each treatment day 
• Not have any trace of vasoactive medications 
 
Subjects will be excluded from the study if they: 
• Are not between 18 and 60 years of age, 
• Do not fall into the moderate risk classification (as described above),  
• Cannot exercise at 75% VO2peak for 45 minutes,  
• Have a known allergy to heparin,  
• Do not have peripheral venous access in the left upper extremity 
• Have cardiovascular, pulmonary or metabolic diseases 
• Have orthopedic problems that limit their exercise 
• Take medications that dilate their arteries such as nitroglycerin, prostacyclin, or 
verapamil 
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PROCEDURES 
 
     Procedures to be used in this investigation are 1) risk stratification, 2) maximal 
exercise test, 3) acute exercise treatments, 4) measure of endothelial function, and 5) 
serial blood draws. 
METHODS 
 
Risk Stratification 
     The risk stratification form summarizes information about the subject’s medical 
history, present diseases/disorders, family history of disease, height and weight, and 
current medications along with information that will be obtained from each subjects 
fasting blood draw. 
     A fasting blood draw performed at the Indiana University Health center will be 
required before any subject can participate in the study.  This test is to help determine the 
risk stratification for exercise.  Each subject will report to the Indiana University Health 
Center (Room 208) and must be fasting for at least 12 hours prior to this test.  A 20-45 ml 
sample of venous blood will be drawn by a certified technician via sterile techniques for 
analysis of cholesterol, triglycerides and glucose.   
Maximal Exercise Test 
     A maximal graded exercise test will be performed to obtain the appropriate exercise 
treatment intensities.  This test is designed to measure the subjects maximal exercise 
capacity.  Each subject will walk or jog on a motor-driven treadmill beginning at a speed 
between 2.5-5.0 mph, 0% grade, with the grade or slope increasing 2.5% every two 
minutes until volitional fatigue, breathlessness, chest discomfort, and/or any other 
symptoms which indicate to yourself or the technicians that you should stop exercise.  
Heart rate via 12-lead EKG will be monitored throughout the test.  Blood pressure will be 
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taken before, during if walking (every stage), and after the test (recovery).  Expired gases 
will also be collected through a unidirectional flow mouthpiece during the test.   
Acute Exercise Treatments 
     Subjects will be asked to perform three 45-minute walking exercise sessions at 25%, 
50%, and 75% of their exercise capacity (on three separate days) obtained from the 
maximal graded exercise test.  Expired gases will be measured through a unidirectional 
flow mouthpiece during the 5th minute of each exercise session to confirm their exercise 
intensity.  The work rate will be adjusted if it is not within ±10% of your target exercise 
intensity.  Expired gases will then be measured again during the 15th minute to confirm 
the new exercise intensity.  Heart rate and blood pressure will be monitored throughout 
each exercise session. 
Endothelial Function 
     For each acute exercise treatment, brachial artery flow-mediated dilation will be used 
as a measurement of endothelial function. Flow-mediated dilation will be measured at 
baseline, immediately post acute exercise and 1, 2, and 3 hours post acute exercise.  Each 
subject will lie on their back for 20 minutes to establish a hemodynamic resting state.  
After the 20 minute acclimation phase, a water based silicon gel will be placed on the 
ultrasound transducer as an impedance adapter for better ultrasound images.  The 
Sonoace Pico ultra sound system using a 7.0 MHz linear transducer will then be used to 
scan the baseline artery of their inner arm, 2-10 cm above the elbow.  Once a clear image 
is obtained, resting blood flow velocity and a baseline image of their artery will be 
captured by the ultrasound. After baseline measurements are captured, a second blood 
pressure cuff will be wrapped around the forearm of the right arm and inflated to 250 mm 
Hg to stop blood flow to the lower arm for 5 minutes. Blood flow velocity will be 
   
258 
recorded 10 seconds after the cuff is deflated and ultrasound images will be captured as 
described above. The health of the artery will be expressed as a percentage of the artery 
expansion with the increased blood flow, compared to the resting diameter. The 
dependent variables will be brachial artery diameter(mm), absolute change in 
brachial artery diameter(mm), and FMD (%).  
Serial Blood Draws 
     For the serial blood draw, a 22-24 gauge venous catheter will be inserted in a vein in 
the subjects left arm by a clinical exercise physiologist who has special IV training and 
practice.  The catheter will remain there for the entire duration of the testing day 
(approximately 6-8 hrs).    The catheter will be flushed with normal saline, and a small 
blood sample (15-20ml) will be collected from the inserted catheter and stored for the 
analysis of IL-6 and TNF-alpha.  For each measurement of FMD performed a subsequent 
blood sample will also be collected.  Following each blood draw, the IV will be flushed 
with a heparin based solution to prevent clotting of the catheter. Once the testing day is 
completed, the catheter will be removed by the same trained clinical exercise 
physiologist.      
Analysis of IL-6 and TNF-alpha 
     The analysis of IL-6 and TNF-alpha will be performed using a high sensitivity 
Enzyme Linked Immunoassay (ELISA) kit and ran in triplicate according to manufacture 
specifications (R & D Systems, Mineapolis, MN).   Briefly, this assay utilizes the 
quantitative sandwich technique.  An antibody is coated to the plate and any plasma IL-6 
or TNF-alpha introduced into the plate is bound by the immobilized antibody.  Following 
a wash of any unbound antibody-enzyme reagent, a substrate is introduced into the well 
with subsequent amplification for color development in proportion to the amount of IL-6 
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or TNF-alpha is bound.  The color absorbance is plotted against the standard curve to 
obtain concentrations of IL-6 and TNF-alpha.  The dependent variables will be plasma 
concentrations of IL-6 (pg/ml) and TNF-alpha (pg/ml).   
 
STATISTICAL METHODS 
 
     Demographics will be analyzed using descriptive statistics.  All data will be expressed 
as mean ± SD.  Significance will be set at p< .05. 
Endothelial Function 
     To investigate the hypotheses evaluating the time course associated with 50% exercise 
intensity and the endothelial response associated with the dose of exercise, a two-way 
(intensity x time) repeated measures ANOVA will be performed.  
Biomarkers 
     To investigate the relationship between IL-6, TNF-alpha and exercise intensity and the 
relationship between IL-6 and TNF-alpha, three Pearson Product Moment Correlations 
will be performed: 1) between IL-6 and intensity, 2) between TNF-alpha and intensity, 
and 3) between IL-6 and TNF alpha.  All exercise intensities will be incorporated into 
each correlation.  To investigate if concentrations of IL-6 and TNF-alpha are significant 
predictors of endothelial function, regression analysis will be performed. 
 
SIGNIFICANCE  
     Endothelial dysfunction is seen in various clinical conditions such as hypertension, 
diabetes, coronary artery disease, and obesity. The role of exercise as a non-
pharmacological intervention is becoming more important in the treatment and 
prevention of disease.  The present study may 1) contribute in identifying a link to the 
possible mechanism associated with the improvement of FMD following acute exercise 
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and 2) indicate an appropriate exercise stimulus that will not exacerbate the inflammatory 
process, yet improve the endothelial response.  As clinicians, the more comprehensive 
understanding we have about the dose response of exercise, and its association with 
endothelial function, the more effective we can prescribe exercise as a non-
pharmacological intervention in combating and treating disease.  
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BRACHIAL ARTERY FMD – STEP BY STEP 
 
     The gold standard of measuring flow mediated dilation (FMD) is with a high 
resolution ultrasound device that is found in the Clinical Exercise Physiology Laboratory.  
The purpose of this paper is to guide you step by step through the Indiana University CEP 
lab Flow Mediated Dilation protocol (updated 5/15/06 for use with MIA). 
 
INCLUSION CRITERIA    
 
     The measurement of flow mediated dilation requires a few steps of preparation.  It is 
important that you review the subjects’ medical/health history questionnaire.  The subject 
should: 
• Not engage in exercise for at least 12 hrs before study 
• Ingest no caffeine at least 4-6hrs before study 
• Ingest no Vitamin C at least 4-6hrs before study 
• Not smoke any tobacco products at least 4-6hrs before study 
• Be fasting for 8 hrs prior to the study 
• Not be on any vaso reactive medications for the past 4 half-lives 
 
     Once you have determined that the subject meets inclusion criteria for the 
measurement of flow-mediated dilation proceed to the initial steps of collecting data. 
 
SUBJECT PREPARATION 
 
     The first step in preparing the subject for data collection is to go over the informed 
consent form.  Once the subject has agreed and consented to the procedure, you can fill 
out a data collection sheet with the following information: 
o ID 
o Age 
o Height 
o Weight 
o BMI 
o Cholesterol 
o VO2Peak  
o Check all risk factors that apply  
 
The next step is to have the subject lie supine on the table for a 20 minute acclimation 
phase (Feet towards the wall and head towards the door) with their right arm extended 
towards the ultrasound machine.  While the subject is lying supine, place the Hokanson 
SC-5 rapid cuff around the subject’s right forearm.  
 
Open the Time Left program for desktop timer. 
 
 
 
   
269 
Entering Subject ID 
     You will need to open the imager program on the MIA.  Once in imager you will need 
to set up the study: 
• Action 
o Setup Study (F2) – Fill out all necessary fields including the file name.  
You will need to discuss how you will code the study with your research 
team.  Once all necessary fields are filled in, click save. Note: you will 
need two file names for each FMD performed; one for baseline and one 
for post occlusion. 
 
Information to enter in the saved file: 
o Study ID (Abbreviation of the study) 
o Condition (BA baseline or BA deflation) 
o Reader ID (Name of Technician) 
o Subject ID (Research #) 
o Image File (Study ID_Research #_Visits (1, 2, 3…(treatments will be 
randomized)_Time (A, B, C…)_FMD Condition( 1=baseline or 2=deflation) 
o Example: BP_R2050_2_C_2 
o All ID’s will have 5 series of #’s.  If the study only has one visit, use 1 
as a place holder, etc. 
 
Now you are ready to start acquiring images.  Make sure you are set in Trigger Mode and 
set up the frame grabber as follows: 
    Baseline: 30 Frames 
    Post Occlusion: 200 Seconds 
 
DATA COLLECTION 
 
Baseline Data  
     For baseline images you should set up your grabber to automatically grab 30 frames 
(10 frames for Doppler and 10 frames for 2D).  It will be important to capture your 
Doppler pulse waves first. The baseline diameter is used as the “Pre” measurement when 
calculating the flow mediated dilation.  Place the linear transducer longitudinally along 
the brachial artery 2-10cm above the antecubital fossa.  In “C” mode obtain and verify 
the artery by visually seeing the color flow.  After verification of the brachial artery 
switch to “PW” mode and press the camera icon or F1 to begin capturing 10 triggered 
frames.  When finished capturing 10 frames press “2D” and continue capturing 10 
triggered frames of the BA.   
 
Note: To obtain baseline BA values, average all acceptable diameter frames to represent 
the baseline diameter. 
 
Flow Mediated Dilation 
     When you’re finished collecting baseline data you will need to set the rapid cuff 
inflator to 250 mm Hg and press to inflate when ready.  Maintain the occlusion for 5 
minutes while maintaining the brachial artery image on the ultrasound screen.  Note: 
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During this 5 minute occlusion period you should set up your post occlusion file in the 
imager program.  For post occlusion images you should set up your grabber to grab for a 
period of time; 200 seconds with the first 10 triggered frames being for Doppler and the 
rest of the 2 minutes post occlusion in 2D mode 
     After the first 4.5 minutes of occlusion start the image grabbing (camera or F1). After 
5 minutes of occlusion, press to rapidly deflate the forearm cuff while maintaining the 
image on the screen (It is important not to lose the image as the rapid velocity of the 
blood will distort the placement of the artery relative to the ultrasound transducer).  
Maintain the image on the screen for a total of 2 minutes post occlusion and then press F1 
or the little camera icon to stop frame grabbing. 
 
DATA ANALYSIS (after completion of the study) 
 
     There may be two observers involved with the data analysis to ensure inter-reliability 
of the measurements taken. 
     You will need to open the file you want to measure in the Brachial Tools program: 
• Open brachial tools 
o File Æ open Æ locate file you want to analyze 
Once the file is open in brachial tools you will need to 
• Train the BA 
• Measure the BA 
• Train the Doppler 
• Measure the Doppler 
 
Note:  First calibrate, define the ROI, and analyze BA (as described below) before you 
analyze the Doppler flow. 
 
Train and measure the Brachial Artery 
The next step will be to calibrate the brachial artery.   
• Action Æ Calibrate 
o Calibrate vertical axis 
• Action Æ Initialize Define ROI 
o Brachial artery ROI- Position the ROI so that the middle of the circle is in 
the center of the artery. Note: It is important to make sure the ROI will be 
ok to analyze the post deflation artery if needed. 
Once you have defined the ROI,  
• Click next Æ Proceed Æ Cancel 
Click the Launch automated analysis (shuttle icon)and click the play button.  This will 
start the analysis where you started and continue through the end of the captured frames. 
You can start and stop this manual analysis as you wish. 
 
Brachial artery Values 
After analyzing the BA you will have a diameter value for each frame grabbed.  The 
Confidence Interval (CI) of the computer must be > 70%.  You can click to eliminate all 
CI that are below 70%.  You can also eliminate a value manually.  If the eliminated 
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values represent greater than 80%, you need to rerun your analysis.  Note: You can go 
frame by frame and manually measure the frame that fell out of the 70% CI the same way 
you trained the ROI. 
 
Note: To obtain the post hyperemia value, look at the BA diameters from 45 seconds post 
deflation (first hyperemic flow) to the end of the captured frames.  Follow these steps 
o Take the highest average of the 10 second interval to be used as this value.  
o You can obtain the 10 second intervals when you create an Excel report through 
the subject manager. 
Train and measure the Doppler 
With the Doppler image on the screen click  
• Action Æ Start flow analysis 
o Calibrate Velocity (vertical) Æ Finish 
o Calibrate Time (horizontal) Æ Finish 
o Define Flow ROI 
Once you have calibrated and defined the ROI for the flow envelope  click Analyze.  This 
will start to measure the envelope that you have trained for the Doppler flows.  Stop the 
analysis when no more Doppler frames are present. 
 
To edit, select each frame analyzed and reject the frames that have either a duplicated 
tracing or do not trace appropriately.  Click save to save all measurements analyzed. 
 
Exporting to Excel 
   After all analysis for the visit day are completed, you can export all files into one excel 
spreadsheet for easier data manipulation.  Click on 
• Subject Information Æ new Æ add all files Æ Save report as follows: 
o Research #_visit #_Final 
o Example: R2059_2_Final 
Results 
     Results are presented as the percent change from baseline.  Alternate results may 
include: 
o Baseline diameter 
o Absolute change in diameter 
o Percent change in diameter 
 
     Intra and Inter observer reliability should be established by the Intra Correlation 
Coefficient (ICC) 
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VENIPUNCTURE AND BLOOD CENTRIFUGATION – STEP BY STEP 
 
Supplies Needed: 
 
• Alcohol 
• Tape 
• Gauze 
• Angiocath 
• PRN adapter 
• Band aids 
• Gloves 
• Tourniquet 
• Normal Saline (NS) 
• Heparin Flush (HEP) 
• Syringe 
• Needle 
• Sharps Container 
• Blood Collection Tubes 
 
Preparation 
   It is important that all of your supplies are prepared and ready to use.  For each 
venipuncture attempt you will need: (1) angiocath, (1) PRN adapter, (1) NS syringe and 
needle (~5ml), (1) HEP syringe and needle (~5ml), (1) band aid, (3) pieces of tape (2 
thin, 1 thick), (2) empty syringes, (1) EDTA blood collection tube, (2-3) alcohol pads, a 
tourniquet, a pair of gloves and some gauze. 
 
Drawing up Fluid 
     Wipe the top of the vile with alcohol and allow it to dry.  Assemble the needle and 
syringe without touching the site that the two connect.  Pull back the syringe according to 
how much fluid you want to draw up.  Insert the needle into the vile and plunge the air 
from the syringe into the vile.  This will create a vacuum and fluid will start to transfer 
from the vile into the syringe.  Draw back on the syringe to the exact amount you desire.  
Pull the needle out of the vile and remove all the air bubble remaining in the fluid by 
taping or “flicking” the syringe.  Plunge the syringe until the fluid is released at the tip of 
the needle and recap.  This syringe is ready to use. 
 
Venipuncture 
     First you want to explain to the subject the procedure and what your about to do to 
him/her. With your gloves off make sure that your angiocath, PRN adapter, band aid, and 
tape are all prepared ready to use.  Tie the tourniquet on the arm superior to the site you 
are targeting and allow a few seconds for the vein to expand up towards the surface.  
Palpate the vein and asses whether or not you want to proceed.  If not, start over and 
place the tourniquet superior to the site you want to attempt.  If you feel that the site is 
appropriate than alcohol the immediate and surrounding area of the vein in a dabbing, yet 
rough manner attempting to clean the area thoroughly.   
 
     Put your gloves on (allowing for the alcohol to dry) and remove the cap from the 
angiocath.  Tell the subject, “your going to feel a little stick,” and stick the subject at a 
very obtuse angle in a smooth, constant motion.  Watch for blood return in the angiocath 
window.  Once you see a return, advance the catheter 1-2 more millimeters, and thread 
the catheter all the way to the base of the skin.  Remove the tourniquet.  As you remove 
the needle from the site, apply pressure directly over the site where you inserted the 
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catheter (this will slow the blood entering the open angiocath).  Discard the needle into 
the sharps container and quickly replace the needle with a PRN adapter.   
    Using one of the thin pieces of tape, place it over the PRN adapter securing it in place.  
Put your NS syringe into the PRN adapter and slowly flush 1-2 ml of fluid.  Draw back 
and you should see some blood enter the syringe.  Once this happens, you know you have 
accessed the vein, and flush the remaining volume from the syringe into the vein.  Place 
the band aid directly over the base of the catheter, close to the skin, and using the other 2 
pieces of tape, tape the catheter securely in place. 
 
Drawing up your Sample 
    When you’re ready to draw up your blood sample, alcohol the PRN adapter (you don’t 
have to alcohol the adapter if you have just entered the vein and are drawing a sample.  
Only if you have the subject is returning after some period of time), put the tourniquet on, 
place a piece of gauze under the PRN adapter, and put the needle of one of your empty 
syringes into the PRN adapter.  Slowly draw up 10 ml of blood, and discard the entire 
syringe.  Put the needle of your other empty syringe into the PRN adapter and slowly 
draw up 10 ml of blood.  Stick the needle into the vaccutainer blood collection tube and 
the blood will passively fill the tube.  Invert the tube 4-5 times slowly; mixing the EDTA 
with the blood so it will not clot.  Discard the empty syringe and needle into the sharps 
container. 
 
Centrifuging and Storage of Blood 
     Within 60 minutes of collection into the EDTA tube, plasma needs to be separated.  
Place the sample tube into the Beckman centrifuge (HPER 076) with an appropriate 
balance (it can be another sample or a water balance).  Centrifuge each sample at a rate of 
1300 RPM for 12 minutes.  Once you have separation of plasma and RBC’s, pipette 1 ml 
each into 3 separate microfuge tubes.  Close caps, and label each tube correctly. Store all 
plasma samples in -80° C until analysis. 
 
Removing the Angiocath 
    When you’re ready to remove the catheter, try to remove most of the tape and band 
aid.  Put an alcohol pad over a piece of gauze and place them over the site of entry with 
the alcohol towards the skin.  As you slowly remove the catheter, apply firm pressure to 
the site.  Hold the pressure for 30-120 seconds and then cover with a band aid for at least 
30 minutes. 
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R AND D IL-6 ASSAY PROCEDURE – STEP BY STEP  
 
It is very important to wear a dust mask and change gloves throughout the assay 
frequently!!! 
 
Before you begin, bring all reagents and samples to room temperature before use. If 
setting up two or more separate plates, Set up all reagents and standards first, and then 
start one plate set up… (incubate 2 hours), minutes and start the second or third one 
immediately. 
 
Items you will need per kit: 
 
• P100, P1000, L300 
• Vortex 
• Pipette aid 
• Dust masks 
• 7 microfuge tubes 
• 1 boxes of 100μl tips 
• 2.5 boxes of 300μl multi-channel tips 
• 2 syringes/needles 
• 1000ml volumetric flask 
• 1000ml-1500ml tip waste beaker 
• 1 5ml pipettes 
• 1 10ml pipettes 
• 5 Reagent Reservoirs 
 
REAGENT PREPARATION 
 
1) Calibrator Diluent RD6-11 – Dilute 10ml of calibrator diliuent concentrate into 
10ml of ultra pure water using a 10ml pipette (total 20ml) and a 40ml beaker. 
 
2) IL-6 Standard – Reconstitute the IL-6 standard with 5ml of calibrator diluent 
using a 5ml pipette.  This reconstitution will be your stock solution of 10pg/ml.  
Allow the stock solution to sit for a minimum of 15 minutes with gentle 
agitation prior to making dilutions. 
 
3) Wash Buffer – Dilute 100ml of wash buffer concentrate into 900ml of ultra 
pure water to prepare 1000ml of wash buffer using a 1000ml volumetric flask. 
 
4) Substrate Solution – Using a 10ml syringe and needle reconstitute 6ml of 
substrate diluent into the lyophilized substrate at least 10 minutes before use.  
Discard Stopper after reconstitution. 
 
5) Amplifier Solution - Using a 10ml syringe and needle reconstitute 6ml of 
amplifier diluent into the lyophilized amplifier at least 10 minutes before use.     
Discard Stopper after reconstitution. 
 
6) Creating the Standards – If 15 minutes has passed, using the same pipette tip: 
 
a. Pipette 500μl  (P1000) of calibrator diluent into (7) sterile microfuge 
tubes.   
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b. Use the stock standard solution and serially dilute 500μl of 10pg/ml into 
the tube labeled 5pg/ml and mix thoroughly. 
c. Take 500μl out of the 5pg/ml and transfer into the 2.5pg/ml tube and mix 
thoroughly. 
d. Continue all they way down to 1.25pg/ml, 0.625pg/ml, 0.312pg/ml, and 
0.156pg/ml. 
e. Do not put anything into the 0 tube which should contain only 500μl of 
calibrator diluent. 
 
ASSAY PROCEDURE 
 
It is recommended that all samples be assayed in duplicate 
 
Once all reagents and standards are prepared as instructed: 
 
1) Using the multi-channel pipette and a reservoir, add 100μl of assay diluent to 
each well.  Change tips after every row.  Be sure to mix the assay diluent prior 
to emptying into the reservoir. 
 
2) Using the P100, add 100μl of standard or sample to each well.  Cover with 
adhesive strip and incubate for 2 hours at room temperature on an orbital shaker 
set at 500rpm. Gently mix standards and samples prior to adding into the well. 
3) Wash 6 times (see wash procedure below) 
 
4) Using the multi-channel pipette and a reservoir, add 200μl of conjugate to each 
well.  Change tips after every row. Cover with adhesive strip and incubate for 2 
hours at room temperature on an orbital shaker set at 500rpm.  Be sure to mix the 
conjugate prior to emptying into the reservoir. 
 
5) Wash 6 times 
 
6) Using the multi-channel pipette and a reservoir, add 50μl of substrate solution 
to each well. Change tips after every row.  Cover with adhesive strip and 
incubate for 60 minutes at room temperature on the benchtop.  Be sure to mix 
the substrate solution prior to emptying into the reservoir. 
 
7) Using the multi-channel pipette and a reservoir, add 50μl of amplifier solution 
to each well.  Change tips after every row.  Cover with adhesive strip and 
incubate for 30 minutes at room temperature on the bench top.  Be sure to mix 
the amplifier solution prior to emptying into the reservoir. 
 
8) Using the multi-channel pipette and a reservoir, add 50μl of stop solution to 
each well.  Change tips after every row.  Read at 490nm and 690nm within 30 
minutes. 
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WASH PROCEDURE 
 
Inclusion of a 30 second soak between each addition of wash buffer and decanting will 
improve the precision of the assay 
 
1) Remove liquid from the wells by inverting the plate and decanting the contents 
2) Remove excess liquid by grasping the plate firmly and smartly rapping the plate 
inverted on a clean paper towel at least 5 times 
3) Fill each well with 400μl of Wash Buffer (Use Plate Washer setting R-D) 
4) Repeat for a total of 6 washes. 
5) After the last wash, smartly rap the inverted plate on a clean paper towel at least 
10 times to remove excess Wash Buffer. 
 
PLATE READER 
 
Running the Program 
Protocol 
• Reading Parameters 
o Endpoint 
o Read mode: normal 
o Need to wavelengths, 490nm and 690nm 
• Plate Layout 
o Standard: put units and values of concentrations from kit book 
• Curve 
o Axis: extrapolation factor 3.0 
o Curve Fit: Linear or whatever the book says 
o This kit does not use blanks. Use multi plate transformation to 
subtract Std 0 from the samples.  Also use Curve interpretation to 
interpret Delta OD.  Use Protocol R and D IL-6 (refer back to the IL-
6 manual and the plate reader manual for instructions) 
Reading 
• System: Administrator login: Admin 
• Display: curves, allows you to look at your standard curve 
Save, export 
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R AND D TNF-α  ASSAY PROCEDURE – STEP BY STEP  
 
Before you begin, bring all reagents and samples to room temperature before use. If 
setting up two separate plates, Start one plate set up… (incubate 3 hours), wait 15 
minutes and start preparing the reagents and set up plate #2. 
 
Items you will need per kit: 
• P200, P1000, L300 
• Vortex 
• 7 microfuge tubes 
• 1 boxes of 200μl tips 
• 2.5 boxes of 300μl multi-
channel tips 
• 2 syringes/needles 
• 1000ml volumetric flask 
• 1000ml-1500ml tip waste beaker 
• ~2 Disposable Pasteur pipettes 
• 1  5 ml pipette 
• 5 reagent reservoirs 
 
REAGENT PREPARATION 
 
7) TNF-alpha Standard – Reconstitute the TNF-alpha standard with the volume of 
calibrator diluent printed on the standard vial label using a 5 ml pipette.  This 
reconstitution will be your stock solution of 32pg/ml.  Allow the stock solution to 
sit for a minimum of 15 minutes with gentle agitation prior to making 
dilutions. 
 
8) Wash Buffer – Dilute 100ml of wash buffer concentrate into 900ml of ultra 
pure water to prepare 1000ml of wash buffer using a 1000ml volumetric flask. 
 
9) Substrate Solution – Using a 10ml syringe and needle reconstitute 6ml of 
substrate diluent into the lyophilized substrate at least 10 minutes before use.  
Discard Stopper after reconstitution. 
 
10) Amplifier Solution - Using a 10ml syringe and needle reconstitute 6ml of 
amplifier diluent into the lyophilized amplifier at least 10 minutes before use.     
Discard Stopper after reconstitution. 
 
11) Creating the Standards – If 15 minutes has passed, using the same pipette tip: 
 
a. Pipette 500μl of calibrator diluent into (7) sterile microfuge tubes.   
b. Use the stock standard solution and serially dilute 500μl of 32pg/ml into 
the tube labeled 16pg/ml and mix thoroughly. 
c. Take 500μl out of the 16pg/ml and transfer into the 8pg/ml tube and mix 
thoroughly. 
d. Continue all they way down to 4pg/ml, 2pg/ml, 1pg/ml, and 0.5pg/ml. 
e. Do not put anything into the 0 tube which should contain only 500μl of 
calibrator diluent. 
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ASSAY PROCEDURE 
 
It is recommended that all samples be assayed in duplicate and you wear a mask 
and gloves throughout the procedure. 
 
Once all reagents and standards are prepared as instructed: 
 
9) Using the multi-channel pipette and a reservoir, add 50μl of assay diluent to 
each well.  Change tips after every row.  Be sure to mix the assay diluent prior 
to emptying into the reservoir. 
 
10) Using the P200, add 200μl of standard or sample to each well.  Cover with 
adhesive strip and incubate for 3 hours at room temperature. Gently mix 
standards and samples prior to adding into the well. 
 
11) Wash 6 times (see wash procedure below) 
 
12) Using the multi-channel pipette and a reservoir, add 200μl of TNF-a HS 
conjugate to each well.  Change tips after every row. Cover with adhesive strip 
and incubate for 2 hours at room temperature.  Be sure to mix the conjugate prior 
to emptying into the reservoir. 
 
13) Wash 6 times 
 
14) Using the multi-channel pipette and a reservoir, add 50μl of substrate solution 
to each well. Change tips after every row.  Cover with adhesive strip and 
incubate for 60 minutes at room temperature.  Be sure to mix the substrate 
solution prior to emptying into the reservoir. 
 
15) Using the multi-channel pipette and a reservoir, add 50μl of amplifier solution 
to each well.  Change tips after every row.  Cover with adhesive strip and 
incubate for 30 minutes at room temperature on the bench top.  Be sure to mix 
the amplifier solution prior to emptying into the reservoir. 
 
16) Using the multi-channel pipette and a reservoir, add 50μl of stop solution to 
each well.  Change tips after every row.  Read at 490nm and 690nm within 30 
minutes. 
 
WASH PROCEDURE 
 
Inclusion of a 30 second soak between each addition of wash buffer and decanting will 
improve the precision of the assay 
 
6) Remove liquid from the wells by inverting the plate and decanting the contents 
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7) Remove excess liquid by grasping the plate firmly and smartly rapping the plate 
inverted on a clean paper towel at least 5 times 
8) Fill each well with 400μl of Wash Buffer (Use Plate Washer setting R-D) 
9) Repeat for a total of 6 washes. 
10) After the last wash, smartly rap the inverted plate on a clean paper towel at least 
10 times to remove excess Wash Buffer. 
 
 
PLATE READER 
 
Running the Program 
Protocol 
• Reading Parameters 
o Endpoint 
o Read mode: normal 
o Need to wavelengths, 490nm and 690nm 
• Plate Layout 
o Standard: put units and values of concentrations from kit book 
• Curve 
o Axis: extrapolation factor 3.0 
o Curve Fit: 4 parameter 
o This kit does not use blanks. The standard 8 should be set to blanks 
on the plate layout so the computer will automatically correct the 
Delta OD.  Also use Curve interpretation to interpret Delta OD.  Use 
Protocol R and D TNF-a (refer back to the TNF-a manual and the 
plate reader manual for instructions) 
Reading 
• System: Administrator login: Admin 
• Display: curves, allows you to look at your standard curve 
Save, export 
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DETERMINATION OF ASSAY VALUES – STEP BY STEP 
 
After performing the assay, you should have three concentration values for each sample 
ran; this would be your sample ran in triplicate.  These values should be exported into an 
Excel document for easy interpretation.  If any values are above the extrapolation of 
the standard curve, you need to dilute and re-run those samples.  Open the excel file 
and arrange the data as suited for your needs.  Below is an example of triplicate data for a 
single subject under 5 different experimental treatment conditions (A-E) 
 
 
 
 
 
The next step is to identify the mean and standard deviation (SD) of each conditions 
triplicate values. 
Subject 1 A B C D E 
  0.8513 3.2736 6.2609 11.307 11.11 
  0.9889 3.4701 6.8751 12.978 12.349 
  0.753 3.76 8.2164 14.216 13.719 
MEAN 0.8644 3.501233 7.117467 12.83367 12.39267 
SD 0.118494 0.24469 1.000026 1.459861 1.305048 
With the mean and standard deviation you can calculate the coefficient of variation 
(CV% = SD/mean*100) as depicted below. 
Subject 1 A B C D E 
  0.8513 3.2736 6.2609 11.307 11.11 
  0.9889 3.4701 6.8751 12.978 12.349 
  0.753 3.76 8.2164 14.216 13.719 
MEAN 0.8644 3.501233 7.117467 12.83367 12.39267 
SD 0.118494 0.24469 1.000026 1.459861 1.305048 
CV 13.7% 7.0% 14.1% 11.4% 10.5% 
The next step will be to eliminate the outlier.  The outlier is the single value that is 
farthest away from the other two values.  An example of the eliminated outliers is seen 
below.  Note that all the CV fall within 10%.  If the CV is greater than 20% after the 
outlier has been removed, you need to rerun the sample.  The mean of the two values 
that are left over should be used to represent the data. 
Note: The coefficient of variation has to be below 20%.  If the CV for all three 
triplicate values is within 20%, you should average all values for your data. 
Subject 1 A B C D E 
  0.8513 3.2736 6.2609 11.307 11.11 
    3.4701 6.8751 12.978 12.349 
  0.753 3.76       
MEAN 0.80215 3.501233 6.568 12.1425 11.7295 
SD 0.069509 0.24469 0.434305 1.181575 0.876105 
CV 8.70% 7.00% 6.60% 9.70% 7.50% 
 
Subject 1 A B C D E 
  0.8513 3.2736 6.2609 11.307 11.11 
  0.9889 3.4701 6.8751 12.978 12.349 
  0.753 3.76 8.2164 14.216 13.719 
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Clinical Exercise Supervisor, Indiana University                August 2003 – December 2006 
 
Owner/Developer, Bandercise Workout System       June 2003 – Present 
     www.Bandercise.com 
 
Exercise Physiologist, Valley Care Health System               November   2000 – June 2003 
 
Personal Fitness Consultant, Bally’s Total Fitness                       April 1997 – March 1999 
 
 
RESEARCH INTERESTS / OBJECTIVES 
 
     My present research interests involve cardiovascular disease and its co-morbidities.  I 
am interested in the mono-layer of cells that lines all blood vessels, the endothelium. 
Specifically, I am interested in studying the endothelial response to an acute 
interventional paradigm that includes the: 1) dose response of exercise and endothelial 
function, 2) determination of the relationship between acute and chronic effects of 
exercise on endothelial function, 3) investigation of the relationship between blood 
pressure and endothelial function, 4) determination of responders and non-responders to 
exercise, 5) determination of the effect of static exercise on endothelial function, 6) 
identification of the exercise mechanism responsible for improvement of endothelial 
function in clinical populations, and 7) investigation of the postprandial endothelial 
response to a high fat meal. 
     Endothelial dysfunction is observed in many clinical populations.  It is my objective to 
identify possible physiological mechanisms associated with the improvement of 
endothelial function which include, but are not limited to 1) inflammation, 2) oxidative 
stress, 3) and insulin resistance.  In order to achieve my main objective, I plan to 
collaborate and establish a working relationship with other physiological and biochemical 
research scientist in the field.  
 
UNIQUE RESEARCH SKILLS 
 
- SPSS statistical program 
- Ultrasonic measurement of endothelial function via flow-mediated dilation (FMD) 
- Angiocath venipuncture placement and blood draw 
- EKG interpretation 
- Ambulatory blood pressure monitoring 
- Biochemical assay analysis 
 
 
 
   
 
MANUSCRIPTS IN PROGRESS 
 
Harris, R.A., J. Padilla, J.P. Wallace. Time course of FMD following acute exercise in 
men. Target Journal: Medicine and Science in Sports and Exercise. 
 
Padilla, J., R.A. Harris, J.P. Wallace. Characterization of post exercise induced shear 
stress.  Target Journal: Vascular Medicine. 
 
 
MANUSCRIPTS UNDER REVIEW 
 
Harris, R.A., J. Padilla, K.P. Hanlon, L.D. Rink, J.P. Wallace.  The interaction of IL-6 
and TNF-alpha on the FMD response to acute exercise in overweight active and inactive 
men. Target Journal: Circulation. 
 
Harris, R.A., J. Padilla, L.D. Rink, J.P. Wallace.  Reproducibility of the Flow-Mediated 
Dilation Response to Acute Exercise in Overweight Men. Target Journal: Ultrasound in 
Medicine and Biology. 
 
 
REFEREED PUBLISHED MANUSCRIPTS 
 
Harris, R.A., D. Koceja. Comparison of electrically and mechanically induced H-reflex 
depression. Electromyogr Clin Neurophysiol. 46(7-8): 2006. 
 
Padilla, J., R.A. Harris, A.D. Fly, L.D. Rink, J.P. Wallace.  The effect of acute exercise 
on endothelial function following a high-fat meal. Eur. J. Appl. Physiol. 98(3): 256-262, 
2006. 
 
Padilla, J., R.A. Harris, A.D. Fly, L.D. Rink, J.P. Wallace.  A comparison between 
active and reactive hyperaemia induced brachial artery vasodilation. Clin. Sci. 110(3): 
387-392, 2006. 
 
Harris, R. A., J. Padilla, L. D. Rink, J.P. Wallace.  Variability of flow mediated 
dilation measurements with reactive hyperemia. Vasc. Med. 11(1):1-6, 2006. 
 
 
NON-DATA BASED PUBLICATIONS 
 
Harris, R. A., J Padilla.  Endothelial dependent dilation and long-term exercise 
training. Med. Sci. Sports Exerc., 38(7):1362, 2006. 
 
 
 
   
 
 
COMPETITIVE PUBLISHED ABSTRACTS  
 
Harris, R.A., K. Kitono, C.T. Robertson, D.K. Koceja. Electrically and Mechanically 
Induced Depression of the Soleus H-Reflex at Different Stimulus Intensities.  Med. 
Sci. Sports Exerc. 38(5):S523, 2006. 
 
Padilla, J., R.A. Harris, A.D. Fly, L.D. Rink, J.P. Wallace.  A Comparison between 
Active and Reactive Hyperemia Induced Brachial Artery Vasodilation. Med. Sci. 
Sports Exerc. 38(5):S196, 2006. 
 
Harris, R.A., J. Padilla, and J. P. Wallace. The effect of repetitive reactive hyperemia on 
flow-mediated dilation measurements. Med. Sci. Sports Exerc. 37(5):S221, 2005. 
 
Padilla, J., R.A. Harris, and J. P. Wallace. Variation of flow-mediated dilation during 
morning hours. Med. Sci. Sports Exerc. 37(5):S221, 2005. 
Harris, R.A., Padilla, J., Park, S., Wallace, J.P.  Blood pressure reduction following 
physical activity: A case study approach.  Med. Sci. Sports Exerc. 36(5):S251, 2004. 
 
Padilla, J. Park, S., Harris, R.A., Wallace, J.P. Ambulatory blood pressure response 
following free-living physical activity in pre- and hypertensive adults.  Med. Sci. Sports 
Exerc. 36(5):S251, 2004. 
 
Wallace, J.P. Padilla, J., Park, S., Harris, R.A.  What is the adherence to free-living 
physical activity? Med. Sci. Sports Exerc. 36(5):S64, 2004. 
 
 
INVITED PRESENTATIONS 
 
Harris, R.A.   The Influence of Diet and Exercise on Endothelial Function: A Series of 
Investigations. University of California, San Diego. La Jolla, California. March 2007. 
 
Harris, R.A.   The Influence of Diet and Exercise on Endothelial Function: A Series of 
Investigations.  The Scripps Research Institute.  La Jolla, California. November 2006. 
 
Harris, R.A.  Arterial Health and Exercise.  Kiwanis Club of Bloomington. Bloomington, 
Indiana. September 2006. 
 
Harris, R.A. Research Grant Winners Symposium.  Graduate and Professional Student 
Organization. Indiana University, Indiana. February 2006. 
 
Harris, R.A. Wellness Related Stress Management Break Out Sessions.  Cornerstone 
Information Systems. Stone Mountain, Georgia. November 2004.           
 
 
   
 
GRANT PROPOSALS 
 
Pending 
     -  HPER Travel Grant in Aid 2007 
         Reproducibility of FMD Following Acute Exercise in Overweight 
         Men 
 
Funded 
     - HPER Graduate Student Research Grant in Aid Fall 2006   $600 
       The Interaction of TNF-alpha, IL-6, and Acute Exercise on 
       Endothelial Function in Overweight Men 
 
     - Research University Graduate School Dissertation Grant in Aid Fall 2006 $1000 
       The Interaction of TNF-alpha, IL-6, and Acute Exercise on 
       Endothelial Function in Overweight Men 
 
     - HPER Graduate Student Research Grant in Aid Spring 2006   $800 
        Interaction of Exercise Intensity, TNF-alpha, and IL-6 on  
       Endothelial Function 
 
     - Gatorade Sports Science Institute Student Grant 2005    $2300 
       Interaction of Exercise Intensity, TNF-alpha, and IL-6 on 
       Endothelial Function 
 
     - HPER Travel Grant in Aid 2005       $400  
       The Effect of Repetitive Reactive Hyperemia on Brachial Artery  
       Flow Mediated Dilation Measurements 
 
     -Graduate and Professional Student Organization Research Grant 2005  $200 
       The Effect of Repetitive Reactive Hyperemia on Brachial Artery  
       Flow Mediated Dilation Measurements 
 
     -HPER Travel Grant in Aid 2004       $400 
       Blood Pressure Reduction Following Physical Activity: 
       A Case Study Approach 
 
Not Funded 
- HPER Graduate Student Grant in Aid 2005  
      - American Heart Association Pre-Doctoral Fellowship 2005    
      - Graduate and Professional Student Organization Research Grant 2006 
  
In Preparation 
     -HPER Graduate Student Research Grant in Aid Fall 2006 
       Interaction of Exercise Intensity, TNF-alpha, and IL-6 on 
       Endothelial Function 
   
 
PROFESSIONAL AFFILIATIONS/CERTIFICATIONS 
 
ACSM Exercise Specialist Professional Certification    2005 – Present 
American College of Sports Medicine                2003 – Present 
CPR Health Care Provider       2001 – Present 
CPR Instructor        2001 – 2005 
 
 
PROFESSIONAL/RESEARCH  MEETINGS ATTENDED 
 
ACSM Integrated Physiology, Indianapolis      2006 
ACSM National Meeting, Tennessee       2005 
ACSM National Meeting, Indianapolis      2004 
ACSM National Meeting, San Francisco      2003 
ACSM National Meeting, St Louis       2002 
 
TEACHING RESPONSIBILITIES 
 
Indiana University, Bloomington, Indiana 
 
Graduate 
K561 Clinical Exercise Physiology Laboratory 
- Body composition (hydrostatic weighing and skinfolds) 
- Heart rate, blood pressure, and double product 
- Heart rate/VO2 relationship 
- EKG 
- Spirometry simulating disease populations 
- Ventilation  
- Cardiac Output: Supine vs. upright 
           
K567 Exercise Specialist Practicum 
- Exercise counseling 
- Body composition (hydrostatic weighing and skinfolds) 
- EKG 
- Pulmonary function 
- Exercise capacity/ Oxygen consumption 
 
Undergraduate 
P409 Exercise Physiology Laboratory 
- Muscular Strength 
- Anaerobic power 
- Predicted max oxygen consumption 
- Ventilatory/Anaerobic thresholds 
- Resting metabolic rate 
- Maximal oxygen consumption 
   
 
- Blood pressure 
- Pulmonary function 
- Body composition (hydrostatic weighing and skinfolds) 
 
E119 Personal Fitness Lecture 
- Understanding health related fitness and wellness 
- Cardiorespiratory exercise prescription 
- Improving muscular strength and endurance 
- Nutrition, health, and fitness 
- Prevention of cardiovascular disease 
- Stress management 
    
E119 Personal Fitness Laboratory 
- Cardiorespiratory endurance fitness test 
- Cardiorespiratory endurance program development 
- Strength and endurance fitness testing 
- Muscular strength and endurance program development 
- Flexibility fitness test 
- Flexibility program development 
 
 
SUPERVISION OF GRADUATE STUDENT CURRICULUM 
 
Clinical Exercise Physiology Masters Student Curriculum 
- EKG 
- Body Composition (skin folds and hydrostatic weighing) 
- Pulmonary Function 
- Metabolic Exercise Testing 
- Exercise Prescription Counseling 
- Adult Fitness Program Supervision 
 
 
SERVICE  
 
Departmental 
- Guest lecture P420 Exercise Leadership for Special Populations (Spring 2007) 
 Topic(s): Obesity and Exercise, Cardiovascular disease and Exercise part I and II. 
 
- Guest lecture K639 Biochemistry of Exercise (Spring 2007) 
 Topic: Angiocath placement 
 
- Guest lecture N317 Diet, Disease, and Fitness (Spring 2006) 
 Topic: Influence of diet on cardiovascular disease 
 
- Supervise clients of the Adult Fitness Program (2003 – 2006) 
   
 
 
- Guest lecture K561 Clinical Exercise Physiology (2004 – 2005) 
 Topic: Endothelial function 
 
- Guest lecture K562 Exercise Prescription in Health and Disease (2004 – 2006)  
 Topic(s): Body composition, Pulmonary function, Blood values 
 
 
Journal Referee 
(JCR 2005 impact factor in italics) 
- American Journal of Physiology: Heart and Circulatory Physiology (Feb. 2007) 3.56
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